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1. AIMS OF THE PRESENT STUDY
The number of people with diabetes mellitus has increased rapidly, reaching 
epidemic proportions, and currently affecting approximately 246 million people 
worldwide. This number is expected to rise to approximately 380 million in 
2025 (Fig 1).1-3 The increase in the number of patients with diabetes mellitus 
will certainly lead to a substantial increase in morbidity and mortality, despite 
improvements in the screening and treatment of diabetic complications.
 Long-term diabetes mellitus appears to have considerable consequences for the 
biometry of the eye. In patients with diabetes mellitus the lens seems to become 
thicker and more convex, compared to that of healthy subjects.4-6 However, in 
previous studies of the diabetic lens no attempt has been made to correct for 
distortions that are inherent to the applied measurement methods. In vivo the lens 
can only be observed through the cornea, and due to the refraction that occurs 
Figure 1 The number of people worldwide with diabetes mellitus (aged 20 – 79 years) 
according to region, in 2007 and 2025. (Source: Diabetes Atlas 3rd Edition, IDF 2006)
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Chapter 1
at the corneal surfaces it is difﬁcult to measure the shape of the lens accurately. 
Therefore, the results of these studies should be interpreted with caution. 
Furthermore, the exact inﬂuence of diabetes mellitus on the shape of the cornea 
is still unknown.
 Well-known ocular complications of acute diabetes mellitus are subjective 
symptoms of blurred vision during hyperglycemia, but the exact cause of these 
symptoms is still unknown. They could be due to changes in the image formation 
process (i.e. the refractive system and/or the retina), or to alterations in the image-
processing system (i.e. the brain). Changes in ocular refractive power during 
dysregulated diabetes mellitus have been frequently reported in the literature, but 
there is no consensus on the exact direction and cause of the refractive change. 
It is unclear whether the refractive error generally becomes more myopic (or 
near-sighted) or, on the contrary, more hyperopic (or far-sighted) in people with 
diabetes mellitus and hyperglycemia. Furthermore, the mechanisms underlying 
these refractive changes are unknown. In general, the image formation of an 
optical system becomes disturbed if one or more of its elements change. In the 
diabetic eye there could be changes in the refractive elements (i.e. the cornea 
and/or the lens), or the retina, that occur with an increase in the duration of the 
disease and with other systemic parameters, such as blood glucose levels, the use 
of insulin, or the presence of diabetic retinopathy. In summary, changes in the 
process of image formation in the eye could explain blurred vision and refractive 
changes in dysregulated diabetes mellitus.  
 It is important to obtain accurate knowledge about the inﬂuence of long-
term diabetes mellitus on the refractive components of the eye. Furthermore, an 
accurate description of the changes in the refractive properties of the eye during 
hyperglycemia could provide insight into the mechanisms underlying blurred 
vision and refractive changes in patients with diabetes mellitus and metabolic 
dysregulation. Therefore, the aims of the present study are:
- To accurately measure the thickness and the shape of the cornea, and the thickness, 
shape and internal structure of the lens in patients with diabetes mellitus type 1 
and type 2 (Chapters 2, 3, and 4).
- To investigate the mechanisms underlying blurred vision and refractive changes 
by measuring the geometry of the cornea and the lens, the ocular refractive error, 
and the retinal thickness of the eye during acute hyperglycemia (Chapters 5, 6, 7 
and 8). 
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2. THE REFRACTIVE PROPERTIES OF THE EYE AND IMAGE 
FORMATION
2.1 Ocular refraction
The process of human vision is complex, and involves various components of 
the eye and the human brain. The initial steps in human vision are the refraction 
of incoming rays of light by the cornea and the lens, and image formation on the 
retina. In the ideal situations, parallel rays of light are focused sharply on the 
retina, a condition known as emmetropia, but if the relaxed eye is unable to bring 
parallel rays of light from a distant object into focus, the condition is referred 
to as ametropia. The three basic conditions that may produce ametropia are: 
myopia (near-sightedness), hyperopia (far-sightedness), and astigmatism (Fig 2). 
A myopic eye has excessive convergent power; the light rays focus in front of the 
retina and a divergent (minus) lens should be used to correct ocular refraction. 
On the contrary, a hyperopic eye has insufﬁcient convergence power to focus 
light rays on the retina. In this condition, the rays focus behind the retina, and 
corrections should be made with a convergent (plus) lens. Astigmatism occurs 
when the cornea (and/or the lens) does not have the same radius of curvature in all 
meridians, and corrections should be made with a cylindrical lens. The average 
Figure 2 The refraction of the eye; diagrams of emmetropia, myopia, hyperopia, and 
astigmatism. In the emmetropic eye the rays of light are focused on the retina. Refractive 
errors of the eye include myopia and hyperopia, when the rays of light are focused in front 
of or behind the retina, respectively. In the astigmatic eye the rays of light are focused on 
a focal line and two focal points are formed, which can be positioned in front of, exactly 
on, or behind the retina.
Emmetropia
Myopia
Hyperopia
Astigmatism
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ocular refractive error can be expressed in the spherical equivalent, which is a 
combination of myopic or hyperopic astigmatism. The spherical equivalent is 
calculated as: power of the sphere (myopic or hyperopic correction) + 0.5 * power 
of the cylindrical correction.
 The refractive power (P) of a surface, which is expressed in diopters (D), 
depends on its radius of curvature (R) and the refractive indices (n
1
 and n
2
) of 
both sides of the surface, and has been deﬁned as:7
Parameters n
1
 and n
2
 are the refractive indices on the incident and the refracted 
side of the surface, respectively. An overview of the various parameters (radius of 
curvature, thickness, and refractive index) of the cornea and the lens, as described 
by Gullstrand8 in 1909, is presented in Figure 3. The total refractive power of the 
human eye is approximately 60 D. The anterior surface of the cornea accounts for 
the largest contribution to the refractive power of the eye, providing approximately 
70% (or ~ 42 D) of the total ocular refraction. The posterior corneal surface and 
the anterior and posterior surface of the lens account for the remaining refractive 
power of the eye. 
Figure 3 Parameters of the Gullstrand eye model: R1 = anterior radius cornea, R2 = 
posterior radius cornea, R3 = anterior radius lens, R4 = posterior radius lens, d1 = 
thickness cornea, d2 = anterior chamber depth, d3 = thickness lens, n1 = refractive index 
cornea, n2 = refractive index aqueous, n3 = refractive index lens, n4 = refractive index 
vitreous.  
Gullstrand eye model
R1 (anterior radius cornea) = 7.7 mm 
R2 (posterior radius cornea) = 6.8 mm
R3 (anterior radius lens) = 10 mm
R4 (posterior radius lens) = -6 mm
d1 (thickness cornea) = 0.5 mm
d2 (anterior chamber depth) = 3.1 mm
d3 (thickness lens) = 3.6 mm
n1 (refractive index cornea) = 1.376
n2 (refractive index anterior chamber) = 1.336
n3 (refractive index lens) = 1.427
n4 (refractive index vitreous) = 1.336
d1
d2
d3
R1
R2
R3
R4
Cornea
Lens
Vitreous
n1
n2
n3
n4
Retina
Anterior chamber
P=  
n n
R
2 1−
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2.2 The cornea
The cornea is the transparent front part of the eye and the absence of blood 
vessels contributes to this remarkable corneal transparency. The cornea receives 
its nutrients predominantly from the aqueous humour and oxygen is obtained via 
diffusion from the air via the tear ﬂuid at the anterior surface and from the aqueous 
humour at the posterior surface. The cornea is innervated by unmyelinated nerve 
ﬁbres which are sensitive to touch, temperature and chemicals; touching the 
cornea causes an involuntary reﬂex to close the eyelid. The human cornea consists 
of ﬁve different layers: epithelium, Bowman’s membrane, stroma, Descemet’s 
membrane, and endothelium.9 The corneal epithelium is a thin multicellular 
layer of fast-growing and easily-regenerating cells. Irregularity or edema of the 
corneal epithelium disrupts the smoothness of the tear ﬁlm, which is a signiﬁcant 
component of the total refractive power of the cornea. Bowman’s membrane 
(anterior limiting membrane) is a tough layer of irregularly-arranged collagen 
ﬁbers that protects the corneal stroma. The corneal stroma (substantia propria) is 
a thick, transparent layer of regularly-arranged collagen ﬁbers, sparsely populated 
with keratocytes. Descemet’s membrane (the posterior limiting membrane) is the 
basement membrane of the corneal endothelium. The corneal endothelium is a 
low-cuboidal monolayer of mitochondria-rich cells responsible for regulating 
ﬂuid and solute transport from the aqueous to the posterior layers of the corneal 
stroma. 
 Although the overall shape of the cornea remains stable with age,10,11 it has 
been shown that with age the asphericity of both the anterior and the posterior 
corneal surface can change, resulting in a slight peripheral thinning of the ageing 
cornea.12 
2.3 The lens
The lens is a transparent, biconvex structure located immediately behind the iris. 
The lens is connected with the surrounding circular ciliary muscle by a complex 
system of zonular ﬁbres. During accommodation the shape of the lens is altered 
by relaxation and contraction of the ciliary muscle, leading to changes in the 
tension of the zonular ﬁbres and consequently to changes in the shape of the 
lens body.  This enables the eye to focus on objects at varying distances. The 
ability of the lens to accommodate from distant to near focus gradually declines 
with age; a condition called presbyopia. Clouding or opaciﬁcation of the lens, 
referred to as cataract, may also occur with age. Cataracts that interfere with 
vision can be corrected by surgery, during which the clouded lens is removed 
and preferably replaced by an artiﬁcial intraocular lens. The lens consists of a 
lens capsule, a layer of epithelial cells and the lens ﬁbres. Figure 4 presents a 
18
Chapter 1
diagram of the human crystalline lens. For the sake of transparency it does not 
contain blood vessels or nerves. The lens capsule is a thick, elastic basal lamina, 
which is generated by the epithelial cells. The zonular ﬁbers are inserted into 
the lens capsule. The epithelial cells only cover the anterior part of the lens, 
and are mitotically active in the pre-equatorial region. After division, the post-
mitotic cells gradually move towards the equator of the lens where they start to 
differentiate into lens ﬁbres. Lens ﬁbers are unusually elongated (up to 12 mm) 
hexagonal cells. In the absence of blood supply the lens ﬁbers obtain nutrients 
from the surrounding ﬂuid, i.e. the aqueous humour that bathes the front of the 
lens. Lens ﬁbers are located immediately underneath the epithelium anteriorly, 
and the lens capsule posteriorly, and form the various parts of the lens body (the 
lens cortex and lens nucleus). They are closely packed and the intercellular space 
is extremely small (<4%). The hexagonal lens ﬁbers are strongly interlocked 
Figure 4 Diagram of the lens and the multiple layers of the lens cells: (A) lens capsule, 
which is a thickened, smooth basement membrane and completely envelops the lens. 
(B) Epithelial cells, which show mitotic activity in the equatorial region of the lens in 
particular. (C) Lens ﬁbers, elongated cells with a hexagonal shape in cross-section. Lens 
ﬁbers ﬁt in close packing order with other lens ﬁbers, the adjacent long sides of the lens 
ﬁbers interlock with grooves and ridges, and ball-and-socket junctions, as indicated.
Cortex
Nucleus
Lens fibers
Subcapsular epithelium
Lens capsule
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by edge protrusions, ball-and-socket junctions, and in the deeper aspects of the 
cortex by grooves-and-ridges. On account of light scattering properties (zones of 
discontinuity) the cortex of the lens is sub-divided into several zones, which have 
been given different names and numbers in different studies.13-16 
 In contrast to the cornea, the size and shape of the lens is highly age-
dependent. The annual increase in thickness of a healthy human lens is 0.024 
mm.17 Furthermore, the lens becomes more convex, with a yearly decrease in the 
anterior and posterior radius of curvature of 0.057 and 0.012 mm, respectively.18 
Generally, with a more convex shape of the refractive surface, the refractive 
power increases. Assuming that the other refractive components of the eye remain 
constant, the more convex shape of the aging lens would increase the refractive 
power of the eye, and a myopic shift in ocular refractive error should occur. 
However, it has been reported that with age (between 30 and 60 years of age) 
ocular refraction actually becomes more hyperopic (Fig 5).19,20 The paradoxical 
feature of the increase in convexity of the lens, with no myopic shift in ocular 
Figure 5 Change in cycloplegic refraction of the human eye with age (after Slataper).20
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refractive error with age, has been called the “lens paradox”.21 The lens paradox 
can be explained by a decrease in the equivalent refractive index of the lens with 
age, which compensates for the more convex shape of the aging lens and therefore 
prevents the eye from becoming more myopic.18,22-25 
2.4 The retina
With a normal refraction of light by the cornea and the lens, a sharp image is 
focused on the retina, and this is often compared to the ﬁlm in a photo camera. 
The retina is a thin layer of neural cells that lines the back of the eyeball, and it 
is the only part of the central nervous system that can be observed directly. The 
retina contains photoreceptor cells (rods and cones) that respond to light; the 
resulting neural signals then undergo complex processing by other neurons of the 
retina. This retinal output takes the form of action potentials in retinal ganglion 
cells whose axons form the optic nerve. From the optic nerve the action potentials 
travel to the brain to be further processed. 
3. DIABETES MELLITUS AND THE REFRACTIVE PROPERTIES OF THE 
EYE 
3.1 Diabetes mellitus 
In general, patients with diabetes mellitus have a relative or absolute shortage of 
insulin, and consequently high blood glucose levels.26 Insulin, which is produced 
by the beta-cells of the islets of Langerhans in the pancreas, regulates blood 
glucose concentration by enabling glucose to enter body cells and by storing an 
overload of glucose or glycogen elsewhere (e.g. in the liver, the muscle ﬁbers, 
or fat tissue). On the other hand, glucagon enhances blood glucose concentration 
by stimulating mainly the formation of glucose from glycogen in the liver. This 
mechanism normally establishes narrow blood glucose levels (between 4.0 
and 7.8 mmol/l) in healthy people. Although the pancreatic beta-cell and its 
secretory product insulin are central in the pathophysiology of diabetes mellitus, 
the mechanisms which cause hyperglycemia differ widely. There are several 
different forms of diabetes, which are caused by a complex interaction of genetic, 
environmental, and life-style factors, but there are two major forms of diabetes 
mellitus: type 1 and type 2. Diabetes type 1 is characterized by an absolute insulin 
deﬁciency due to a genetic defect leading to defective insulin secretion. It accounts 
for 5 - 10% of all patients with diabetes mellitus.27 The onset of diabetes type 1 
is sudden, and it usually affects people at a relative young age. Patients with 
diabetes type 1 have to use insulin to prevent the development of ketoacidosis and 
General introduction
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diabetic coma. Diabetes mellitus type 2 has a genetic predominance that causes 
insulin resistance, and/or the induction of a relative insulin shortage because of 
the inability of the pancreas to produce sufﬁcient insulin to encounter the induced 
insulin resistance as the underlying etiology.28 It is the most common type, 
representing approximately 90% of the diabetes population globally.29 The onset 
of diabetes type 2 is gradual, and it usually starts at an older age in people with 
various risk factors, such as for example obesity. Patients with diabetes type 2 
are not dependent on exogenous insulin, but may require it to control their blood 
glucose levels if this is not achieved with dietary restrictions alone or with oral 
hypoglycemic agents.
 The characteristic initial symptoms of diabetes mellitus are excessive urine 
production (polyuria), excessive thirst and increased ﬂuid intake (polydipsia), 
and subjective symptoms of blurred vision, but these symptoms are likely to be 
absent if the blood glucose level is only mildly elevated. Considering the fact 
that diabetes mellitus is a common disease, and that it is often under-diagnosed, 
ophthalmologists and optometrists should always take it into consideration in 
patients with blurred vision.30 Other symptoms include fatigue, and increased 
susceptibility to infections, particularly of the skin and genitalia.31 Chronic 
elevation of the blood glucose level results in damaged blood vessels. The 
resulting problems are grouped in microvascular complications (due to damage 
of the small blood vessels) and macrovascular complications (due to damage 
of the large arteries). Macrovascular illness leads to cardiovascular disease and 
mortality, to which accelerated atherosclerosis is a contributor. Microvascular 
complications include diabetic neuropathy, diabetic nephropathy, and diabetic 
retinopathy.32
3.2 Sustained refractive changes and diabetes mellitus
Sustained or chronic refractive errors that are reported in patients with diabetes 
mellitus not only include myopia, but also a tendency towards hyperopia, or no 
change in ocular refraction at all. Epidemiological studies (Barbados Eye Study, 
Los Angeles Latino Eye Study) revealed that diabetes mellitus was an independent 
risk factor for the development of moderate myopia (> -3 D)33 and low-grade 
myopia (< -1 D)34. Furthermore, in the Danish adult population, a predominance 
of myopia was reported in patients with diabetes, compared to non-diabetics.35-37 
Poor metabolic control of diabetes mellitus has also been suggested as a risk factor 
for myopia.38 In contrast, in other population studies (Beaver Dam Eye Study, a 
rural South Indian population) the presence of diabetes mellitus was related to an 
increased shift towards hyperopia,39,40 and no associations were found between 
refractive error and glycemic control or duration of diabetes.41 Furthermore, 
22
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diabetes mellitus was not associated with a shift in ocular refraction in other 
epidemiological studies (Andhra Pradesh Eye Disease Study, Blue Mountains Eye 
Study).42,43 In summary, the relationship between diabetes mellitus and chronic 
refractive changes is controversial and needs to be conﬁrmed in further studies. 
As in healthy individuals, large myopic shifts in ocular refraction have not been 
consistently observed in patients with long-term diabetes mellitus, despite the 
signiﬁcant increase in thickness and convexity of the diabetic lens. 
3.3 Changes in the cornea with diabetes mellitus
Diabetes mellitus can lead to structural changes in the epithelial44-49 and endothelial 
cells of the cornea,50-54 which may result in diabetic keratopathy.  Diabetic 
keratopathy becomes manifest as recurrent corneal erosions, superﬁcial punctuate 
keratopathy, persistent epithelial defects, decreased corneal sensitivity,55,56 
endothelial dysfunction, and delayed wound healing. Because of this increased 
risk of corneal complications, refractive surgery may be contra-indicated in 
patients with diabetes mellitus.57,58 It is unclear from the literature whether 
diabetes mellitus causes a change in the thickness of the cornea. Some studies 
have reported that the cornea is thicker in diabetic than in healthy subjects,59-61 
but other studies reported no difference between the corneal thickness of subjects 
with diabetes and that of healthy subjects.62-63 
3.4 Changes in the lens with diabetes mellitus 
In patients with diabetes mellitus the lens is thicker than in healthy subjects,4,5,64-69 
and this is mainly due to thickening of the cortex of the lens.70,71 Other biometric 
changes in the lens include a steepening of the anterior and posterior surfaces 
of the lens and a decrease in the depth of the anterior chamber.4,5 These changes 
appear to be more pronounced in diabetes mellitus type 1 than in diabetes mellitus 
type 2. The duration of the disease, as well as the level of retinopathy, have been 
reported as important determinants of lens biometry. With each year of diabetes 
the thickness of the lens increases with an additional 70% of the annual age-
related increase.4,5 Until now, however, the profound increase in lens dimensions 
with diabetes mellitus is not fully understood. It could be due to an accelerated 
growth of the lens, but it could also be caused by osmotic swelling of the lens, 
either as a result of an increase in cell membrane permeability or deﬁcient ion-
pumping. More knowledge about changes in the histology and ultrastructure of 
the lens with diabetes mellitus could provide insight into the cause of the increase 
in the size of the diabetic lens. For more details see section 4.2: The lens and the 
sorbitol pathway. 
 Another  lens complication that is related to diabetes mellitus is the early 
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development of cataract.72-75 Cataract can be induced by hypoglycemia,76 and it can 
already be present as juvenile cataract (snowﬂake cataract, affecting the anterior 
and posterior cortical layer of the lens in young individuals with diabetes),77 or 
as age-related cataract (nuclear, cortical, and posterior sub-capsular cataract).78 
Juvenile cataract is characterized by rapid swelling of the lens, inducing a 
myopic shift of refraction.79 However, hyperopic refractive power changes with 
acute diabetic cataract have also been reported.80,81 Furthermore, studies of young 
subjects with diabetes mellitus type 1, with no detectable cataract after slit-lamp 
examination, suggest that there is an increased scatter of light in diabetic subjects 
that appears to correlate with the level of the glycated hemoglobin (HbA1c) and 
the severity of diabetic retinopathy.82-86 
3.5 Changes in the retina with diabetes mellitus
Diabetic retinopathy is the most common ocular disease in patients with diabetes 
mellitus, and it is the most frequent cause of blindness among adults aged 20-79 
years.87-90 The duration of diabetes has been shown to be an important determinant 
in the onset and progression of diabetic retinopathy: respectively 97% and 80% 
of the patients with diabetes type 1 and type 2 will have retinopathy after 15 
years.91,92 An interesting observation is that diabetic retinopathy is less likely to 
develop in patients with diabetes mellitus and myopia of -5 D or more.93,94 
 Diabetic macular edema is a microvascular complication that is associated with 
diabetic retinopathy, and it is the major cause of visual impairment in patients with 
diabetes mellitus.95,96 Diabetic macular edema appears to occur more frequently 
as the severity of diabetic retinopathy increases, but it can develop during all 
stages of diabetic retinopathy.97,98 Risk factors that contribute to the progression of 
diabetic macular edema include elevated blood glucose levels, increased duration 
of the diabetes, and the severity of diabetic retinopathy.99,100 Diabetic macular 
edema is probably caused by a breakdown of the inner blood-retina barrier,101 
but its exact origin is still not fully understood. The degree of retinal thickening 
has been found to be signiﬁcantly correlated with visual acuity.102 Furthermore, 
macular edema may induce a hyperopic shift in ocular refraction, since it implies 
a relative shortening in the axial length of the eye. 
4. ACUTE HYPERGLYCEMIA AND THE REFRACTIVE PROPERTIES OF 
THE EYE
4.1 Transient refractive changes during acute hyperglycemia
In the 19th century it was already recognized that changes in blood glucose 
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levels can inﬂuence visual acuity and ocular refraction in patients with diabetes 
mellitus.103-106 Since then, both myopic shifts106-112 and hyperopic shifts113-127 have 
been reported. It has been suggested that myopia develops under hyperglycemic 
conditions, and that after treatment of the dysregulated diabetes mellitus the 
refraction will change towards more hyperopia or less myopia.109,122,128-130 However, 
there are also studies that have reported hyperopic changes in refraction during 
acute episodes of hyperglycemia.116,118,132-134 This lack of consensus may partly 
be explained by the fact that different analytical approaches were adopted in the 
studies mentioned above. Although the majority of investigators was interested 
in the response of the eye when elevated blood glucose levels were reduced to 
near-normal values, changes at the time of maximal acute hyperglycemia were 
also reported. Therefore, it is important to deﬁne the time-point of the refractive 
changes, i.e. whether they are present at the time of maximal acute hyperglycemia 
or after the initiation of treatment for acute hyperglycemia. Previous reports 
describe the refractive shifts at different time-points after the start of the study. 
Another explanation for the inconsistency in the literature on refractive changes 
during hyperglycemia could be the following: both hyperopic and myopic shifts 
could result from morphological changes in the image formation system of the eye. 
A decrease in the radius of curvature or the equivalent refractive index of the lens 
could induce a myopic or a hyperopic change in ocular refraction, respectively. It 
could be hypothesized that there is a balance between changes in the shape and 
the refractive index of the lens, which eventually determine the overall refractive 
outcome.111,115,131,132 The effect of hyperglycemia on ocular refractive power can 
be dramatic when treatment is started, and may differ from the sort of changes 
that occur when the diabetes is under control. In most cases the refractive shifts 
with hyperglycemia are reversible once effective metabolic control is achieved. 
Therefore, it is not advisable to change or issue a new prescription for glasses for 
newly diagnosed patients or patients with poorly controlled diabetes. 
4.2 The lens and the sorbitol pathway
The mechanisms underlying changes in the shape of the lens with accompanying 
shifts in refractive power during hyperglycemia are still unclear. Current opinion 
favors the view that the hydration of the lens changes as a result of osmotic changes. 
The glucose level of the aqueous humor varies directly with the glucose level of 
the blood.135 As the concentration of glucose in the aqueous humor increases, the 
glucose level within the lens also increases, because the intracellular glucose level 
in the lens is not regulated by insulin.136,137 The glucose in the lens is metabolized 
via the sorbitol pathway, which consists of two enzymes (aldose reductase and 
sorbitol dehydrogenase) which catalyze the conversion of glucose into its sugar 
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alcohol sorbitol and the further conversion of sorbitol to fructose. These sugar 
alcohols tend to accumulate within the lens ﬁbres, because they are membrane 
impermeable.138 Consequently, an osmotic gradient between the hypertonic lens 
and the aqueous humor is built up, resulting in an inﬂux of water from the aqueous 
humor, producing lenticular swelling.136 This may lead to a decrease in the radius 
of curvature and equivalent refractive index of the lens, resulting in changes in 
ocular refractive power.     
5. METHODS USED IN THE PRESENT STUDY
In order to accurately measure the refractive properties of the diabetic and 
healthy eye the following methods were applied in the present study: corrected 
Scheimpﬂug imaging, Hartmann-Shack aberrometry, and optical coherence 
tomography. These measurement methods will be explained in more detail in the 
following paragraphs. 
5.1 Corrected Scheimpﬂug imaging 
The Scheimpﬂug camera, which can be regarded as a modiﬁed slit-lamp, produces 
a sharp image of the whole anterior eye segment. The Scheimpﬂug technique 
Figure 6 Diagram of the Scheimpﬂug principle: the object, lens, and image planes 
intersect in one line. This provides a sharp image of the anterior segment of the eye.
Lens
Image
Object
Intersection of object, 
lens and image planes
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is based on the principle that the image of an obliquely positioned object is 
formed in such a way that the object, lens, and image planes intersect in one line, 
thus increasing the depth of focus of the object plane. Figure 6 illustrates the 
Scheimpﬂug principle, which is achieved by tilting the image plane. Because of 
an increased depth of focus and the relatively high resolution of the Scheimpﬂug 
image, it is possible to detect small changes in the shape of the cornea and the lens. 
However, the image of the anterior eye segment, according to the Scheimpﬂug 
principle, is sensitive to two types of distortion. Type 1 distortion is the result of 
the geometry of the Scheimpﬂug camera. The image becomes distorted because 
the magniﬁcation is not constant over the image, since the image and object 
plane are not parallel to each other.139 Type 2 distortion is due to the refraction 
at the various ocular surfaces.140-142 For example, the anterior lens surface, as 
shown on a Scheimpﬂug image, has been refracted by the anterior and posterior 
corneal surface. The posterior lens surface is observed through both the cornea 
and the lens, and correction for type 2 image distortion has been shown to be 
necessary,18,143 and has been described in detail by Dubbelman et al.17,18,144 If these 
corrections are made, Scheimpﬂug imaging provides accurate measurements of 
the geometry of the anterior eye segment.17,18,144 
5.2 Hartmann-Shack aberrometry
Hartmann-Shack aberrometry is a technique that measures not only the ocular 
refractive power (sphere and cylinder), but also minute imperfections (higher 
order aberrations) of an optical system. An aberrometer operates by focusing an 
extremely ﬁne beam of infrared light (wavelength 780 nm) on the retina. When 
the light beam scatters back from the eye fundus, a 32 x 32 array of micro-lenses 
captures these rays of light. Corresponding to their focal points, each micro 
lens forms a spot on a charge-coupled device (CCD) camera. To reconstruct the 
wavefront of the eye, the spot images or Hartmann-Shack images are analyzed to 
evaluate the displacements of x and y positions of the central points of the spots 
from a perfect grid pattern.145 Figure 7 presents a diagram of the Hartmann-Shack 
principle.
5.3 Calculation of the equivalent refractive index of the lens
The various layers of the lens have different refractive indices: the refractive 
index is highest at the very center, and lowest at the periphery of the lens.8 In the 
present study we calculated the equivalent refractive index of the lens, which 
is an approximation of the average refractive index of the lens. This is possible 
by combining the data of the corrected Scheimpﬂug images on the geometry of 
the anterior eye segment, a measurement of the axial length of the eye, and a 
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Figure 7 Diagram of the Hartmann-Shack principle: minute aberrations of the eye can 
be determined by comparing the measured wave-front with the wave-front of an optically 
perfect eye.  
Figure 8 Iterative method to calculate the refractive index of the lens (n3). Parameters 
involved are: corneal thickness (d1), anterior chamber depth (d2), lens thickness (d3), 
radius anterior corneal surface (R1), radius posterior corneal surface (R2), radius 
anterior lens surface (R3), and radius posterior lens surface (R4) (after Dubbelman et 
al.18,144
Video sensor Micro lenslet array
Perfect wavefrontFront view video sensor
Video sensor Micro lenslet array
Aberrated wavefrontFront view video sensor
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measurement of the refractive error by means of aberrometry. The equivalent 
refractive index could then be calculated through an iterative process (Fig 8), 
which has been developed by Dubbelman et al.18,144
5.4 Optical coherence tomography
Optical coherence tomography (OCT) is a non-invasive, transpupillary imaging 
technique which can visualize retinal structures in vivo with a high resolution. 
Cross-sectional images of the retina are produced through the optical back-
scattering of light in a fashion analogous to B-scan ultrasonography. This makes 
it possible to differentiate the anatomic layers within the retina and to measure 
the thickness of the retina.146 
6. GENERAL OVERVIEW 
In order to accurately determine the thickness and the shape of the cornea, and 
the thickness, shape and internal structure of the lens, we measured the anterior 
eye segment in patients with diabetes mellitus type 1 and type 2 and in healthy 
subjects by means of corrected Scheimpﬂug imaging (Chapters 2, 3, and 4). 
The inﬂuence of diabetes mellitus type 1 and type 2 on the thickness, radius of 
curvature, power, and asphericity of the cornea is described in Chapter 2. It was 
important to ﬁnd out whether the thickness and shape of the cornea change with 
diabetes mellitus, in order to determine the contribution of the cornea in sustained 
diabetic refractive changes. Furthermore, Chapters 3 and 4 describe the inﬂuence 
of diabetes mellitus type 1 and type 2 on the thickness, radius of curvature, 
equivalent refractive index, power and internal structure of the crystalline lens. 
We studied the previously reported profound effect of diabetes mellitus on the 
thickness and shape of the lens, and added to this knowledge the inﬂuence of 
diabetes mellitus on the equivalent refractive index and the refractive power of 
the lens (Chapter 3). Furthermore, the origin of the increased size of the diabetic 
lens was investigated by analyzing the internal structure of the lens (Chapter 4). 
 In Chapters 5, 6, 7 and 8 the underlying mechanisms of blurred vision and 
refractive changes were investigated by measuring the geometry of the cornea 
and the lens, the ocular refractive error, and the retinal thickness of the eye during 
episodes of acute hyperglycemia. The ocular refraction and geometry of the eye 
of 25 patients with diabetes mellitus were measured during the presence and 
absence of hyperglycemia and subjective symptoms of blurred vision (Chapter 
5). Chapter 6 describes changes in ocular refraction and the lens in a patient with 
newly diagnosed diabetes mellitus, acute severe hyperglycemia and symptoms of 
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ABSTRACT
Purpose To determine the inﬂuence of diabetes mellitus (DM) type 1 and type 2 
on the thickness, radius of curvature, power, and asphericity of the cornea.
Methods In this observational cross-sectional study, 102 patients with DM type 1, 
101 patients with DM type 2, and 69 healthy subjects were measured by means 
of Scheimpﬂug imaging to determine central corneal thickness and the radius 
and asphericity of the anterior and posterior corneal surfaces. Corneal power was 
calculated from these parameters. Several systemic parameters (e.g, duration of 
diabetes, glycated hemoglobin,  blood glucose levels, and type of medication) 
and ocular comorbidity (e.g, stage of retinopathy) were recorded.
Results Patients with DM type 1 and 2 had signiﬁcantly smaller posterior 
corneal radii (P < 0.05) than healthy subjects (men: 6.49/6.48/6.64 mm; women: 
6.36/6.30/6.49 mm). As a result, the optical power of the posterior corneal surface 
of the patients with diabetes differed from that of the healthy subjects (P < 0.01; 
men: DM, 26.2 D; healthy, 26.0 D; women: DM, 26.3 D; healthy, 26.2 D). 
However, corneal thickness, anterior radius and asphericity, and overall corneal 
power did not differ signiﬁcantly between the groups. Furthermore, none of the 
systemic factors or ocular comorbidity had any inﬂuence on the corneal thickness 
or shape.
Conclusions DM affects the posterior corneal radius, resulting in a small change 
in posterior corneal power. However, chronic DM does not seem to signiﬁcantly 
inﬂuence the overall corneal power.
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INTRODUCTION
 
The optical components of the eye that are mainly responsible for the refraction 
of the incoming light are the cornea and the lens. Diabetes mellitus (DM) 
causes changes in the shape of the lens. These changes, which occur in the 
radius, thickness, and refractive index of the lens, are believed to be the origin 
of the refractive changes that are often observed in patients with diabetes.1–4 
In addition to diabetes-induced changes in the lens, various corneal changes 
caused by DM have also been reported. As a result of structural and functional 
abnormalities of the cornea, such as an impaired epithelial barrier function,5,6 
decreased endothelial function,7,8 and altered endothelial cell morphology,9–11 
patients with DM may develop complications such as recurrent corneal erosions, 
superﬁcial punctuate keratitis, decreased sensitivity,12,13 delayed wound healing, 
and corneal edema after vitrectomy.14,15 Because of this increased risk of corneal 
complications, refractive surgery, for example, is questionable in patients with 
DM.16,17 Furthermore, in patients with chronic DM type 1 and type 2, an increased 
central corneal thickness (CCT) has been reported.18–20 Lee et al18 found that CCT 
was signiﬁcantly increased in patients who had DM for > 10 years (595.9 ± 4.2 
mm) compared with a healthy control group (567.8 ± 3.8 mm; P < 0.001) or 
patients who had DM for < 10 years (582.2 ± 3.7 mm; P < 0.05). However, other 
studies report that CCT is not increased in DM type 1 or type 2.21,22 
 No reports have yet been made with regard to the inﬂuence of DM on posterior 
and anterior corneal radius of curvature and asphericity. As a result, the long-
term effect of DM on corneal shape is not known, and it is unclear whether the 
cornea could also play a role in explaining the refractive changes in patients with 
chronic DM. Therefore, the aim of this study was to measure corneal thickness, 
radius of curvature, power, and asphericity in patients with chronic DM type 1 
and type 2 and compare these parameters to those of healthy subjects. In this 
study, Scheimpﬂug imaging is used because it allows an accurate measurement 
of the corneal thickness and also of the radius and asphericity of both the anterior 
and the posterior corneal surface. Furthermore, the inﬂuence of several systemic 
factors on the cornea, such as the duration of diabetes, glycated hemoglobin 
values, and actual blood glucose values, was also studied, as well as the stage of 
diabetic retinopathy and the use of insulin.
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MATERIALS AND METHODS
In this cross-sectional study, a total of 272 subjects (69 control subjects, 102 
patients with DM type 1 and 101 patients with DM type 2) were measured in the 
Department of Ophthalmology at the VU University Medical Center in Amsterdam. 
Subjects with glaucoma, or a history of intraocular surgery and subjects, who had 
worn contact lenses in the previous 2 years, were excluded. Age, duration of 
diabetes, glycated hemoglobin levels, and the type of medication were recorded. 
Blood glucose levels were measured with a blood glucose analyzer (HemoCue 
Diagnostics BV, Oisterwijk, the Netherlands). Two independent ophthalmologists 
(BP, PR) used the EURODIAB classiﬁcation system to determine the stage of 
diabetic retinopathy from two-ﬁeld digital color 45° fundus photographs.23 
For practical reasons, the EURODIAB levels of retinopathy were sub-divided 
into three categories; retinopathy absent (EURODIAB level 0), retinopathy 
present (EURODIAB levels 1, 2, 3) and retinopathy after photocoagulation 
or proliferative retinopathy (EURODIAB level 4 or 5). The diagnosis of DM 
type 1 or type 2 was established according to the guidelines issued by the World 
Health Organization.24 The Medical Ethics Committee of the VU University 
Medical Center in Amsterdam approved the protocol of this study, and written 
informed consent was obtained from all participants, according to the tenets of 
the Declaration of Helsinki. 
 The right eye of each participant was studied. Refractive error was measured 
with an IRX3 aberrometer (Imagine Eye Optics, Paris, France), and calculated 
as: equivalent refractive error (ERE) = sphere + (cylinder / 2). The ERE varied 
between -9.6 and 5.8 D (mean ± SD: -1.0 ± 2.6 D) in the control group, between 
-10.3 and 4.0 D (mean ± SD: -1.2 ± 2.1) in the DM type 1 group and between 
-10.1 and 7.1 D (mean ± SD: -0.5 ± 2.6) in the DM type 2 group. 
 Images of the cornea were obtained with a Topcon SL-45 Scheimpﬂug camera, 
equipped with a charge coupled device (CCD) camera (St-9XE, SBIG astronomical 
instruments) with a range of 16 bits of grey values (512 x 512 pixels, pixel size 
20 x 20 μm, magniﬁcation: 1x). All Scheimpﬂug images were taken along the 
optical axis. One series of three Scheimpﬂug images was made in both horizontal 
(0°) and vertical (90°) meridians. Ray-tracing was used to correct the images 
for distortion due to the geometry of the Scheimpﬂug camera and due to the 
refraction of the anterior corneal surface. Consequently, this provided an accurate 
measurement of the corneal thickness and the shape of the posterior surface of the 
cornea (Fig. 1). This method has been described in detail by Dubbelman et al.25 
Since the Scheimpﬂug images of the diabetic and control subjects were also used 
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uncorrected corrected
7.5 mm
to study the shape of the lens, 1.0% cyclopentolate and 5% phenylephrine eye-
drops were administered to each right eye to obtain maximal pupillary dilation 
and paralysis of accommodation. 
 To provide a description of the asphericity of the cornea, the following conic 
of revolution26-28 was used:
 
         (1)
   
The curvature c = 1/r, r is the radius of curvature at the vertex (x0,y0). The conic 
constant k indicates how fast a surface steepens (k > 1) or ﬂattens (k < 1) with 
distance from the apex. Therefore, the value of k describes the degree to which 
an aspherical surface differs from the equivalent spherical surface. The surface 
Figure 1 Corrected Scheimpﬂug imaging provides an accurate measurement of the 
thickness, shape and asphericity of the cornea; the aperture of 7.5 mm has been indicated 
in the corrected image. Note the change in the corneal thickness and the shape of the 
posterior surface after correction.
y
c x x
kc x x
y= −
+ − −
+( )
( )
0
0
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represents a hyperboloid when k < 0, a paraboloid when k = 0, a prolate spheroid 
when 0 < k < 1, a circle when k = 1, and an oblate spheroid when k > 1. This 
conic of revolution was ﬁtted for both anterior and posterior corneal surfaces at 
an aperture of 7.5 mm. Finally, in horizontal and vertical meridians, the corneal 
thickness, the radius at the vertex and the k value were determined.
 The following formulas were used to calculate the power (P) of the anterior 
and the posterior surface of the cornea in diopters, with the refractive index of air 
(n0), the cornea (n1), and the aqueous humor (n2), the anterior radius (ra) and the 
posterior radius (rp):
         (2)
  
         (3)
The overall corneal power (P) was calculated with the Lensmaker’s equation,29 
with corneal thickness t:
         (4)
   
 Statistical analysis of corneal thickness, radius and asphericity in all participants 
was performed with independent Student’s t-tests, linear regression and analysis 
of variance (ANOVA) with multiple comparisons, using the Bonferroni post hoc 
method. Multiple regression analysis was applied to adjust for age in the analysis 
of corneal asphericity, and to correct for gender in the analysis of corneal radius. 
A quadratic covariate (age-mean age)2 was used in the statistical analysis for 
ERE, since ERE is known to slightly change with age.30-32 Two-sided p-values < 
0.05 were considered to be statistically signiﬁcant. All analyses were performed 
with SPSS 12.0.1 software.
P = anterior 
n n
ra
1 0−
P = posterior 
n n
rp
2 1−
P= P P P P anterior posterior anterior posterior+ − t
n1
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Control group
(n = 69)
DM type 1
(n = 102)
DM type 2
(n = 101)
Age in years; ( range) 36.6 ± 14.2; (18-65) 39.9 ± 10.8; (18-60) 56.4 ± 7.0; (36-65)*
Equivalent refractive error (Dpt) a -1.02 ± 2.58 -1.22 ± 2.12 -0.52 ± 2.59
Gender (male/female) (n) 29 / 40 58 / 44 54 / 47
Duration of diabetes (years) b 21.0 ± 11.7 8.8 ± 7.5**
Glycated hemoglobin (%) 8.1 ± 1.6 7.5 ± 1.4**
Actual blood glucose (mg/dl) 175 ± 83 143 ± 58**
Medication (n / total n)
   Insulin 102 / 102 59 / 101
   Other (oral anti-diabetics or diet) 0 / 102 42 / 101
Retinopathy (n / total n) c
   Retinopathy absent  
      EURODIAB 0 52 / 102 64 / 101
   Retinopathy present 
      EURODIAB 1 12 / 102 13 / 101
      EURODIAB 2 7 / 102 9 / 101
      EURODIAB 3 1 / 102 3 / 101
      EURODIAB 5 1 / 102 0 / 101
   Retinopathy after photocoagulation
      EURODIAB 4 29 / 102 12 / 101
Data are presented as mean ± SD. a Equivalent refractive error was corrected for age in the three groups. 
b Duration of diabetes was corrected for age in the two diabetic groups. c Retinopathy was subdivided 
into three categories; retinopathy absent (EURODIAB level 0), retinopathy present (EURODIAB level 
1,2,3), and retinopathy after photocoagulation or proliferative retinopathy (EURODIAB level 4 or 5). 
*Signiﬁcantly different, compared to the control group and the DM type 1 group, p < 0.001. **Signiﬁcantly 
different, compared to the DM type 1 group, p < 0.001.
Table 1 Baseline characteristics of the control group and the two diabetic groups 
RESULTS
Table 1 presents the baseline characteristics of the three groups. Mean age was 
signiﬁcantly different in the DM type 2 group compared to the control group 
and the DM type 1 group (p < 0.001). No statistically signiﬁcant difference was 
found in ERE between the three groups (p = 0.37). The mean central corneal 
thickness (CCT) was 0.578 mm (SE 0.004) in the control group, 0.586 mm (SE 
0.003) in the DM type 1 group, and 0.578 mm (SE 0.003) in the DM type 2 
group. No statistically signiﬁcant correlation was found between CCT and age 
and no signiﬁcant differences in CCT were observed between the three groups 
(p = 0.19).
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Control group
(n = 69)
DM type 1
(n = 102)
DM type 2
(n = 101)
males 
(n = 29)
females 
(n = 40)
males
 (n = 58)
females 
(n = 44)
males 
(n = 54)
females
 (n = 47)
Anterior cornea
mean radius (mm) 7.86 ± 0.04 7.70 ± 0.03 7.87 ± 0.04 7.69 ± 0.03 7.82 ± 0.04 7.62 ± 0.03
0° 7.90 ± 0.04 7.73 ± 0.03 7.89 ± 0.04 7.74 ± 0.03 7.83 ± 0.04 7.66 ± 0.04
90° 7.83 ± 0.04 7.68 ± 0.03 7.85 ± 0.04 7.64 ± 0.04 7.80 ± 0.04 7.59 ± 0.03
power (Diopters) 47.8 ± 0.2 48.8 ± 0.2 47.8 ± 0.2 48.9 ± 0.2 48.1 ± 0.2 49.4 ± 0.2
Posterior cornea
mean radius (mm) 6.64 ± 0.04 6.49 ± 0.04 6.49 ± 0.04 6.36 ± 0.04 6.48 ± 0.04 6.30 ± 0.03
0° 6.74 ± 0.04 6.56 ± 0.04 6.62 ± 0.04 6.51 ± 0.03 6.61 ± 0.04 6.41 ± 0.03
90° 6.54 ± 0.05 6.43 ± 0.04 6.35 ± 0.04 6.22 ± 0.04 6.32 ± 0.04 6.18 ± 0.04
power (Diopters) -6.03 ± 0.04 -6.17 ± 0.03 -6.17 ± 0.04 -6.27 ± 0.03 -6.19 ± 0.04 -6.36 ± 0.03
Overall cornea
power (Diopters) 41.8 ± 0.2 42.7 ± 0.2 41.7 ± 0.2 42.5 ± 0.2 42.0 ± 0.2 43.0 ± 0.2
Table 2 Radius (± SE) and power of the anterior and posterior surface of the cornea for 
males and females in the three groups
 The anterior and posterior corneal radius differed signiﬁcantly between males 
and females in all three groups (p < 0.01 and p < 0.05, respectively); therefore, 
the analyses were performed with correction for gender. Values of the anterior 
and posterior radius and the power of the cornea of the males and females in 
the three groups are summarized in Table 2. Comparisons were made between 
the groups with regard to the 0º and 90º meridians, and the results appeared to 
be similar for both meridians. No signiﬁcant difference in anterior radius and 
anterior corneal power was found between the three groups. However, two-way 
analysis of variance revealed a signiﬁcant difference in mean posterior radius 
and power of the cornea between the three groups (p < 0.001). Table 3 shows 
that the mean posterior radius was signiﬁcantly smaller and that the power of the 
posterior cornea was signiﬁcantly larger in the two diabetic groups, compared to 
the control group. However, the power of the whole cornea was not affected by 
DM (Table 3). 
 Asphericity is expressed in the conic constant (k-value), which is an indication 
of how rapidly a surface ﬂattens (k < 1) or steepens (k > 1) with distance from 
the apex. Simple linear regression showed that in the control group the k-value 
of both corneal surfaces was age-dependent.33 With age, the k-value of the 
anterior corneal surface increased (p = 0.03), whereas the k-value of the posterior 
surface decreased (p = 0.002). Therefore, corrections for age had to be made. 
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Mean anterior asphericity was 0.88 (SE 0.01) in the DM type 1 group, 0.88 (SE 
0.01) in the DM type 2 group, and 0.88 (SE 0.01) in the control group. Anterior 
asphericity did not differ between the three groups. This was also the case for the 
posterior asphericity. Mean posterior asphericity was 0.69 (SE 0.02) in the DM 
type 1 group, 0.72 (SE 0.02) in the DM type 2 group, and 0.69 (SE 0.02) in the 
control group. No signiﬁcant difference was found when comparing the three 
groups.
 Figure 2 provides an illustration of the marginal inﬂuence of DM on the shape 
of the cornea. In the present study, it was found that the radius of the posterior 
corneal surface was 0.14 mm (DM type 1) and 0.18 mm (DM type 2) smaller 
compared to that of the control group. This results in a thickening of the diabetic 
cornea in the periphery, because the CCT and the anterior corneal radius did not 
change. At a distance of 3.75 mm from the apex of the cornea, the peripheral 
thickening is approximately 20 μm and 26 μm for the DM type 1 group and the 
DM type 2 group, respectively. 
 In order to determine associations between the corneal parameters (CCT, radius 
and asphericity) and several systemic factors, such as duration of DM, levels 
of glycated hemoglobin, actual blood glucose levels, and use of insulin, simple 
linear regression analysis was performed for each of the variables in the two 
diabetic groups. No associations were found between the systemic factors and the 
Difference in the means
(± SE)
95% Conﬁdence Interval for 
the difference in the means
P-value
Mean posterior radius (mm)
Control group - DM type 1 0.14 ± 0.04 0.05 to 0.23 0.001
Control group - DM type 2 0.18 ± 0.04 0.09 to 0.28 < 0.001
DM type 1 - DM type 2 0.04 ± 0.04 -0.05 to 0.13 0.82
Posterior power (Diopters)
Control group - DM type 1 0.14 ± 0.04 0.04 to 0.23 0.001
Control group - DM type 2 0.18 ± 0.04 0.08 to 0.27 < 0.001
DM type 1 - DM type 2 0.04 ± 0.04 -0.04 to 0.13 0.75
Overall power (Diopters)
Control group - DM type 1 0.19 ± 0.21 -0.32  to  0.70 > 0.99
Control group - DM type 2 -0.13 ± 0.21 -0.64  to  0.39 > 0.99
DM type 1 - DM type 2 -0.32 ± 0.20 -0.79  to  0.16 0.33
Table 3 Results of multiple regression analysis of the posterior radius and power, 
corrected for gender, when comparing the three groups; differences in the means are 
presented with standard errors
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Figure 2 Illustration of the change in posterior corneal radius due to diabetes, resulting 
in a peripheral thickening of the cornea; the mean corneal shape is indicated for the 
control group (solid line), and for the DM type 2 group (dashed line). The central corneal 
thickness and the anterior corneal radius did not change.
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corneal parameters. It was also found that the level of retinopathy (retinopathy 
absent, retinopathy present and retinopathy after photocoagulation or proliferative 
retinopathy) did not signiﬁcantly inﬂuence any of the corneal parameters.
DISCUSSION
The aim of the present study was to determine the inﬂuence of DM on the 
shape, thickness and power of the cornea by measuring these corneal parameters 
in patients with chronic DM type 1 and type 2, and compare them to those of 
healthy subjects. Several studies have investigated the effect of hyperglycaemia 
on refraction, but there seems to be no agreement on the exact cause of refractive 
change in unstable diabetes. It has been reported that refractive changes in 
patients with chronic DM are caused by alterations in the lens,1-4 but the exact 
contribution of the cornea to these refractive changes is still unknown. Corneal 
topographic parameters were measured in patients who received intensive 
treatment for acute severe hyperglycemia by Sonmez et al.34 They concluded 
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that changes in these corneal topographic parameters might be a potential source 
of error for refractive and cataract surgery during the treatment period of acute 
hyperglycemia. In patients with chronic DM, this study is the ﬁrst in which 
corneal shape has been measured by means of corrected Scheimpﬂug imaging. It 
is important to correct the Scheimpﬂug images for distortion due to the geometry 
of the camera and refraction of the anterior corneal surface in order to obtain an 
accurate measurement of the corneal thickness and posterior corneal surface.25 
The anterior corneal shape did not seem to be affected by DM, but the posterior 
corneal radius decreased due to the inﬂuence of DM, and this resulted in a small, 
but signiﬁcant change in posterior corneal power. However, the posterior corneal 
power contributes little to the overall refractive state of the eye, and even in the 
total corneal power (both anterior and posterior) no signiﬁcant difference was 
found between the diabetic groups and the control group. Therefore, chronic DM 
does not seem to signiﬁcantly inﬂuence the overall corneal power.
 In this study, the CCT of the two diabetic groups did not differ from that of 
the control group. These results are in agreement with the ﬁndings of Inoue et al, 
who found no signiﬁcant differences in CCT between 99 subjects with DM type 
2 and 97 healthy subjects.10 In smaller study groups, Keoleian et al.21 and Ziadi et 
al.22 also reported no differences in CCT between subjects with DM and healthy 
subjects. In the present study, CCT appeared not to be dependent on various 
systemic parameters such as duration of DM, glycated hemoglobin, actual blood 
glucose levels, and use of insulin. In 81 subjects with DM type 1, Busted et al 
also reported no signiﬁcant correlations between diabetes duration, blood glucose 
levels or use of insulin and CCT.19 However, in contrast to the present study they 
found an association between the level of retinopathy and CCT. In diabetic subjects 
with proliferative retinopathy, CCT was 566 µm compared to 544 µm and 527 µm 
in diabetic subjects without retinopathy and healthy subjects, respectively. Lee et 
al. reported that CCT increased signiﬁcantly with increasing duration of DM in 
200 diabetic subjects.18  Mean CCT was 596 μm, 582 μm and 567 μm in subjects 
with DM of more than 10 years, subjects with DM of less than 10 years, and 
healthy subjects, respectively. A main difference between the present study and 
the studies mentioned above were the measuring methods (Scheimpﬂug imaging 
versus ultrasound pachymetry). In order to perform ultrasound pachymetry, the 
velocity of sound in the cornea is needed. It could be that DM causes a change 
in this velocity of sound, because the different corneal layers are known to be 
affected by DM.5,8,9 This could result in a difference between the CCT of healthy 
subjects and the CCT of subjects with DM.  
 Several studies have shown that DM causes changes in corneal endothelial 
cell morphology, similar to those induced by aging.35,36 It could therefore be 
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hypothesized that DM causes premature aging of the eye. In healthy subjects, 
corneal asphericity was found to be age-dependent.33 Consequently, in diabetic 
subjects it could be assumed that asphericity would be affected more than in 
healthy subjects. This study shows that this is not the case, because no signiﬁcant 
change in the asphericity of the anterior or the posterior corneal surface was 
found. DM only has a signiﬁcant inﬂuence on the radius of the posterior corneal 
surface. Nonetheless, this inﬂuence is so small that it does not change the optical 
power of the diabetic cornea.
REFERENCES
1. Dobbs RE, Smith JP, Chen T, et al. Long-term follow-up of lens changes with 
Scheimpﬂug photography in diabetics. Ophthalmology 1987;94:881.90.
2. Logstrup N, Sjolie AK, Kyvik KO, et al. Lens thickness and insulin dependent diabetes 
mellitus: a population based twin study. Br J Ophthalmol 1996;80:405.8.
3. Sparrow JM, Bron AJ, Brown NA, et al. Biometry of the crystalline lens in early-onset 
diabetes. Br J Ophthalmol 1990;74:654.60.
4. Sparrow JM, Bron AJ, Phelps Brown NA, et al. Biometry of the crystalline lens in late 
onset diabetes: the importance of diabetic type. Br J Ophthalmol 1992;76:428.33.
5. Gekka M, Miyata K, Nagai Y, et al. Corneal epithelial barrier function in diabetic 
patients. Cornea 2004;23:35.7.
6. Morishige N, Chikama TI, Sassa Y, et al. Abnormal light scattering detected by 
confocal biomicroscopy at the corneal epithelial basement membrane of subjects with 
type II diabetes. Diabetologia 2001;44:340.5.
7. McNamara NA, Brand RJ, Polse KA, et al. Corneal function during normal and high 
serum glucose levels in diabetes. Invest Ophthalmol Vis Sci 1998;39:3.17.
8. Saini JS, Mittal S. In vivo quantiﬁcation of corneal endothelium function. Acta 
Ophthalmol Scand 1996;74:468.72.
9. Schultz RO, Matsuda M, Yee RW, et al. Corneal endothelial changes in type I and type 
II diabetes mellitus. Am J Ophthalmol 1984;98:401.10.
10. Inoue K, Kato S, Inoue Y, et al. The corneal endothelium and thickness in type II 
diabetes mellitus. Jpn J Ophthalmol 2002;46:65.9.
11. Itoi M, Nakamura T, Mizobe K, et al. Specular microscopic studies of the corneal 
endothelia of Japanese diabetics. Cornea 1989;8:2.6.
12. Schwartz DE. Corneal sensitivity in diabetics. Arch Ophthalmol 1974;91:174.8.
13. Rosenberg ME, Tervo TM, Immonen IJ, et al. Corneal structure and sensitivity in type 
1 diabetes mellitus. Invest Ophthalmol Vis Sci 2000;41:2915.21.
14. Foulks GN, Thoft RA, Perry HD, et al. Factors related to corneal epithelial 
Inﬂuence of DM on corneal thickness and shape
49
complications after closed vitrectomy in diabetics. Arch Ophthalmol 1979;97:1076.8.
15. Perry HD, Foulks GN, Thoft RA, et al. Corneal complications after closed vitrectomy 
through the pars plana. Arch Ophthalmol 1978;96:1401.3.
16. Halkiadakis I, Belfair N, Gimbel HV. Laser in situ keratomileusis in patients with 
diabetes. J Cataract Refract Surg 2005;31:1895.8.
17. Fraunfelder FW, Rich LF. Laser-assisted in situ keratomileusis complications in 
diabetes mellitus. Cornea 2002;21:246.8.
18. Lee JS, Oum BS, Choi HY, et al. Differences in corneal thickness and corneal 
endothelium related to duration in diabetes. Eye 2006;20:315.8.
19. Busted N, Olsen T, Schmitz O. Clinical observations on the corneal thickness and the 
corneal endothelium in diabetes mellitus. Br J Ophthalmol 1981;65:687.90.
20. Olsen T, Busted N, Schmitz O. Corneal thickness in diabetes mellitus. Lancet 
1980;1:883.
21. Keoleian GM, Pach JM, Hodge DO, et al. Structural and functional studies of the 
corneal endothelium in diabetes mellitus. Am J Ophthalmol 1992;113:64.70.
22. Ziadi M, Moiroux P, d’Athis P, et al. Assessment of induced corneal hypoxia in 
diabetic patients. Cornea 2002;21:453.7.
23. Aldington SJ, Kohner EM, Meuer S, et al. Methodology for retinal photography 
and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. 
Diabetologia 1995;38:437.44.
24. World Health Organization. Fact sheets on Diabetes Mellitus [WHO web site]. March 
1, 2007. Available at:http://www.who.int/mediacentre/factsheets/fs138/en/. Accessed 
September, 2006. 
25. Dubbelman M, Van der Heijde GL. The shape of the aging human lens: curvature, 
equivalent refractive index and the lens paradox. Vision Res 2001;41:1867.77.
26. Malacara D, ed. Geometrical and instrumental optics. Boston: Academic Press, 
1988.
27. Atchison DA, Smith G, ed. Optics of the human eye. Oxford: Butterworth-Heinemann, 
2000.
28. Kiely PM, Smith G, Carney LG. Meridional variations of corneal shape. Am J Optom 
Phys Opt 1984;61:619.26.
29. Rabbetts RB, ed. Clinical visual optics. Oxford: Butterworth-Heinemann, 1998.
30. Lee KE, Klein BE, Klein R, et al. Changes in refraction over 10 years in an adult 
population: the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 2002;43:2566.71.    
31. Wu SY, Yoo YJ, Nemesure B, et al. Nine-year refractive changes in the Barbados Eye 
Studies. Invest Ophthalmol Vis Sci 2005;46:4032.9.
32. Guzowski M, Wang JJ, Rochtchina E, et al. Five-year refractive changes in an older 
population: the Blue Mountains Eye Study. Ophthalmology 2003;110:1364.70.
33. Dubbelman M, Sicam VA, Van der Heijde GL. The shape of the anterior and posterior 
50
Chapter 2
surface of the aging human cornea. Vision Res 2006;46:993.1001.
34. Sonmez B, Bozkurt B, Atmaca A, et al. Effect of glycemic control on refractive 
changes in diabetic patients with hyperglycemia. Cornea 2005;24:531.7.
35. Carlson KH, Bourne WM, McLaren JW, et al. Variations in human corneal endothelial 
cell morphology and permeability to ﬂuorescein with age. Exp Eye Res 1988;47:27.41.
36. Chang SW, Hu FR. Changes in corneal autoﬂuorescence and corneal epithelial barrier 
function with aging. Cornea 1993;12:493.9.


CHAPTER 3
N.G.M. Wiemer, M. Dubbelman, P.J. Kostense, P.J. Ringens, B.C.P. Polak
THE INFLUENCE OF DIABETES MELLITUS TYPE 1 
AND 2 ON THE THICKNESS, SHAPE AND EQUIVALENT 
REFRACTIVE INDEX OF THE HUMAN CRYSTALLINE LENS
Accepted for publication (Ophthalmology)
54
Chapter 3
ABSTRACT
Purpose: To study the inﬂuence of diabetes mellitus (DM) type 1 and type 2 on 
the thickness, radius of curvature, equivalent refractive index and power of the 
crystalline lens. 
Methods: Lens thickness and the radius of the anterior and posterior surfaces of 
the lens were measured in 114 patients with DM type 1, 112 patients with DM type 
2 and 75 healthy control subjects by means of corrected Scheimpﬂug imaging. 
Ocular refractive error was determined with Hartmann-Shack aberrometry. 
The equivalent refractive index and the power of the lens were calculated from 
these parameters. Several systemic parameters (e.g. duration of DM, glycated 
hemoglobin, capillary blood glucose levels, and type of medication) and ocular 
comorbidity (e.g. level of diabetic retinopathy) were recorded.
Results: The lenses of the patients with DM type 1 were signiﬁcantly thicker and 
more convex, compared to those of the control group (p < 0.001). Furthermore, 
there was a signiﬁcant decrease in the equivalent refractive index of their lenses, 
compared to the control group. No difference in lens parameters was found between 
the patients with DM type 2 and the control group. In the DM type 1 group, the 
duration of DM was an important determinant of lens biometry; the independent 
effect of the duration of DM per year on lens thickness, anterior radius, posterior 
radius and equivalent refractive index was respectively 95%, 88%, 207%, and 
45% of the effect of age per year. Lens power and ocular refractive error were not 
affected by DM type 1 or type 2. 
Conclusions: The results of the present study show that DM type 1 has a major 
impact on lens biometry. Furthermore, the difference in effect of DM type 1 and 
type 2 on lens biometry may indicate a fundamental difference in pathogenesis. 
The decrease in equivalent refractive index of the lens appeared to compensate 
for the profound increase in lens convexity in patients with DM type 1, resulting 
in no signiﬁcant change in lens power or ocular refraction with the duration of 
DM.
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INTRODUCTION
The human lens continues to grow throughout life, due to the addition of new 
lens ﬁbers. As a result, the lens becomes thicker and more convex with age.1,2 
In patients with diabetes mellitus (DM) the lens has been found to become even 
thicker and more convex, compared to that of healthy subjects.3-11 In patients 
with DM type 1, Sparrow et al.5 found that the duration of DM is a powerful 
determinant of lens biometry. After correction for the effect of age, they reported 
that the independent effect of the duration of DM per year on lens thickness and 
curvature was respectively 68% and 88% of the effect of age per year. 
 The normal increase in convexity of the lens with age could be expected to result 
in an increase in lens power, and thus a tendency towards myopia. Nevertheless, 
in the healthy eye no such tendency could be observed and it was even found that 
there was a hyperopic shift in refractive error.12,13 This paradoxical occurrence of 
an increase in lens convexity with no myopic shift in ocular refractive error has 
been called the “lens paradox”.14 An explanation for this lens paradox was found 
in a decrease in the refractive index of the lens with age, which compensates for 
the more convex shape of the lens with age.2, 15-18
 As mentioned above, the increase in convexity of the diabetic lens with the 
duration of DM has been reported to be very large. Nevertheless, as in healthy 
subjects, large myopic shifts with age have not been consistently observed in 
patients with DM. Fledelius19 reported a myopic shift in patients with DM, 
compared to subjects with no DM. However, in the Beaver Dam Eye Study and 
in a study of a large rural South Indian population, a tendency towards hyperopia 
was found in patients with DM.20,21 Furthermore, no inﬂuence of DM on ocular 
refraction was observed in the Blue Mountains Eye Study.22,23 Therefore, the 
question that arises is whether the change in shape of the diabetic lens is perhaps 
smaller than previously reported, or that the large change in shape of the lens is 
compensated by a decrease in the equivalent refractive index, similar to that in 
the healthy eye. A decrease in the equivalent refractive index of the lens would 
prevent the diabetic eye from becoming more myopic with increasing age and 
duration of DM. 
 In order to answer this question, an accurate measurement of the biometry of 
the lens is necessary to make it possible to calculate the equivalent refractive 
index of the lens. This measurement can be obtained with corrected Scheimpﬂug 
imaging,2, 24 in which the distortion due to the refraction of the front and back 
surface of the cornea and the front surface of the lens is taken into account by 
individual ray-tracing. The correction of Scheimpﬂug images has been shown to 
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be important, because the refraction that occurs at the various ocular interfaces, 
and the distortion due to the geometry of the Scheimpﬂug camera, produce a 
distorted image of the anterior eye segment.2, 24, 26 
  Therefore, the aim of the present study was to accurately measure lens biometry 
in subjects with DM type 1 and type 2 by means of corrected Scheimpﬂug imaging, 
in order to study the inﬂuence of DM on the thickness and shape of the lens. We 
also calculated the equivalent refractive index of the lens from the Scheimpﬂug 
parameters, in combination with the equivalent refractive error and axial eye 
length measurements.1, 24 This, together with the calculation of the power of the 
lens, made it possible to investigate a compensation mechanism for the changes 
in lens biometry caused by DM. All lens parameters (thickness, anterior and 
posterior radius, equivalent refractive index and power) were compared to those 
of control subjects. Finally, in the two DM groups we investigated the inﬂuence 
of several systemic factors, such as the duration of DM, glycated hemoglobin 
(HbA1c), capillary blood glucose levels, the level of diabetic retinopathy (DRP), 
and the use of insulin, on lens biometry.  
MATERIALS AND METHODS
In this cross-sectional study, the right eye of a total of 301 subjects (75 control 
subjects, 114 patients with DM type 1 and 112 patients with DM type 2) was 
measured at the Department of Ophthalmology of the VU University Medical 
Center in Amsterdam. The diagnosis of DM type 1 or type 2 was established 
according to the guidelines issued by the World Health Organization.27 Participants 
with cataract, glaucoma, a history of intraocular surgery, or ocular pathology 
other than DRP were excluded. Age, duration of DM, HbA1c, and the type of 
medication were recorded. Capillary blood glucose levels were measured with a 
blood glucose analyzer (HemoCue Diagnostics BV, Oisterwijk, the Netherlands) 
before the ocular measurements were made. The Medical Ethics Committee of 
the VU University Medical Center in Amsterdam approved the protocol of the 
study, and written informed consent was obtained from all participants, according 
to the tenets of the Declaration of Helsinki. 
Ocular measurements
The right eye of each participant was measured after the administration of 1.0% 
cyclopentolate and 5% phenylephrine eye-drops to obtain maximal pupillary 
dilation and paralysis of accommodation. Images of the lens were obtained with 
a Topcon SL-45 Scheimpﬂug camera, equipped with a charge-coupled device 
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(CCD) camera (St-9XE, SBIG astronomical instruments, Santa Barbara, USA) 
with a range of 16 bits of grey values (512 x 512 pixels, pixel size 20 x 20 μm, 
magniﬁcation: 1x). One series of three Scheimpﬂug images was made in the 
vertical (90°) meridian along the optical axis. Ray-tracing was used to correct 
the images for distortion due to the geometry of the Scheimpﬂug camera and the 
refraction of the different ocular surfaces. The method used to correct Scheimpﬂug 
images has been described in detail by Dubbelman et al. (Fig 1).2 By combining 
the measurements of the corneal thickness (d1), the depth of the anterior chamber 
(ACD), the anterior (R1) and posterior (R2) radius of the cornea, the lens thickness 
(d3) and the anterior (R3) and posterior (R4) radius of the lens, the axial length 
of the eye, and the ocular refraction, it is possible to calculate the equivalent 
refractive index of the lens (n lens) by means of an iterative process.2, 24 
 The following formulas were applied to calculate the power (P) of the anterior 
and the posterior surface of the lens in diopters (D), with the refractive indices of 
the aqueous humor (n2), the lens (n 
lens
), the vitreous (n4), and the radius of the 
anterior (R3) and the posterior (R4) surface of the lens:
         (1)
       
Figure 1 Uncorrected (a) and corrected (b) Scheimpﬂug images of an 25 year old female. 
Note the thicker cornea (d1), lens (d3) and the increased anterior chamber depth (ACD) 
after correction for the distortions due to the geometry of the Scheimpﬂug camera and the 
refraction of the various ocular surfaces. R1 = anterior radius cornea, R2 = posterior 
radius cornea, R3 = anterior radius of the lens, R4 = posterior radius of the lens.
ba
R3
R4
d3
ACD
R1
R2
d1
P = anterior 
n n
R
lens − 2
3
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         (2)
       
The lens power (P) was calculated with the Lensmaker equation,28 with lens 
thickness (d3):
         (3)
      
In some older participants and participants who had DM for a long time, the 
posterior surface of the lens was not visible. Therefore, d3, R4, n
 lens
, and lens 
power could only be determined in 67 of the 75 control subjects, in 55 of the 
114 patients with DM type 1, and in 32 of the 112 patients with DM type 2. The 
other parameters (R3 and ACD) could be measured in all 301 subjects. The ocular 
refractive error was measured with an IRX3 aberrometer (Imagine Eye Optics, 
Paris, France), and calculated as: equivalent refractive error = sphere + (cylinder 
/ 2). The axial length of the eye was measured with an IOL-master (Carl Zeiss 
Inc., North America). The ACD was determined by measuring the distance from 
the anterior surface of the cornea to the anterior surface of the lens. 
 The level of DRP was graded from two-ﬁeld digital color 45° fundus 
photographs by two independent ophthalmologists (BP, PR) according to the 
EURODIAB classiﬁcation system.29 For practical reasons, the EURODIAB 
levels of retinopathy were sub-divided into three categories; retinopathy absent 
(EURODIAB level 0), retinopathy present (EURODIAB levels 1, 2, 3) and 
retinopathy after photocoagulation or proliferative retinopathy (EURODIAB 
level 4 or 5).
Statistical analysis
First of all, preliminary analysis of the lens biometry was performed by means 
of simple linear regression of the lens parameters against age in each group 
separately. The linearity of the effect of age on the lens parameters was determined 
from normal probability plots of regression-standardized residuals; the age-effect 
was linear in each group. Multiple linear regression analysis was then applied 
to test the inﬂuence of various independent variables (such as duration of DM, 
HbA1c or capillary blood glucose levels) on the lens parameters in the DM 
groups. Furthermore, multiple linear regression analysis was also performed to 
study signiﬁcant differences between the three groups. The independent variable 
P = posterior 
n n
R
lens4
4
−
P= P P P P anterior posterior anterior posterior+ − d
nlens
3
Inﬂuence of DM on the shape of the lens
59
age and/or duration of DM was added to adjust for the effect of age and/or the 
duration of DM. A difference in regression slopes between the groups was tested 
by adding a product-term to the model. In the analysis of the equivalent refractive 
error, a quadratic covariate (age-mean age)2 was added to the model, since the 
equivalent refractive error is known to change slightly with age.12, 20, 22 All data 
were approximately normally distributed, and two-sided p-values < 0.05 were 
considered to be statistically signiﬁcant. All analyses were performed with SPSS 
14.0 software.
RESULTS
The baseline characteristics of the three groups are presented in Table 1. The 
mean age in the two diabetic groups differed signiﬁcantly from that of the 
control group (p < 0.001). No statistically signiﬁcant difference was found in the 
equivalent refractive error or axial eye length between the three groups. There 
was a signiﬁcant difference in the duration of DM, HbA1c and blood glucose 
levels between the two DM groups. 
 Preliminary simple linear regression analyses demonstrated the important and 
signiﬁcant effect of age on lens biometry and ACD in the three groups. This 
effect has been shown in Figures 2 to 6. From these graphs it can also be seen 
that the slopes of the regression lines of the lens parameters of the DM type 
1 group are steeper than those of the control group or the DM type 2 group. 
These preliminary results were conﬁrmed by the multiple regression analyses, in 
which adjustments were made for the effect of age. DM type 1 appeared to be a 
powerful and signiﬁcant determinant of lens biometry. After adjustment for age, 
the lenses of the patients with DM type 1 were signiﬁcantly thicker, were more 
convex, and had a lower equivalent refractive index and ACD than those of the 
control group (Table 2). 
 Furthermore, a signiﬁcant difference in the regression slopes of lens thickness 
d3 (95% CI: 0.001 to 0.018; p = 0.021), anterior radius R3 (95% CI: -0.064 to 
-0.009; p = 0.009), posterior radius R4 (95% CI: -0.043 to -0.002; p = 0.031), 
equivalent refractive index nlens (95% CI: -0.001 to -0.0001; p = 0.006) and 
ACD (95% CI: -0.017 to -0.001; p = 0.025) was found between the DM type 
1 group and the control group. DM type 2 had no signiﬁcant effect on the lens 
parameters or ACD (Table 2), and the regression slopes of the lens parameters 
(d3, R3, R4, n lens, and ACD) in the DM type 2 group did not differ from those 
of the control group. To investigate whether the difference in lens parameters was 
entirely due to the inﬂuence of DM, comparisons with adjustments for age and 
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Control group
(n = 75)
DM type 1
(n = 114)
DM type 2
(n = 112)
Age in y; ( range) 36.8 ± 13.5;(18-64) 41.0 ± 11.6;(18-65)* 58.5 ± 8.6; (36-76)*
Gender (male/female) (n) 32 / 43 62 / 52 62 / 50
Equivalent refractive error (D)a -0.94 ± 2.64 -0.62 ± 2.48 0.20 ± 2.72
Axial eye length (mm) 24.0 ± 1.2 23.6 ± 1.0 23.5 ± 0.8
Duration of diabetes (y)a 22.5 ± 12.0 9.0 ± 7.4***
Glycated hemoglobin (%) 8.0 ± 1.5 7.5 ± 1.5**
Capillary blood glucose (mmol/l) 9.6 ± 4.5 8.0 ± 3.4***
Medication (n / total n)
   Insulin 114 / 114 (100%) 65 / 112 (58%)
   Other (oral anti-diabetics or diet) 0 / 114 (0%) 47 / 112 (42%)
Retinopathy (n / total n)b
   Retinopathy absent  
      EURODIAB 0 56 / 114 (49%) 76 / 112 (67%)
   Retinopathy present 
      EURODIAB 1 13 / 114 (11%) 12 / 112 (11%)
      EURODIAB 2 9 / 114 (8%) 9 / 112 (8%)
      EURODIAB 3 1 / 114 (0.9%) 3 / 112 (3%)
Retinopathy after photocoagulation 
or proliferative retinopathy
      EURODIAB 4 34 / 114 (30%) 12 / 112 (11%)
      EURODIAB 5 1 / 114 (0.9%) 0 / 112 (0%)
Data are presented as mean ± SD. aComparisons between the groups in equivalent refractive error and duration 
of diabetes were adjusted for age. bRetinopathy was sub-divided into three categories; retinopathy absent 
(EURODIAB level 0), retinopathy present (EURODIAB level 1,2,3), and retinopathy after photocoagulation 
or proliferative retinopathy (EURODIAB level 4 or 5). * Signiﬁcantly different compared to the control 
group, p = 0.04 (DM type 1) and p < 0.001 (DM type 2). ** Signiﬁcantly different compared to the DM type 
1 group, p = 0.02. *** Signiﬁcantly different compared to the DM type 1 group, p < 0.01.  
Table 1 Baseline characteristics of the control group and the two DM groups (DM type 
1 and type 2)
duration of DM were made between the three groups. No signiﬁcant differences 
in lens parameters or ACD were found between the three groups after correction 
for age and duration of DM. 
 In the DM type 1 group the duration of DM was found to have a signiﬁcant 
inﬂuence on the lens parameters d3, R3, R4, n lens, and ACD (p < 0.05) (Table 
3). In this group, the independent effect of the duration of DM per year on d3, 
R3, R4, n lens, and ACD was 95%, 88%, 207%, 45%, and 75% of the effect of 
age per year, respectively. The important effect of the duration of DM on a DM 
type 1 lens is illustrated in Figure 7, which shows a 37-year age-effect and an 
additional 31-year duration of DM effect on lens biometry. In the DM type 2 
group, a signiﬁcant effect of the duration of DM on R3 was found (Table 3). 
The effect of the duration of DM on the lens parameters was equal in males and 
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Figure 3 Graph of preliminary data of the anterior lens radius (R3) against age in the 
three groups. Slopes are presented with standard errors (± SE), r = regression coefﬁcient. 
Control group: R3 = 12.79 (± 0.41) - 0.064 (± 0.010) * age, n = 75, r = 0.58, p < 0.001. 
DM type 1: R3 = 13.11 (± 0.40) - 0.101 (± 0.010) * age, n = 114, r = 0.70, p < 0.001. DM 
type 2: R3 = 12.27 (± 0.72) - 0.053 (± 0.012) * age, n = 112, r = 0.38, p < 0.001.
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Figure 2 Graph of preliminary data of the lens thickness (d3) against age in the three 
groups. Slopes are presented with standard errors (± SE), r = regression coefﬁcient. 
Control group: d3 = 3.14 (± 0.07) + 0.021 (± 0.002) * age, n = 67, r = 0.83, p < 0.001. 
DM type 1: d3 = 3.00 (± 0.15) + 0.031 (± 0.004) * age, n = 55, r = 0.71, p < 0.001. DM 
type 2: d3 = 3.10 (± 0.29) + 0.021 (± 0.006) * age, n = 32, r = 0.59, p = 0.001.
62
Chapter 3
Figure 4 Graph of preliminary data of the posterior lens radius (R4) against age in the 
three groups. Slopes are presented with standard errors (± SE), r = regression coefﬁcient. 
Control group: R4 = 6.49 (± 0.17) - 0.015 (± 0.005) * age, n = 67, r = 0.38, p = 0.002. 
DM type 1: R4 = 6.89 (± 0.33) - 0.037 (± 0.009) * age, n = 55, r = 0.48, p < 0.001. DM 
type 2: R4 = 6.27 (± 0.74) - 0.015 (± 0.014) * age, n = 32, r = 0.19, p = 0.29.
Figure 5 Graph of preliminary data of the equivalent refractive index (nlens) of the lens 
against age in the three groups. Slopes are presented with standard errors (± SE), r = 
regression coefﬁcient. Control group: nlens = 1.444 (± 0.003) - 0.0004 (± 0.0001) * age, 
n = 67, r = 0.58, p < 0.001. DM type 1: nlens = 1.452 (± 0.003) - 0.0007 (± 0.0001) * 
age, n = 55, r = 0.74, p < 0.001. DM type 2: nlens = 1.441 (± 0.008) - 0.0004 (± 0.0001) 
* age, n = 32, r = 0.44, p = 0.012.
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Figure 6 Graph of preliminary data of the anterior chamber depth (ACD) against age 
in the three groups. Slopes are presented with standard errors (± SE), r = regression 
coefﬁcient. Control group: ACD = 4.04 (± 0.12) - 0.016 (± 0.003) * age, n = 75, r = 0.53, 
p < 0.001. DM type 1: ACD = 4.27 (± 0.11) - 0.025 (± 0.003) * age, n = 112, r = 0.68, 
p < 0.001. DM type 2: ACD = 3.90 (± 0.22) - 0.013 (± 0.004) * age, n = 114, r = 0.31, 
p = 0.001.
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females in the two DM groups. 
 No signiﬁcant effect of age on the lens power (Fig 8) or the equivalent refractive 
error could be demonstrated in any of the three groups. Furthermore, neither the 
lens power nor the equivalent refractive error differed between the groups. No 
signiﬁcant association was found between the duration of DM and lens power or 
equivalent refractive error.   
 In order to determine associations between the lens biometry and various 
systemic factors, such as HbA1c, capillary blood glucose levels, and use of 
insulin, multiple regression analysis was performed for each of these variables in 
the two DM groups. HbA1c and capillary blood glucose levels had no signiﬁcant 
inﬂuence on the various lens parameters. In the DM type 2 group there was no 
difference in the lens parameters of patients who used insulin, patients who took 
oral medication, and patients who were on a diet. After adjustment for age only, 
R3 in the DM type 1 group was signiﬁcantly decreased in patients with DRP 
after photocoagulation or proliferative DRP (EURODIAB 4 or 5), compared to 
patients with no DRP (mean difference [± SE] = 0.82 [± 0.25] mm, 95% CI = 
0.21 to 1.43 mm, p = 0.005) or with mild DRP (EURODIAB 1, 2, or 3) (mean 
difference [± SE] = 1.08 [± 0.24] mm, 95% CI = 0.51 to 1.65 mm, p < 0.001). In 
the DM type 2 group, R3 was only signiﬁcantly decreased after adjustment for age 
in patients with DRP after photocoagulation or proliferative DRP (EURODIAB 
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Mean values for 
both groups 
(± SE)
Difference in 
the means
(± SE)
95% Conﬁdence 
Interval for the 
difference in the 
meansa
P-valuea
d3 (mm)
Control group and DM type 
1*
3.95 ± 0.03 and 
4.15 ± 0.03
-0.20 ± 0.04 -0.30  to  -0.09 < 0.001
Control group and DM type 2
3.95 ± 0.03 and 
3.85 ± 0.05
0.10 ± 0.06 -0.05  to  0.25  0.287
R3 (mm)
Control group - DM type 1*
9.72 ± 0.14 and 
8.61 ± 0.11
1.11 ± 0.17 0.69  to  1.52 < 0.001
Control group - DM type 2
9.72 ± 0.14 and 
10.12 ± 0.13
-0.40 ± 0.22 -0.92  to  0.12 0.196
R4 (mm)
Control group - DM type 1*
5.89 ± 0.07 and 
5.52 ± 0.08
0.37 ± 0.11 0.11  to  0.63  0.003
Control group - DM type 2
5.89 ± 0.07 and 
5.79 ± 0.12
0.09 ± 0.15 -0.27  to  0.46 > 0.99
n 
lens
Control group - DM type 1*
1.429 ± 0.001 
and 1.425 ± 
0.001
0.004 ± 0.001 0.001  to  0.007 0.007
Control group - DM type 2 
1.429 ± 0.001 
and 1.428 ± 
0.001
0.001 ± 0.002 -0.003  to  0.005 > 0.99
ACD (mm)
Control group - DM type 1*
3.29 ± 0.04 and 
3.16 ± 0.03
0.13 ± 0.05 0.11  to  0.25 0.027
Control group - DM type 2 
3.29 ± 0.04 and 
3.37 ± 0.04
-0.08 ± 0.06 -0.23  to  0.07 0.597
d3 = lens thickness; R3 = anterior lens radius; R4 = posterior lens radius; n lens = equivalent refractive 
index of the lens; ACD = anterior chamber depth. SE = standard err   of the means. a Bonferroni post hoc 
corrections were applied to these data. * Signiﬁcantly different compared to the control group, p < 0.05.
Table 2 Differences in the various lens parameters and anterior chamber depth, adjusted 
for age, when comparing the DM groups (DM type 1 and type 2) with the control group
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Figure 8 Graph of preliminary data of the power (P) of the lens against age in the three 
groups. Slopes are presented with standard errors (± SE), r = regression coefﬁcient. 
Control group: P = 24.95 (± 0.73) - 0.010 (± 0.020) * age, n = 67, r = 0.07, p = 0.61. DM 
type 1: P = 25.15 (± 1.05) - 0.009 (± 0.030) * age, n = 55, r = 0.001, p = 0.99. DM type 
2: P = 24.76 (± 2.06) - 0.015 (± 0.039) * age, n = 32, r = 0.07, p = 0.70.
Figure 7 The 37-year age-effect in a healthy lens (left Scheimpﬂug image) and the 37-
year age-effect with an additional 31-year duration of DM effect in a DM type 1 lens 
(right Scheimpﬂug image). With increasing duration of DM, the lens (d3) becomes thicker 
and more convex (R3 and R4), and the depth of the anterior chamber (ACD) decreases.
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4 or 5), compared to patients with mild DRP (EURODIAB 1, 2, or 3) (mean 
difference [± SE] = 0.61 [± 0.25] mm, 95% CI = 0.01 to 1.22 mm, p = 0.045). In 
both diabetic groups, the tests for linear trend were signiﬁcant (DM type 1: p < 
0.001 and DM type 2: p = 0.008), which means that R3 decreases as the severity 
of DRP increases. However, R3 or any of the other lens parameters of patients 
in the two DM groups were not affected by the level of DRP after adjustment for 
age and duration of DM. 
DISCUSSION
The aim of the present study was to study the inﬂuence of DM on the thickness, 
shape, equivalent refractive index, and power of the lens by measuring these 
parameters in patients with DM type 1 and type 2, and to compare them with 
those of control subjects. The results of this study conﬁrm the previous ﬁndings 
that DM type 1 has a profound effect on lens biometry. Furthermore, it adds to this 
knowledge the calculation of the equivalent refractive index of the lens, which was 
found to decrease signiﬁcantly with age and duration of DM. It was also found 
that DM type 1 appeared to have a large impact on lens biometry, whereas DM 
type 2 did not affect the lens thickness, shape or equivalent refractive index.   
Corrected Scheimpﬂug imaging2, 24 was used to measure the lens biometry. It is 
important to correct the Scheimpﬂug images, because of the distortion due to the 
geometry of the camera and the refraction of the different ocular surfaces. This 
method has been shown to be accurate and reproducible in both in vivo and in 
vitro method validation experiments.1, 2, 24 
 Several studies have investigated the effect of DM type 1 on the thickness and/
or shape of the lens.3-5, 7-11 In the present study, an increase in average lens thickness 
of 0.2 mm was found in the DM type 1 group, which is in agreement with the 
results of Fledelius et al.4 and Pierro et al..9 Furthermore, the duration of DM had 
an important effect on the thickness and shape of the lens. The independent effect 
of the duration of DM on lens thickness and the anterior and posterior radius 
was 95%, 88%, and 207%, respectively, of the age-effect per year. Sparrow et 
al. reported 68%, 88% and 52% for the lens thickness, anterior and posterior 
radius, respectively.5 The difference between the percentages for lens thickness 
and posterior radius could be due to the fact that Sparrow et al. used uncorrected 
Scheimpﬂug imaging, which could possibly have resulted in an underestimation 
of the lens thickness, and especially the posterior radius.
 Despite the signiﬁcant changes in lens biometry that were found in the DM 
type 1 group, ocular refraction did not change signiﬁcantly with the duration 
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of DM. This is in contrast to the ﬁndings of Fledelius et al., who explained a 
myopic shift in DM with an increase in lens thickness.4 In the present study the 
equivalent refractive index of the lens was calculated, and it was found to decrease 
signiﬁcantly with age in the control group, and to decrease even more with age 
and duration of DM in the DM type 1 group. Therefore, the additional decrease in 
equivalent refractive index of the lens appeared to compensate for the profound 
increase in lens convexity due to DM type 1. The fact that the lens power was 
not affected by the duration of DM, and also did not differ between the groups, 
conﬁrms this ﬁnding.
 The origin of the decrease in equivalent refractive index of the lens remains 
unclear. It has been suggested that the water content of the healthy lens increases 
with age,30 and that this could result in a decrease in refractive power. This could 
also be true for the diabetic lens. Furthermore, the increase in the dimensions 
of the diabetic lens may be due to an abnormality in the growth of the lens, a 
swelling of the lens, or a decrease in central compaction of the mature lens ﬁbers. 
The growth of the healthy lens has been reported to be almost entirely due to an 
increase in one of the zones (C2) of the cortex.31-33 A close analysis of the size of 
the alternating light and dark zones in the cortex and the size of the nucleus of the 
diabetic lens could possibly identify the cause of the increase in dimensions of 
the lens in patients with DM, i.e., if the rate of production of the lens ﬁbers was 
enhanced, an increase in zone C2 of the cortex would occur. On the other hand, 
if cellular or extracellular overhydration occurred, resulting in a swelling of the 
lens as a whole or an increase in the size of the individual lens ﬁbers, there would 
be an increase in all the different zones of the lens.   
 Surprisingly, no signiﬁcant differences in lens biometry were found between the 
DM type 2 group and the control group, and no signiﬁcant effect of the duration 
of DM on the lens could be determined, except for the anterior lens radius. These 
results agree with the ﬁndings of Sparrow et al., who observed a signiﬁcant effect 
of the duration of DM on lens biometry in a DM type 1 group, but not in a DM 
type 2 group.6 They suggested that this was because the exact duration of the 
disease was unknown in DM type 2. Nonetheless, the duration of DM type 2 is 
generally under-estimated, which would even amplify any genuine relationship of 
lens biometry with duration of DM. In the present study the posterior lens radius 
(and thus the lens thickness and the equivalent refractive index of the lens) was 
not easy to examine because of the thickening of the lens with age. This resulted 
in less measurements of DM type 2 lenses. However, the anterior chamber depth 
could be examined in all DM type 2 patients, and no change was found with the 
duration of DM. This indicates that any effect of the duration of DM on lens 
thickness in the DM type 2 group would have been minor. Furthermore, it can be 
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concluded that DM type 1 and type 2 most likely have a different impact on lens 
biometry. 
 All patients with DM type 1, and 58% of the patients with DM type 2, used 
insulin. The effect of insulin on lens biometry was investigated in the DM type 
2 group, but no association was found between the lens parameters and the use 
of insulin in this group. Despite the fact that in vitro studies have shown that 
insulin can stimulate mitogenesis of the epithelial cells of the lens, and that it is 
capable of inducing hypertrophy in epithelial tissues,34,35 there is no agreement 
on the effect of insulin on lens biometry in the results of clinical studies. Pierro 
et al.9 reported a lack of correlation between lens thickness and insulin dosage 
in insulin-dependent DM patients, and Sparrow et al.5 observed an increase in 
the anterior clear zone of the lens with an increase in the daily insulin dose. 
Furthermore, in the present study the effect of DM control on lens biometry was 
determined by means of HbA1c and capillary blood glucose levels. No signiﬁcant 
association was found between blood glucose levels and lens biometry, which is 
in accordance with the ﬁndings of Pierro et al..9 However, it could be that a more 
prolonged follow-up of the blood glucose levels could provide evidence for an 
association between DM control and lens biometry. 
 A relationship between the level of retinopathy and lens biometry was found 
in both DM groups. A longer duration of DM increases the risk of developing 
retinopathy,36,37 and with a longer duration of DM the lens thickness and convexity 
have been found to increase. This was likewise concluded by Pierro et al.9 and 
Sparrow et al..5 However, after adjusting for both age and duration of DM, the 
association between the level of retinopathy and lens biometry disappeared. This 
indicates that the association was presumably entirely due to the inﬂuence of the 
duration of DM, and not a diffusion of a growth factor from the posterior eye 
segment, as hypothesized by Sparrow et al..6
 In conclusion, the results of the present study indicate that DM type 1 has 
a major impact on lens biometry. The substantial differences in effect on lens 
biometry between DM type 1 and type 2 may indicate a fundamental difference 
in pathogenesis. In patients with DM type 1, the decrease in equivalent refractive 
index of the lens appeared to compensate for the profound increase in lens 
convexity, resulting in no signiﬁcant change in lens power or ocular refraction 
with the duration of DM.  
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ABSTRACT
Purpose: To investigate the effect of diabetes mellitus (DM) type 1 and type 2 on 
the internal structure of the lens.   
Design: Observational cross-sectional study
Methods: Scheimpﬂug photography was used to image the lens of the right eye of 
213 patients with DM (type 1: 107, type 2: 106) and 75 healthy control subjects. 
The densitogram of the Scheimpﬂug image was used to indicate the nucleus and 
the different layers of the cortex of the lens. Lenses with cataract were excluded. 
Results: The nucleus and the different cortical layers of the DM type 1 lenses 
were signiﬁcantly thicker, compared to those of the control group (p < 0.001). 
A signiﬁcant association was found between the duration of DM type 1 and 
both the anterior and posterior cortex, its different layers, and the nucleus (p < 
0.001). The increase in the anterior and posterior cortex with the duration of DM 
was comparable to that of the nucleus. No important differences in the internal 
structure of the lens were found between the patients with DM type 2 and the 
control group.
Conclusions: DM type 1 has a signiﬁcant effect on the internal structure of the 
lens. The difference in effect of DM type 1 and type 2 on internal lens structure 
suggests an essential difference in pathogenesis. Furthermore, the results of the 
present study may indicate that the increase in the size of the lens with DM type 1 
is the result of a generalized swelling of the lens, affecting all its different parts.
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INTRODUCTION
It is well-known that the human lens continues to grow throughout life, and that 
it becomes more convex and thicker with age.1-3 In patients with diabetes mellitus 
(DM), the lens has been reported to become even thicker and more convex with 
age, compared to that in healthy subjects.4-12 After adjustment for the effect of age, 
the independent effect of the duration of DM per year on lens thickness was more 
than 70% of the effect of age per year.6,7
 The physiological thickening of the normal lens with age has been reported to 
be primarily due to an increase in the anterior and posterior cortex of the lens.13-
16 This was investigated by means of Scheimpﬂug photography, which provides 
a detailed image of the various anatomic regions of the lens (i.e. the cortex 
and the nucleus, as well as alternating light and dark areas within the anterior 
and posterior cortex).17 These different light and dark areas can be categorized 
according to the Oxford Clinical Cataract Classiﬁcation and Grading System.13,18 
In this system the cortical areas are divided into four zones: C1 to C4. Zones C1 
and C3 are zones of high light scatter, whereas zones C2 and C4 are zones of low 
light scatter (Fig 1). It appeared that the increase in the cortex of the normal lens 
with age was entirely the result of an increase in one particular zone (C2) of the 
anterior and posterior cortex.13,14,16 
 The origin of the profound increase in the dimensions of the lens in DM has 
not yet been explained. Sparrow et al. found that the increase in lens biometry in 
patients with DM type 1 was due to an increase in both the cortex and the nucleus 
of the lens, and they observed that the cortex of the diabetic lens was affected 
more than the nucleus.6 This effect was markedly less apparent in patients with 
DM type 2.7 However, these studies did not investigate the inﬂuence of DM on 
the different cortical zones of the lens. Knowledge about changes in the internal 
structure of the lens with DM could provide insight into the cause of the increase 
in the size of the diabetic lens. For example, an increase in the C2 zone of the 
cortex of the lens, as observed in the physiologically ageing lens, could imply 
an enhanced rate of lens ﬁber production. On the other hand, an increase in all 
different zones of the lens could be the result of cellular or extracellular swelling 
of the lens. Furthermore, in order to examine the thickness of the different layers 
within the lens, an accurate measurement of the lens is necessary. This can be 
obtained with corrected Scheimpﬂug imaging, which takes into account the 
distortion caused by the geometry of the Scheimpﬂug camera and the refraction 
of the cornea and the lens itself.2,3,19 
 The aim of the present study was to investigate the various cortical zones 
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and the nucleus of the crystalline lens in patients with DM type 1 and 2, and in 
healthy control subjects, by means of corrected Scheimpﬂug imaging.2,3 In the 
two diabetic groups we also investigated the inﬂuence on the internal structure 
of the lens of several systemic factors, such as the duration of DM, glycated 
hemoglobin (HbA1c), capillary blood glucose, the level of diabetic retinopathy 
(DRP), and the use of insulin. 
METHODS
In the present study, the right eye of 288 subjects (75 healthy control subjects, 
107 patients with DM type 1 and 106 patients with DM type 2) was examined 
at the Department of Ophthalmology of the VU University Medical Center in 
Amsterdam. The diagnosis of DM type 1 or type 2 was determined according 
to the guidelines published by the World Health Organization.20 The baseline 
characteristics of the three groups are presented in Table 1. Subjects with 
cataract, glaucoma, a history of intraocular surgery, or ocular pathology other 
than DRP were excluded from the study. Capillary blood glucose levels were 
measured with a blood glucose analyzer (HemoCue Diagnostics BV, Oisterwijk, 
the Netherlands). The Medical Ethics Committee of the VU University Medical 
Center in Amsterdam approved the protocol of this study, and all participants 
have given their written informed consent, in accordance with the tenets of the 
Declaration of Helsinki. 
Ocular measurements 
1.0% Cyclopentolate and 5% phenylephrine eye-drops were administered to 
obtain maximal pupillary dilation and paralysis of accommodation. Images of the 
lens were obtained with a Topcon SL-45 Scheimpﬂug camera, equipped with a 
charge-coupled device (CCD) camera (St-9XE, SBIG Astronomical Instruments, 
Santa Barbara, USA) with a range of 16 bits of grey values (512 x 512 pixels, 
pixel size 20 x 20 μm, magniﬁcation: 1x). One series of three Scheimpﬂug images 
was made in the vertical (90°) meridian along the optical axis. The initial stage 
in the analysis of the Scheimpﬂug images was to identify the different zones 
within the lens. It was not possible to measure each zone in the lens accurately 
for all 288 subjects, and therefore the number of measurements differed for each 
zone. This was mainly because the posterior region of the lens was difﬁcult to 
visualize in some older participants and in patients who had had DM for a long 
time. The Oxford Clinical Cataract Classiﬁcation and Grading System was used 
to distinguish the different layers in the anterior and posterior cortex of the lens 
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(Fig 1).13 This system makes use of the gradient of a densitogram, indicated in the 
lower part of Figure 1. The densitogram itself (upper part of Figure 1) consists 
of the grey values of the Scheimpﬂug image along a sagittal strip of 8 pixels ( 
1 pixel = ± 0.025 mm) on either side of a line through the vertex of the anterior 
lens surface. The gradient of the densitogram represents the rate of change of 
the densitogram, and from the maxima of this gradient the different layers in 
the anterior and posterior cortex could be determined. Zone C1 consists of a 
narrow dark (C1α, or anterior clear zone) and light (C1β, or line of disjunction) 
zone behind the lens capsule. For the sake of convenience, no distinction was 
made between these two sub-zones within the C1 zone in the present study. Zone 
Figure 1 Scheimpﬂug image of a 32-year old healthy male. According to the Oxford 
Classiﬁcation System, the different anterior and posterior cortical zones (C1 – C3) and 
the nucleus can be deﬁned from the local maximums of the gradient of the densitogram. 
In the present study the anterior cortex is represented by a summation of zones C1, C2, 
and C3. The same holds true for the posterior cortex. The nucleus is deﬁned as the region 
between the anterior and posterior C3 zones.
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C2 is a zone of low light scatter and the subsequent C3 zone is a zone of high 
light scatter. In the present study the nucleus was deﬁned as the area between 
the anterior and posterior C3 zone, because the C4 low light scatter zone was 
difﬁcult to distinguish. Furthermore, the anterior cortex is a summation of the 
anterior C1 to C3 zones, and the same holds true for the posterior cortex. After 
the different cortical zones had been determined, the Scheimpﬂug image was 
corrected for distortion due to the geometry of the Scheimpﬂug camera and due 
to the refraction of the different ocular surfaces, by means of ray-tracing.2,3 
The level of DRP was determined, from two-ﬁeld digital color 45° fundus 
photographs, by two independent ophthalmologists (BP, PR) who used the 
EURODIAB classiﬁcation system.21 For practical reasons, the EURODIAB levels 
of DRP were sub-divided into three categories; DRP absent (EURODIAB level 
0), DRP present (EURODIAB levels 1, 2, 3) and DRP after photocoagulation 
and/or proliferative DRP (EURODIAB level 4 or 5). 
Statistical analysis
Firstly, preliminary analysis was carried out by means of simple linear regression 
of the various zones of the lens to test the inﬂuence of age on the lens zones in 
each group separately. The linearity of the effect of age on the lens zones was 
determined from normal probability plots of regression-standardized residuals; 
the age-effect was linear in each group. Multiple linear regression analysis was 
then performed to analyze the effect of other covariates (such as duration of DM, 
HbA1c or capillary blood glucose levels) on the internal structure of the lens in 
the two DM groups. Multiple linear regression analysis was also performed to 
study differences between the three groups. The independent variables of age 
and/or duration of DM were added to the model to adjust for the effect of age and/
or the duration of DM. Differences in regression slopes between the groups were 
investigated by adding a product-term to the model. All data were approximately 
normally distributed, and two-sided p-values < 0.05 were considered to be 
statistically signiﬁcant. All analyses were performed with SPSS 14.0 software. 
RESULTS
The mean age of the control group differed signiﬁcantly from that of the DM type 
2 group (p < 0.001), but was comparable to that of the DM type 1 group (Table 
1). Furthermore, the duration of DM was signiﬁcantly longer in the DM type 1 
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Control group
(n = 75)
DM type 1
(n = 107)
DM type 2
(n = 106)
Age in yrs; ( range) 36.8 ± 13.5; (18-64) 40.3 ± 10.8; (18-65) 58.1 ± 8.4; (36-76)*
Gender (male/female) (n) 32 / 43 61 / 46 58 / 48
Duration of diabetes (y)a 22.5 ± 11.6 9.0 ± 7.4**
Glycated hemoglobin (%) 8.1 ± 1.6 7.5 ± 1.5**
Capillary blood glucose 
(mmol/l)
9.5 ± 4.5 7.9 ± 3.3**
Medication (n / total n)
   Insulin 107 / 107 (100%) 62 / 106 (58%)
   Other 
   (oral anti-diabetics or diet)
0 / 107 (0%) 44 / 106 (42%)
Retinopathy (n / total n)b
   Retinopathy absent  
      EURODIAB 0 54 / 107 (51%) 72 / 106 (68%)
   Retinopathy present 
      EURODIAB 1 12 / 107 (11%) 10 / 106 (9%)
      EURODIAB 2 8 / 107 (7%) 9 / 106 (9%)
      EURODIAB 3 1 / 107 (1%) 3 / 106 (3%)
Retinopathy after 
photocoagulation     or 
proliferative retinopathy
      EURODIAB 4 31 / 107 (29%) 12 / 106 (11%)
      EURODIAB 5 1 / 107 (1%) 0 / 106 (0%)
Data are presented as mean ± SD. aComparisons between the groups in duration of DM were adjusted 
for age. bRetinopathy was sub-divided into three categories; retinopathy absent (EURODIAB level 0), 
retinopathy present (EURODIAB level 1,2,3), and retinopathy after photocoagulation or proliferative 
retinopathy (EURODIAB level 4 or 5). * Signiﬁcantly different compared to the control group, p < 0.001. 
** Signiﬁcantly different compared to the DM type 1 group, p < 0.01.  
Table 1 Baseline characteristics of the control group and the two DM groups (DM type 
1 and type 2)
group, compared to the DM type 2 group (p < 0.01). The metabolic control of DM 
was slightly worse in the DM type 1 group than in the DM type 2 group (HbA1c: 
p = 0.009 and capillary blood glucose level: p = 0.004) (Table 1).     
 Preliminary analysis showed that age appeared to have an important effect on 
the internal structure of the lens in all three groups. This is illustrated in Figures 2 
and 3, which show graphs of the effect of age on the anterior and posterior cortex 
and the nucleus of the lens (Fig 2), and on the cortical zones of the lens (Fig 3) 
in the three groups. In the control group the lens thickness was found to increase 
with age, primarily because of an increase in the anterior and posterior cortex of 
the lens (Fig 2). This increase was approximately 1.6 times greater in the anterior 
cortex than in the posterior cortex. Furthermore, it was entirely due to an increase 
in the C2 zone of the cortex (Fig 3). From these graphs it can also be seen that 
the slopes of the regression lines of all the different lens zones of the DM type 1 
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Figure 2 Preliminary graphs of the effect of age on the anterior (a) and posterior (b) 
cortex, and the nucleus (c) of the lens in the control group and the two DM groups. See 
Figure 1 for the classiﬁcation of the different zones of the lens. In the control group 
the anterior and posterior cortex increased signiﬁcantly with age (anterior cortex [± 
standard error] = 0.43 [± 0.04] + 0.011 [± 0.001]*age, n = 75, r = 0.78, p < 0.001; 
posterior cortex [± standard error] = 0.29 [± 0.04] + 0.007 [± 0.001]*age, n = 55, r = 
0.67, p < 0.001).
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Figure 3 Preliminary graphs of the effect of age on the C1, C2, and C3 zones of the 
anterior (a-c) and posterior cortex (d-f) of the lens in the control group and the two DM 
groups. See Figure 1 for the classiﬁcation of the different zones of the lens. In the control 
group the C2 zones of the anterior and posterior cortex increased signiﬁcantly with age 
(anterior C2 [± standard error] = -0.07 [± 0.03] + 0.011 [± 0.001]*age, n = 75, r = 0.88, 
p < 0.001; posterior C2 [± standard error] = -0.04 [± 0.02] + 0.006 [± 0.001]*age, n = 
65, r = 0.79, p < 0.001).
group are steeper than those of the control group or the DM type 2 group. 
 The multiple regression analyses supported the preliminary results. After 
adjustment for age, both the anterior and posterior cortex, and also the nucleus of 
the lens in the DM type 1 group, appeared to be signiﬁcantly thicker than in the 
control group (Table 2). Furthermore, the zones C1, C2 and C3 of the anterior and 
posterior cortex of the lens were signiﬁcantly increased in the DM type 1 group, 
compared to the control group (Table 2). A product-term added to the multiple 
regression analysis showed that the regression slopes of the anterior cortex (95% 
CI: 0.005 to 0.014; p < 0.001) and the posterior cortex (95% CI: 0.002 to 0.011; 
p = 0.003) differed signiﬁcantly in the DM type 1 group and the control group. A 
differentiation of zones C1 – C3 within the anterior and posterior cortex showed 
that there was a signiﬁcant difference in the regression slopes of the C1 zone 
(95% CI: 0.0003 to 0.003; p = 0.017) and the C3 zone (95% CI: 0.002 to 0.009; 
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Table 2 Differences in the internal lens parameters, adjusted for age, when comparing 
the DM groups (DM type 1 and type 2) with the control group
Internal regions lens (mm) Mean values (± SE)
Difference 
(± SE)
95% CIa P-valuea
C1 anterior (mm)
Control group - DM type 1* 0.22 ± 0.01 and 0.27 ± 0.01 0.05 ± 0.01 0.03  to  0.07 < 0.001
Control group - DM type 2 0.22 ± 0.01 and 0.22 ± 0.01 0.01 ± 0.01 -0.03  to  0.02 > 0.99
C2 anterior (mm)
Control group - DM type 1* 0.44 ± 0.02 and 0.55 ± 0.01 0.11 ± 0.02 0.06 to 0.16 < 0.001
Control group - DM type 2 0.44 ± 0.02 and 0.38 ± 0.02 -0.05 ± 0.03 -0.01 to 0.11 0.154
C3 anterior (mm)
Control group - DM type 1* 0.31 ± 0.01 and 0.39 ± 0.01 0.09 ± 0.02 0.04 to 0.13 < 0.001
Control group - DM type 2 0.31 ± 0.01 and 0.33 ± 0.01 0.03 ± 0.02 -0.08 to 0.02 0.540
Total anterior (mm) b  
Control group - DM type 1* 0.95 ± 0.02 and 1.20 ± 0.02 0.25 ± 0.03 0.17 to 0.32 < 0.001
Control group - DM type 2 0.95 ± 0.02 and 0.95 ± 0.02 -0.01 ± 0.04 -0.08 to 0.10 > 0.99
Nucleus (mm)
Control group - DM type 1* 2.32 ± 0.03 and 2.53 ± 0.02 0.21 ± 0.03 0.13 to 0.29 < 0.001
Control group - DM type 2* 2.32 ± 0.03 and 2.45 ± 0.03 0.14 ± 0.04 0.04 to 0.24 0.004
C1 posterior (mm)
Control group - DM type 1* 0.13 ± 0.01 and 0.17 ± 0.01 0.04 ± 0.01 0.02  to  0.06 < 0.001
Control group - DM type 2 0.13 ± 0.01 and 0.14 ± 0.01 0.01 ± 0.01 -0.04  to  0.02 > 0.99
C2 posterior (mm)
Control group - DM type 1* 0.20 ± 0.01 and 0.24 ± 0.01 0.04 ± 0.01 0.01  to  0.08  0.010
Control group - DM type 2* 0.20 ± 0.01 and 0.13 ± 0.02 -0.07 ± 0.01 -0.12  to  -0.02  0.003
C3 posterior (mm)
Control group - DM type 1* 0.23 ± 0.01 and 0.27 ± 0.01 0.03 ± 0.01 0.001  to  0.07  0.038
Control group - DM type 2 0.23 ± 0.01 and 0.22 ± 0.01 -0.02 ± 0.02 -0.03  to  0.06 0.946
Total posterior (mm) b
Control group - DM type 1* 0.55 ± 0.02 and 0.65 ± 0.02 0.10 ± 0.02 0.04  to  0.16  < 0.001
Control group - DM type 2 0.55 ± 0.02 and 0.50 ± 0.03 -0.05 ± 0.03 -0.04  to  0.13  0.501
SE = standard error of the means. a Adjustment for multiple comparisons were made by means of the 
Bonferroni post hoc method. b Total = a summation of C1, C2, and C3. * Signiﬁcantly different compared 
to the control group, p < 0.05.
p < 0.001) of the anterior cortex, and in all zones of the posterior cortex (C1 95% 
CI: 0.001 to 0.004; p = 0.003, C2 95% CI: 0.001 to 0.006; p = 0.016, C3 95% 
CI: 0.0004 to 0.005; p = 0.046) in the DM type 1 group and the control group. 
No difference was found in the regression slopes of the nucleus between the DM 
type 1 group and the control group. To investigate whether the difference in lens 
zones was entirely due to the inﬂuence of DM, comparisons with adjustments for 
age and duration of DM were made between the three groups, but no signiﬁcant 
differences in thickness of the lens zones were found. Figure 4 is a schematic 
drawing of the effect of DM type 1 on the lens; all zones of the DM type 1 lens are 
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Figure 4 Schematic drawing of the cortex, its various zones, and the nucleus of the lens of 
a 41-year old healthy control subject (upper part) and a 41-year old subject with a 22.5-
year duration of DM type 1 (lower part) to indicate the increase in size of all zones of the 
diabetic lens, compared to those of the control lens.  
anterior posterior
control
DM type 1
C1 C2 C1C2C3C3
nucleus
increased in size, compared to the control lens. The curvature and the thickness 
of the control lens and the DM type 1 lens are similar to the outcomes of the 
Scheimpﬂug measurements in the present study, representing the average values 
for a 41-year old healthy control subject and a 41-year old patient who had DM 
type 1 for 22.5 years. However, hypothetical lens equators (dotted lines) have 
been added to the drawing, because these parts of the lens are obscured by the iris 
and can not be seen on a Scheimpﬂug image.
 Unlike DM type 1, DM type 2 had little effect on the cortex and the nucleus of 
the lens. The patients with DM type 2 had a small increase in nuclear thickness, 
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Table 3 The independent effect of the duration of DM per year on the various cortical 
zones of the lens and the nucleus in the two DM groups
DM type 1 DM type 2
Lens regions
(mm)
Slope 
duration
(95% CI)
n R p
Slope duration
(95% CI)
n R p
Anterior cortex
C1 zone 0.002(0.001 to 0.003) 107 0.43 0.002
0.001
(-0.001 to 0.003)
106 0.11 0.268
C2 zone 0.006(0.003 to 0.009) 107 0.74 < 0.001
0.002
(-0.002 to 0.006)
106 0.44 0.346
C3 zone 0.005(0.003 to 0.008) 107 0.43 0.010
0.0004
(-0.003 to 0.003)
106 0.03 0.981
Totala 0.008(0.004 to 0.012) 107 0.75 < 0.001
0.003
(-0.002 to 0.008)
106 0.33 0.280
Nucleus 0.009(0.005 to 0.012) 96 0.54 < 0.001
-0.001
(-0.008 to 0.005)
77 0.12 0.710
Posterior cortex
C1 zone 0.002(0.0002 to 0.003) 55 0.31 0.023
-0.001
(-0.004 to 0.003)
32 0.06 0.781
C2 zone 0.005(0.002 to 0.008) 57 0.45 < 0.001
0.0005
(-0.006 to 0.007)
33 0.03 0.878
C3 zone 0.002(0.0003 to 0.004) 79 0.26 0.020
0.0001
(-0.003 to 0.003)
59 0.01 0.924
Totala 0.008(0.005 to 0.012) 55 0.53 < 0.001
-0.002
(-0.014 to 0.009)
32 0.08 0.687
Duration slopes are adjusted for age in a multiple regression analysis. a Total = a summation of C1, C2, and 
C3. n = number of subjects included, R = multiple regression coefﬁcient, p = probability level, signiﬁcant if 
p < 0.05. 
but also a small decrease in the C2 zone of the posterior cortex of the lens, 
compared to the control group (Table 2). No signiﬁcant difference was found in 
the anterior cortex or zones C1 and C3 of the posterior cortex of the lens between 
the DM type 2 group and the control group, and there was also no difference in 
the regression slopes of the various lens zones between these two groups. 
 The anterior and posterior cortex, and the nucleus of the lens in the DM type 1 
group were signiﬁcantly affected by the duration of DM (Table 3). In the DM type 
1 group the lens thickness was found to increase with the duration of DM, due 
to an increase in the anterior and posterior cortex, and in the nucleus of the lens. 
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This increase was the same in the anterior and posterior cortex and the nucleus 
(Table 3). The effect of the duration of DM on the lens zones was the same for 
males and females in the DM type 1 group. No signiﬁcant effect of the duration of 
DM on the various lens zones was found in the DM type 2 group (Table 3). 
 The metabolic control of DM (i.e. HbA1c and capillary blood glucose levels) 
had no inﬂuence on the various zones of the lens in the two DM groups. In the 
DM type 2 group the various lens zones were not affected by the use of insulin. 
Furthermore, the internal structure of the lens did not differ in patients with 
different levels of DRP in the two DM groups.
DISCUSSION
The aim of the present study was to investigate the various zones within the 
human crystalline lens in patients with DM type 1 and type 2, and to compare 
them to those of healthy control subjects. The results showed that DM type 1 had 
a profound effect on the internal structure of the lens. In patients with DM type 
1 the cortex, the different cortical zones (C1, C2, and C3), and the nucleus of the 
lens were signiﬁcantly thicker than those of the control group. Furthermore, the 
duration of DM type 1 was an important determinant of internal lens structure; 
both the anterior and the posterior cortex, as well as the nucleus increased with 
an increasing duration of DM. It was also found that, in contrast to the effect of 
DM type 1 on the lens, DM type 2 had very little effect on the different zones of 
the lens.  
 Measurements of the internal structure of the lens were performed with 
corrected Scheimpﬂug imaging. The correction of the Scheimpﬂug images is 
important, because of the distortion of the images that is inherent to Scheimpﬂug 
photography. Both in vivo and in vitro validation experiments have shown that 
this method is accurate and reproducible.2,22 The different layers of the lens were 
classiﬁed according to the Oxford Clinical Cataract Classiﬁcation and Grading 
System13, and the thickness of these layers was objectively determined by pointing 
out the maxima of the gradient of the densitogram of each Scheimpﬂug image. 
This method has been described in detail by Dubbelman et al.,16 who measured 
the change in the internal structure of the lens with age and accommodation in a 
group of 102 healthy subjects. In that study, and in an earlier Scheimpﬂug study,14 
it was found that the physiological thickening of the lens with age was the result 
of an increase in the thickness of the anterior and posterior cortex, which was 
entirely caused by an increase in the C2 zone. This was also found in the healthy 
control group in the present study. 
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 The origin of the profound increase in the dimensions of the lens with DM type 
1 still remains unclear. It could be hypothesized that there is an increased growth 
of the individual lens ﬁbers. An enhanced production rate of lens ﬁbers could 
have been stimulated by the use of insulin, which has been reported to induce 
mitogenesis of the epithelial cells of the lens.23,24 However, if this hypothesis was 
plausible, one would expect the size of the cortical C2 zone to be enlarged, since 
only this particular zone is known to increase in size with age in the healthy 
lens.13,14,16 However, it could also be that the increased thickening of the diabetic 
lens is due to cellular or extracellular overhydration. This would cause an increase 
in the size of the individual lens ﬁbers and, as a result, the swelling of the lens as 
a whole, i.e. an increase in the thickness of all the different zones of the lens. The 
results of the present study seem to support this second theory of lens swelling 
more than the ﬁrst hypothesis of enhanced growth. We found a general increase 
in all the different layers of the lens with DM type 1, and the use of insulin did 
not seem to have any effect on the lens zones. It is reasonable to assume that a 
swelling of the lens or its individual lens ﬁbers is the result of an inﬂux of water 
in the lens. Indirect evidence for this might be provided by the measurement of a 
decrease in the equivalent refractive index of the lens, which has been observed 
in a large group of patients with long-term DM type 1 (Wiemer, unpublished 
data, 2007). It is further supported by a case-report of a patient with DM and 
severe hyperglycemia, in whom so-called sugar-cracks, or ﬂuid-ﬁlled cavities 
within the lens interstitium were observed.25 It was hypothesized that these sugar-
cracks were most likely the result of overhydration of the lens, which could have 
been caused by an increase in the osmotic pressure within the lens, due to the 
accumulation of glucose and its metabolic products within the lens.8,26
 No important effect of DM type 2 on the different zones of the lens was found 
in the present study, which agrees with the ﬁndings of Sparrow et al..7 Therefore, 
DM type 1 and DM type 2 appear to have a different impact on the lens. It is 
unlikely that the fact that the exact duration of DM is not known in patients with 
DM type 2 would have reduced the possible effect of DM type 2 on the lens. In 
general, the duration of DM type 2 is under-estimated, so this would even amplify 
any true association of the internal structure of the lens with the duration of DM. 
 We found no signiﬁcant association between the metabolic control of DM 
and the internal structure of the lens. In a previous study of lens thickness and 
blood glucose Pierro et al. also found no relationship between lens biometry 
and metabolic parameters.10 However, it could be possible that more prolonged 
monitoring of the blood glucose levels could provide evidence for a correlation 
between the metabolic control of DM and the internal structure of the lens, because 
the present study had a cross-sectional design. Furthermore, no relationship was 
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found between the level of retinopathy and the internal structure of the lens. 
Earlier studies have reported ﬁndings; Sparrow et al.7 noted that with proliferative 
retinopathy the cortex of the lens in DM type 2 was increased, and Pierro et al.10 
found that lens thickness was associated with the level of retinopathy in DM type 
1.
 In conclusion, the results of the present study show that DM type 1 has a 
profound effect on the internal structure of the lens. It appears that DM type 1 and 
DM type 2 have different underlying pathophysiological mechanisms, since there 
was dissimilarity in their effect on the internal lens structure. Furthermore, the 
increase in lens dimensions with DM type 1 seems to be the result of a generalized 
swelling of the lens, affecting all its different parts. 
REFERENCES
1. Brown NA. The change in lens curvature with age. Exp Eye Res 1974;19:175-183.
2. Dubbelman M, Van der Heijde GL. The shape of the aging human lens: curvature, 
equivalent refractive index and the lens paradox. Vision Res 2001;41:1867-1877.  
3. Dubbelman M, Van der Heijde GL, Weeber HA. The thickness of the aging human lens 
obtained from corrected Scheimpﬂug images. Optom Vis Sci 2001;78:411-416.  
4. Brown NA, Hungerford J. The inﬂuence of the size of the lens in ocular disease. Trans 
Ophthalmol Soc UK 1982;102:359-363. 
5. Fledelius HC, Miyamoto K. Diabetic myopia--is it lens-induced? An oculometric study 
comprising ultrasound measurements. Acta Ophthalmol (Copenh) 1987;65:469-473.  
6. Sparrow JM, Bron AJ, Brown NA, Neil HA. Biometry of the crystalline lens in early-
onset diabetes. Br J Ophthalmol 1990;74:654-660. 
7. Sparrow JM, Bron AJ, Phelps Brown NA, Neil HA. Biometry of the crystalline lens in 
late onset diabetes: the importance of diabetic type. Br J Ophthalmol 1992;76:428-433.
8. Bron AJ, Sparrow J, Brown NA, Harding JJ, Blakytny R. The lens in diabetes. Eye 
1993;7:260-275.
9. Logstrup N, Sjolie AK, Kyvik KO, Green A. Lens thickness and insulin dependent 
diabetes mellitus: a population based twin study. Br J Ophthalmol 1996;80:405-408.
10. Pierro L, Brancato R, Zaganelli E, et al. Correlation of lens thickness with blood 
glucose control in diabetes mellitus. Acta Ophthalmol Scand 1996;74:539-541.
11. Klein BE, Klein R, Moss SE. Correlates of lens thickness: the Beaver Dam Eye Study. 
Invest Ophthalmol Vis Sci 1998;39:1507-1510.
12. Saw SM, Wong TY, Ting S, et al. The Relationship Between Anterior Chamber 
Depth and the Presence of Diabetes in the Tanjong Pagar Survey. Am J Ophthalmol 
2007;144:325-326.
90
Chapter 4
13. Sparrow JM, Bron AJ, Brown NA, Ayliffe W, Hill AR. The Oxford Clinical Cataract 
Classiﬁcation and Grading System. Int Ophthalmol 1986;9:207-225. 
14. Smith GT, Smith RC, Brown NA, et al. Changes in light scatter and width measurements 
from the human lens cortex with age. Eye 1992;6:55-59.
15. Cook CA, Koretz JF, Pfahnl A, Hyun J, Kaufman PL. Aging of the human crystalline 
lens and anterior segment. Vision Res 1994;34:2945-2954.
16. Dubbelman M, Van der Heijde GL, Weeber HA, Vrensen GF. Changes in the 
internal structure of the human crystalline lens with age and accommodation. Vision Res 
2003;43:2363-2375. 
17. Goldmann H. Senile changes of the lens and the vitreous. Am J Ophthalmol 1964;57:1-
13. 
18. Brown NA, Bron AJ. Lens disorders: a clinical manual of cataract diagnosis. Oxford: 
Butterworth-Heinemann, 1996:23-26.
19. Fink W. Refractive correction method for digital charge-coupled device-recorded 
Scheimpﬂug photographs by means of ray tracing. J Biomed Opt 2005;10:024003. 
20. World Health Organization. Fact sheets on Diabetes Mellitus. Available at: http://
www.who.int. Accessed January, 2007. 
21. Aldington SJ, Kohner EM, Meuer S, et al. Methodology for retinal photography 
and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. 
Diabetologia 1995;38:437-444.
22. Dubbelman M, Van der Heijde GL, Weeber HA. Change in shape of the aging human 
crystalline lens with accommodation. Vision Res 2005;45:117-132.
23. Reddan JR, Dziedzic DC. Insulin-like growth factors, IGF-1, IGF-2 and somatomedin 
C trigger cell proliferation in mammalian epithelial cells cultured in a serum-free medium. 
Exp Cell Res 1982;142:293-300.
24. Reddan JR, Wilson-Dziedzic D. Insulin growth factor and epidermal growth factor 
trigger mitosis in lenses cultured in a serum-free medium. Invest Ophthalmol Vis Sci 
1983;24:409-416.
25. Tangelder GJ, Dubbelman M, Ringens PJ. Sudden reversible osmotic lens damage 
(“sugar cracks”) after initiation of metformin. N Engl J Med 2005:15;353:2621-2623.
26. Saito Y, Ohmi G, Kinoshita S, et al. Transient hyperopia with lens swelling at initial 
therapy in diabetes. Br J Ophthalmol 1993;77:145-148.


CHAPTER 5
N.G.M. Wiemer, M. Dubbelman, P.J. Ringens, B.C.P. Polak
MEASURING THE REFRACTIVE PROPERTIES OF 
THE DIABETIC EYE DURING BLURRED VISION 
AND HYPERGLYCEMIA USING ABERROMETRY AND 
SCHEIMPFLUG  IMAGING
Accepted for publication (Acta Ophthalmol)
94
Chapter 5
ABSTRACT
Purpose: To measure refraction and geometry of the diabetic eye during the 
presence and absence of hyperglycemia and blurred vision, using aberrometry 
and Scheimpﬂug imaging.
Methods: Aberrometry and Scheimpﬂug imaging were used to examine ocular 
refraction and higher order aberrations, as well as the shape of the cornea and the 
lens, in 25 patients with diabetes mellitus. From these parameters, the equivalent 
refractive index of the lens was calculated. Using paired t-tests, comparisons were 
made between a ﬁrst series of measurements (visit 1), in the presence of blurred 
vision and hyperglycemia (> 10.0 mmol/l), and a second series of measurements 
(visit 2) under normal conditions.
Results: Mean difference in blood glucose between visit 1 and visit 2 was 5.9 mmol/
l (SD 3.1) (p < 0.0001). Both small hyperopic and myopic shifts of equivalent 
refractive error (ERE) were found in 9 patients (mean absolute difference ERE: 
0.38 D [SD 0.12]; p = 0.02). Furthermore, higher order aberrations (RMS error) 
were slightly increased in 4 patients (mean difference RMS error: 0.07 µm [SD 
0.02]; p = 0.04) during visit 1, compared to visit 2. No signiﬁcant changes could 
be observed in the shape of the cornea or lens in any of the patients. No signiﬁcant 
correlations were found between the changes in blood glucose and the measured 
parameters of the diabetic eyes.  
Conclusions: The present study suggests that subjective symptoms of blurred 
vision during hyperglycemia are not necessarily caused by changes in the 
refractive properties of the diabetic eye. 
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INTRODUCTION
Symptoms of blurred vision due to metabolic dysregulation are a well-known 
feature of diabetes mellitus (DM). It is generally believed that this blurred vision 
in patients with DM is caused by a variation in blood glucose levels, which induces 
changes in ocular refractive error. However, there seems to be no consensus in 
the literature with regard to the direction and origin of these refractive changes. 
Myopic shifts (Duke-Elder 1925; Turtz & Turtz 1958; Birnbaum & Leu 1975; 
Gwinup & Villarreal 1976; Fledelius et al. 1990; Mantyjarvi 1988; Furushima et 
al. 1999), as well as hyperopic shifts (Huggert 1954; Varma et al. 1980; Planten 
1975; Planten et al. 1978; Eva et al. 1982; Kluxen & Scholz 1987; Imai & Matsuda 
1992; Saito et al. 1993; Okamoto et al. 2000; Herse 2005; Giusti 2003; Sonmez 
et al. 2005; Tai et al. 2006) have often been reported in patients with severe acute 
hyperglycemia, or during intensive treatment of acute metabolic dysregulation. 
Already in 1925, Duke-Elder described a myopic shift in hyperglycemic condition 
and a hyperopic shift after a rapid decrease in blood glucose levels. He stated 
that these refractive changes were most likely caused by changes in the lens. A 
change in lens thickness could actually be measured during hyperglycemia in 
more recent studies in which ultrasound biometry was used. After inducing acute 
hyperglycemia in 7 healthy subjects, Furushima et al. (1999) found an increase 
in lens thickness of 1 mm and a myopic shift of -2 diopters. Kato et al. (2000) 
reported a signiﬁcant increase in lens thickness (0.3 mm) after rapid control of 
hyperglycemia. Nevertheless, it is often assumed that a change in the refractive 
index of the lens could also play a role in explaining the refractive changes in 
patients with DM. Planten et al. (1975) found 1 to 3 diopters of hyperopia in 23 
diabetic patients with acute hyperglycemia. They suggested that this hyperopia 
was caused by changes in the refractive indices of the different layers of the lens, 
because they found no changes in the thickness or position of the lens. Using 
Scheimpﬂug photography, Kluxen et al. (1987) reported a maximum of 6 diopters 
hyperopia in one patient with severe hyperglycemia. They measured an increase 
in lens thickness of 0.4 mm, and suggested a decrease in the refractive index of the 
lens. Saito et al. (1993) performed measurements with slit-lamp photography and 
ultrasound biometry in ﬁve patients with newly diagnosed DM. They suggested 
that the refractive index of the lens decreased, due to water inﬂux, and that this 
caused hyperopia (max. 4.9 diopters) and lens swelling (max. 0.3 mm) after 
control of acute metabolic dysregulation. Okamoto et al. (2000) found hyperopia 
(max. 3.8 diopters), but no changes in lens thickness in 14 diabetic patients. As 
a result, it was also assumed that there was a decrease in the refractive index of 
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the lens. This was also hypothesized by Tai et al. (2006), who reported hyperopia 
(max. 2 diopters) in 8 out of 24 diabetic patients, but no change in ocular biometry, 
measured with Orbscan II and ultrasound biometry. However, no studies have yet 
investigated how acute hyperglycemia affects the shape and refractive index of 
the lens.  
 In previous studies focusing on blurred vision in patients with DM, the refractive 
error of the eye has usually been described in terms of sphere and cylinder only. 
Various other optical errors (higher order aberrations) were generally not taken 
into account, although they are known to affect visual acuity (Applegate et al. 
2003). Furthermore, Shahidi et al. (2004) reported an increase in the higher order 
aberrations in 22 patients with chronic DM. No studies have yet investigated the 
inﬂuence of acute hyperglycemia on the higher order aberrations of the eye. 
 It is still unclear whether the higher order aberrations and the shape and refractive 
index of the lens could also play a role in explaining blurred vision in patients 
with DM. The aim of the present study was to evaluate the mechanism underlying 
blurred vision and refractive changes in DM, using aberrometry and corrected 
Scheimpﬂug imaging (Dubbelman & van der Heijde 2001). With aberrometry it is 
possible to detect small changes in refraction and higher order ocular aberrations. 
Furthermore, corrected Scheimpﬂug imaging makes it possible to measure the 
exact shape of the lens, from which the equivalent refractive index of the lens can 
be calculated (Dubbelman et al. 2005). In the present study, the refractive error 
and the higher order aberrations, as well as the shape of the cornea and the lens 
were accurately measured during the presence and absence of hyperglycemia and 
subjective symptoms of blurred vision.
MATERIALS AND METHODS
Between May 2005 and December 2006, 229 patients with DM type 1 or type 
2, who visited the Department of Ophthalmology at the VU University Medical 
Center in Amsterdam, were questioned about the presence of subjective symptoms 
of blurred vision. Capillary blood glucose levels were determined with a blood 
glucose analyzer (HemoCue Diagnostics BV, Oisterwijk, the Netherlands). 
Patients with subjective complaints of blurred vision and elevated blood glucose 
levels (> 10.0 mmol/l) were included in the study. These patients were measured 
during two visits; during the ﬁrst visit (visit 1) the measurements were performed 
when subjective symptoms of blurred vision and elevated blood glucose levels 
were present. The patients were then instructed to return for another series of 
measurements (visit 2) when the blurred vision had disappeared and the blood 
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glucose levels were lower (< 10.0 mmol/l). The mean follow-up time between 
visit 1 and visit 2 (when the blurred vision and hyperglycemia were absent) was 
51 days (SD 64). Changes in ocular biometry with age over this short period 
of time are negligible (Dubbelman & van der Heijde 2001; Dubbelman et al. 
2006; Jonsson et al. 2006; Olsen et al. 2007). Age, DM type 1 or type 2, duration 
of diabetes, glycated hemoglobin levels (HbA1c), and type of medication were 
recorded. Patients with cataract, glaucoma, macular edema, or a history of 
intraocular surgery were excluded. The Medical Ethics Committee of the VU 
University Medical Center in Amsterdam approved the study protocol, and 
written informed consent was obtained from all participants, according to the 
tenets of the Declaration of Helsinki.
Ophthalmological measurements
The right eye of each patient was studied after administration of 1.0% 
cyclopentolate and 5.0% phenylephrine eye-drops to obtain maximal pupillary 
dilation and paralysis of accommodation. Refractive error and higher order 
aberrations were measured with an IRX3 aberrometer (Imagine Eye Optics, 
Paris, France), which performs wavefront analysis of the eye according to the 
Hartmann-Shack principle. This aberrometer operates by focusing an extremely 
ﬁne beam of infrared light (780 nm) on the retina. When the light beam scatters 
back from the fundus through the pupil, a 32 x 32 array of micro lenses captures 
these rays of light. Corresponding to their focal points each micro lens forms a 
spot on a CCD camera. To reconstruct the wavefront of the eye, the spot images 
or Hartmann-Shack images are analyzed, using a software program that has 
been developed to evaluate the displacements of x and y positions of the central 
points of the spots from a perfect grid pattern (Liang et al. 1994). During both 
visits, the mean pupil diameter was measured at 5.0 mm, and two series of three 
aberrometry measurements were made of each patient. The equivalent refractive 
error of each eye was calculated as: equivalent refractive error (ERE) = sphere + 
(cylinder / 2). A refractive change of more than 0.2 diopters (D) was considered to 
be signiﬁcant, according to the accuracy of the aberrometer at a 5 mm pupil size 
(Cheng et al. 2003; Salmon & van de Pol 2005). Furthermore, the higher order 
aberrations of each eye were summarized in root mean square (RMS) errors, 
including the third up to the sixth Zernike orders (Thibos et al. 2002). The RMS 
errors are expressed in micrometers (μm).
 In order to determine ocular geometry, images of the cornea and lens were 
obtained with a Topcon SL-45 Scheimpﬂug camera, the ﬁlm of which was 
replaced by a charge-coupled device (CCD) camera (St-9XE, SBIG astronomical 
instruments) with a range of 16 bits of grey values (512 x 512 pixels, pixel size 
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20 x 20 μm, magniﬁcation: 1x). Two series of three Scheimpﬂug images were 
made in the vertical (90°) meridian during both visits. Ray-tracing was applied 
to correct the images for distortion due to the geometry of the Scheimpﬂug 
camera and due to the refraction of the anterior surface of the cornea and the 
lens (Dubbelman & van der Heijde 2001). Consequently, this made it possible to 
obtain an accurate measurement of the corneal thickness (d1), anterior (R1) and 
posterior (R2) corneal radii of curvature, lens thickness (d3) and the anterior (R3) 
and posterior (R4) radii of curvature of the lens. This method for the correction 
of Scheimpﬂug images has been validated and described in detail by Dubbelman 
et al (2005). 
 The equivalent refractive index of the lens (n lens) can be calculated by 
combining measurements of refractive error, intraocular distances, and the radii of 
the cornea and lens (Figure 1). Therefore, axial eye-length was also measured in 
those patients whose posterior lens surface was clearly visible on the Scheimpﬂug 
images. The axial eye-length was measured with the IOL master (Carl Zeiss 
Inc., North America). The anterior chamber depth (d2) was determined with 
Scheimpﬂug imaging by measuring the distance from the anterior surface of the 
cornea to the anterior surface of the lens. The equivalent refractive index of the 
lens was calculated by means of an iterative process, which has been described 
by Dubbelman et al (2005).
 Finally, two independent ophthalmologists (BP, PR) used the EURODIAB 
classiﬁcation system to determine the stage of diabetic retinopathy from two-ﬁeld 
Figure 1 Schematic eye with the parameters that were included for the calculation of the 
equivalent refractive index of the lens using corrected Scheimpﬂug imaging, aberrometry 
and axial eye-length measurements.
d1 d2 d3 d4
n1 n2 n3 n4
d1 = corneal thickness
d2 = anterior chamber depth
d3 = lens thickness
d4 = axial eye length
R1 = anterior radius cornea
R2 = posterior radius cornea
R3 = anterior radius lens
R4 = posterior radius lens
n1 = refractive index cornea (n1 = 1.376)
n2 = refractive index aqueous (n2 = 1.336)
n3 = refractive index lens (unknown)
n4 = refractive index vitreous (n4 = 1.336)
R1 R2 R4R3
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45° digital color fundus photographs (Aldington et al. 1995; Higgins et al. 2007; 
Olafsdottir et al. 2007).
RESULTS
Of the 229 patients with DM who were questioned and whose blood glucose was 
measured at baseline, 25 patients with both subjective complaints of blurred vision 
and hyperglycemia were included in the study (10.9 %). Excluded from the study 
were 42 patients who had hyperglycemia but no complaints of blurred vision, 2 
patients with blurred vision and no hyperglycemia, and 160 patients with normal 
blood glucose and no blurred vision. Table 1 summarizes the characteristics of 
the 25 diabetic patients (type 1: N=15; type 2: N=10) (9 females and 16 males). 
At visit 1 (when blurred vision and hyperglycemia were present), the mean age 
was 46.6 years (SD 15.6) and the mean duration of DM was 20.6 years (SD 12.7). 
The mean capillary blood glucose levels were 14.1 mmol/l (SD 3.5) at visit 1 and 
8.1 mmol/l (SD 2.5) at visit 2. These blood glucose levels differed signiﬁcantly 
between visit 1 and visit 2 (mean difference: 5.9 mmol/l (SD 3.1 and 95% CI 4.7 
– 7.2); p < 0.0001 (paired t-test)), but there was no signiﬁcant difference in the 
glycated hemoglobin levels (HbA1c). 
 Figure 2 presents graphs of the measured parameters of the right eyes of the 
      
Patient
ERE 
during 
visit 1
ERE during 
visit 2
Absolute 
difference in 
the means
95% 
conﬁdence 
intervals
P value
Change in ERE 
during blurred 
vision 
      
3 -0.73 ± 0.07 -0.95 ± 0.06 0.22 ± 0.09 0.11 – 0.32 0.006 hyperopic
8 -1.37 ± 0.05 -1.15 ± 0.04 0.21 ± 0.06 0.14 – 0.28 0.0009 myopic
9 -0.13 ± 0.06 -0.46 ± 0.04 0.33 ± 0.07 0.25 – 0.42 0.0002 hyperopic
13 -7.53 ± 0.13 -7.07 ± 0.06 0.47 ± 0.14 0.31 – 0.63 0.001 myopic
16 -4.64 ± 0.12 -5.04 ± 0.13 0.41 ± 0.17 0.21 – 0.61 0.007 hyperopic
19 0.47 ± 0.02 0.82 ± 0.11 0.35 ± 0.11 0.22 – 0.48 0.002 myopic
20 -0.67 ± 0.16 -0.26 ± 0.08 0.41 ± 0.17 0.21 – 0.61 0.003 myopic
23 -1.42 ± 0.16 -0.97 ± 0.03 0.45 ± 0.16 0.26 – 0.63 0.003 myopic
25 2.23 ± 0.22 1.63 ± 0.08 0.60 ± 0.23 0.33 – 0.86 0.022 hyperopic
      
Data are presented as mean ± SD. P-values < 0.05 were considered to be statistically signiﬁcant (t-test)
 
Table 2 The equivalent refractive error (ERE); small statistically signiﬁcant differences 
were found in 9 of the 25 patients with diabetes mellitus between the two visits.
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Figure 2 Graphs of the optical properties of the right eyes of 25 patients with DM during 
visit 1 (in the presence of subjective blurred vision and hyperglycemia) and during visit 
2 (in the absence of subjective blurred vision and hyperglycemia). Equivalent refractive 
error ERE (a); Higher order aberrations RMS (b); Anterior radius cornea R1 (c); 
Posterior radius cornea R2 (d); Corneal thickness d1 (e); Anterior chamber depth d2 (f); 
Anterior radius lens R3 (g); Posterior radius lens R4 (h); Lens thickness d3 (i); Refractive 
index lens nlens (j).
Data are presented as mean ± SD. P-values < 0.05 were considered to be statistically significant (t-test)       
* Significantly different compared to visit 1, p < 0.05
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25 diabetic patients during visit 1 and visit 2. A comparison of both visits made 
it clear that a small signiﬁcant difference in ERE (> 0.2 D) could be observed in 
9 of the 25 patients: 4 patients had a hyperopic shift and 5 patients became more 
myopic during hyperglycemia (mean absolute difference in ERE: 0.38 D (SD 0.13 
and 95% CI 0.29 – 0.47); p = 0.02 (t-test)) (Figure 2a and Table 2). Furthermore, 
higher order aberrations (RMS errors) were slightly, but signiﬁcantly increased 
in 4 of the 25 patients (mean increase in RMS error: 0.07 μm (SD 0.02 and 95% 
CI 0.04 – 0.09); p = 0.04) at visit 1, compared to visit 2 (Figure 2b). The mean 
differences in ERE and RMS errors between the two visits were not dependent on 
the difference in blood glucose levels during the two visits.
 No signiﬁcant change in corneal thickness or in anterior or posterior corneal 
radius was observed in any of the patients between visit 1 and visit 2 (Figures 2c, 
2d and 2e). A small, but signiﬁcant change in the anterior chamber depth (mean 
change of d2: 0.06 mm (SD 0.02 and 95% CI 0.04 – 0.08); p = 0.02) was found in 
8 patients, in 3 of whom the change of ERE was signiﬁcant (Figure 2f). There was 
no signiﬁcant difference in the anterior radius of the lens, the posterior radius of 
the lens or the lens thickness between visit 1 and visit 2 in any of the 25 patients 
(Figures 2g, 2h and 2i). To obtain maximal mydriasis in this diabetic study group 
was difﬁcult. As a result, the posterior surface of the lens was visible in 8 of the 
25 patients and a posterior radius of the lens could be determined in 6 patients. 
Therefore, calculation of the equivalent refractive index of the lens was possible 
for those 6 patients, 3 of whom had a signiﬁcant change in ERE. Nevertheless, 
no signiﬁcant change was found in the equivalent refractive index of the lens 
between visit 1 and visit 2 in any of the patients (Figure 2j). Finally, no signiﬁcant 
correlation could be found between the difference in capillary blood glucose 
levels during the two visits and the mean difference in the shape of the cornea or 
lens, or the equivalent refractive index of the lens during the two visits. 
  
DISCUSSION
Several studies have reported on the effect of hyperglycemia on ocular refractive 
error, but there seems to be no agreement on the direction and exact origin of 
refractive alterations in patients with DM. Changes in the shape and refractive 
index of the lens have been assumed to play a causal role in the diabetic refractive 
changes, but these parameters have not been measured before, due to limitations 
of the measurement instruments. Moreover, higher order aberrations have not yet 
been studied during hyperglycemia. Therefore, in the present study, the higher 
order aberrations of the diabetic eye, as well as the shape of the cornea and the 
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lens, were measured during the presence and absence of symptoms of blurred 
vision and hyperglycemia, in order to explain the mechanism underlying blurred 
vision in patients with DM. 
 Of a total of 229 patients who were screened for the present study, 10.9 % 
had both hyperglycemia and complaints of blurred vision. However, only small 
changes in ERE were found in 9 of the 25 patients included in the study. This 
is in contrast to the ﬁndings of other studies, which reported larger changes in 
ERE during hyperglycemia than were found in the present study. However, these 
studies included patients with more serious and longer lasting hyperglycemia. 
In 5 newly diagnosed diabetic patients, who had more elevated average plasma 
glucose levels (22.6 mmol/l) than the patients in the present study (14.1 mmol/l), 
Saito et al. (1993) reported hyperopic shifts of maximal 4.9 diopters. Tai et al. 
(2006) found a hyperopic shift of 2 diopters in 8 diabetic patients with average 
glucose levels of 19.0 mmol/l. Moreover, it has been demonstrated by Okamoto 
et al. (2000) that the degree of hyperopia is correlated to the rate of reduction of 
the blood glucose levels. It could hypothesized that longer phases of elevated 
blood glucose levels, resulting in higher glucose levels in the aqueous humour, 
are necessary to induce formation of higher sorbitol levels in the lens which then 
could cause tissue swelling. Therefore, it could be that in the present study a 
higher and more prolonged blood glucose level was needed to induce a larger 
change in ERE.
 In the present study, ERE and higher order aberrations were measured for a 
pupil size of 5 mm. For this pupil size the accuracy of the aberrometer to measure 
ERE is estimated to be 0.2 D (Cheng et al. 2003; Salmon & van de Pol 2005). 
In 9 of 25 patients a signiﬁcant change in ERE of on average 0.38 D was found. 
The depth of focus at a pupil size of 5 mm is approximately 0.4 D (Atchison & 
Smith 2000), which is within the same range as the change in ERE. It must be 
noted that under physiological conditions the mean pupil size is approximately 3 
mm which results in a depth of focus of approximately 0.7 D (Atchison & Smith 
2000; Charman 1991). Furthermore, the repeatability of measuring subjective 
ERE has been reported to be 0.74 D (Leinonen et al. 2006). Therefore, the results 
of the present study indicate that it is unlikely that the blurred vision during 
hyperglycemia was caused by the small refractive changes. 
 Only a minimal increase in the higher order aberrations (0.07 µm) could be 
measured in 4 diabetic patients. According to Applegate et al. (2003), an increase 
in the RMS error of 0.07 µm should hardly decrease visual acuity. Therefore, the 
observed changes in RMS error in the present study were too small to directly 
affect visual acuity and cause symptoms of blurred vision. 
 Small changes in ERE were observed, but no changes in the geometry of 
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the cornea and lens were found in the present study. This is in agreement with 
the results of several other studies, in which no changes were found in ocular 
biometry. Planten et al. (1975) reported 1 to 3 diopters of hyperopia in 23 diabetic 
patients with acute hyperglycemia, but no changes in lens thickness measured 
with ultrasound biometry. Moreover, Okamoto et al. (2000) found hyperopia 
of maximal 3.8 diopters, with no changes in lens thickness. Finally, Tai et al. 
(2006) reported hyperopia of maximal 2 diopters, but they could not determine 
any change in ocular biometry. In contrast to previous studies, the shape of the 
lens was measured during hyperglycemia in the present study. In the shape of 
the lens no signiﬁcant change was found which could provide an explanation for 
the symptoms of blurred vision in patients with DM. In 8 patients, 3 of whom 
had signiﬁcant changes in ERE, only small, but signiﬁcant changes in anterior 
chamber depth were found. This result is in agreement with the ﬁndings of Tai et 
al. (2006), who also reported small, signiﬁcant changes in anterior chamber depth 
during hyperglycemia.  
 Although several previous studies hypothesized that DM affects the refractive 
index of the lens, in the present study there was no evidence of changes in the 
equivalent refractive index due to hyperglycemia. However, the equivalent 
refractive error of the lens could only be calculated in 6 patients, due to poor 
visualization of the posterior side of the lens. This was caused by a combination 
of the thickness of the diabetic lens and difﬁcult mydriasis, both of which are 
well-known diabetic complications (Sparrow et al. 1990; Sparrow et al. 1992; 
Alio et al. 1989). 
 Although signiﬁcant differences were found between the visits in the present 
study, it must be noted that these changes should be interpreted in the light of the 
high accuracy and precision of the methods that have been used. Only marginal 
changes were found in refractive error and higher order aberrations of the diabetic 
eyes, which did not seem to be large enough to explain the complaints of blurred 
vision. This leads to the conclusion that the symptoms of blurred vision due to 
hyperglycemia should also be attributed to other factors. It could be that changes 
in other visual areas (e.g. retina or optical cerebral cortex) cause subjective 
complaints of blurred vision, or that more serious and long-lasting hyperglycemia 
is needed to induce changes in ERE, higher order aberrations or shape of the 
cornea and lens which could cause blurred vision.
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A 27-year old man with no history of ophthalmologic disease was diagnosed with 
diabetes mellitus after persistent genital infections and severe weight-loss. At the 
time of the diagnosis his serum blood glucose level was 28.7 mmol/L (glycated 
hemoglobin level 16.0 %), but insulin treatment reduced this level to 8.2 mmol/L 
within seven days. Four days after he had been diagnosed with diabetes mellitus 
he developed subjective symptoms of blurred vision and needed glasses to watch 
television. These symptoms led to his referral to our ophthalmology department. 
At that time his cycloplegic objective refraction (spherical equivalent) was 
+2.44 diopters (RE) and +2.23 diopters (LE). Slit-lamp examination revealed no 
opacities or abnormalities in the anterior eye segment, and fundoscopic evaluation 
of the retina showed no symptoms of diabetic retinopathy or other abnormalities. 
The axial eye length was measured and corrected Scheimpﬂug images of the 
anterior eye segment were obtained, in order to accurately measure the shape 
of the cornea and the lens,1 and to calculate the equivalent refractive index of 
the lens.2 Three weeks after diagnosis his blood glucose levels were well under 
control (serum blood glucose: 6.8 mmol/L) and the symptoms of blurred vision 
had disappeared; cycloplegic objective refraction was +1.17 diopters (RE) and 
+1.29 diopters (LE). Comparisons at follow-up showed that during metabolic 
dysregulation there were hyperopic shifts in ocular refraction of +1.27 diopters 
(RE) and +0.94 diopters (LE). Furthermore, corrected Scheimpﬂug images of both 
eyes showed that the lens thickness had increased, and that the anterior surface of 
the lens was more convex (Figure). The equivalent refractive index of the lens in 
both eyes had decreased (Figure). No changes could be observed in the shape of 
the cornea, the shape of the posterior lens surface, or the axial eye length. 
 Blurred vision, due to a variation in blood glucose levels, is a well-known 
complication of diabetes mellitus. It has been suggested that the predominant 
cause of refractive changes during hyperglycemia is a change in the shape and/
or the refractive index of the lens.3,4 However, previous studies have not been 
able to demonstrate this, due to a lack of available measurement methods. By 
means of corrected Scheimpﬂug imaging we found a change in both the shape 
and the refractive index of the lens. This may explain the fact that both myopic5 
and hyperopic6 shifts have been reported in patients with diabetes and metabolic 
dysregulation. A small change in the shape of the lens, accompanied by a relatively 
large change in equivalent refractive index of the lens, as observed in this 
patient, appears to result in a hyperopic shift of refraction during hyperglycemia. 
Alternatively, if there is a large change in the shape of the lens, in combination with 
a small change in the equivalent refractive index, a myopic shift of refraction will 
predominate. Therefore, it seems that there is a delicate balance between changes 
in the shape and the equivalent refractive index of the lens during hyperglycemia, 
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Figure Corrected Scheimpﬂug images of the right (RE) and left eye (LE) at time T = 0 
days, when blurred vision and hyperglycemia were present, and at T = 21 days, when 
vision and blood glucose levels had returned to normal. An increase in the thickness 
and the anterior convexity of the lens can be observed in the images that were taken 
at T = 0. The values (with standard errors of the mean) of the various lens parameters 
and the refractive error at different times are presented in tables for the RE and LE. 
The diagram shows the various parameters: d2 (depth of the anterior chamber in mm), 
d3 (lens thickness in mm), R3 (anterior radius of curvature lens in mm), R4 (posterior 
radius of curvature lens in mm), n3 (equivalent refractive index lens), and SE (spherical 
equivalent in diopters). 
RE LE
T = 0 T = 7 days T = 21 days
d3
R3
R4
n3
4.17 (0.01)
9.15 (0.08)
5.63 (0.03)
1.417 (0.002)
4.01 (0.01)
10.31 (0.10)
5.73 (0.02)
1.427 (0.001)
LE
3.89 (0.06)
10.59 (0.15)
5.77 (0.01)
1.430 (0.002)
SE 2.23 (0.16) 1.72 (0.05) 1.29 (0.01)
d2 2.74 (0.01) 2.90 (0.01) 2.96 (0.02)
T = 0 T = 7 days T = 21 days
d3
R3
R4
n3
4.18 (0.01)
9.14 (0.03)
5.93 (0.06)
1.421 (0.0004)
4.06 (0.01)
10.49 (0.04)
5.84 (0.04)
1.428 (0.002)
RE
3.95 (0.002)
10.82 (0.14)
5.80 (0.06)
1.434 (0.001)
SE 2.44 (0.23) 1.48 (0.06) 1.17 (0.04)
d2 2.74 (0.01) 2.85 (0.01) 2.92 (0.01)
R3 R4
d3
n3
Cornea Lens
d2
T = 0
T = 21 days
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ABSTRACT
Purpose: To measure the refractive properties of the healthy human eye during 
acute hyperglycemia by means of Scheimpﬂug imaging and Hartmann-Shack 
aberrometry.
Methods: Acute hyperglycemia was induced in ﬁve healthy subjects (2 males, 3 
females, mean age 24.8 years (SD 4.6)) by means of an oral glucose tolerance test 
(OGTT) after subcutaneous somatostatin injection. Before and every 30 minutes 
after the OGTT measurements with Scheimpﬂug imaging and Hartmann-Shack 
aberrometry were performed. The main outcome measures were the thickness 
and shape of the lens, and the ocular refractive error and higher order aberrations. 
The equivalent refractive index of the lens was calculated from these parameters. 
Measurements at baseline and during hyperglycemia were analyzed by means of 
Wilcoxon signed rank sum tests.
Results: During hyperglycemia (mean blood glucose level at baseline: 4.0 mmol/
l; mean maximal blood glucose level: 18.4 mmol/l) no changes could be found in 
the refractive properties within the group. In one subject, a hyperopic shift (0.4 
D) was observed, together with a more convex shape of the anterior lens surface 
and a decrease in the equivalent refractive index of the lens.
Conclusions: The present study shows that hyperglycemia generally does not 
cause changes in the refractive properties of the healthy eye. Nevertheless, in 
one subject a hyperopic shift accompanied by a change in shape and refractive 
index of the lens was measured. This ﬁnding could provide an explanation for 
the mechanism underlying the refractive changes that are often observed during 
hyperglycemia.
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INTRODUCTION
Transient refractive changes, due to a variation in blood glucose levels, are well-
known complications of diabetes mellitus (DM). Both myopic shifts [2, 6, 9, 20, 
28, 33] and hyperopic shifts [8, 15, 11, 22, 29, 34] have been reported in patients 
with DM after several days or weeks of hyperglycemia. It has been suggested 
that the predominant cause of the refractive changes is a change in the thickness 
of the lens [13, 14, 16, 22, 26], or shape of the lens [18] and/or a change in 
its refractive index [21, 24, 26, 30]. Two studies have been conducted in which 
hyperglycemia was induced under controlled circumstances to investigate 
refractive changes during hyperglycemia. Firstly, Gwinup et al. [12] administered 
glucose intravenously to ten patients with DM. A myopic shift of maximal -0.75 
D was measured with autorefractometry. Secondly, Furushima et al. [10] induced 
hyperglycemia in 7 healthy, young subjects through somatostatin injections and 
an oral glucose load. They measured a large change in ocular refraction (-2.0 
diopters (D)) and thickness of the lens (1.0 mm) with autorefractometry and 
ultrasound biometry. The results of these two studies indicated that induced 
hyperglycemia can cause changes in refraction and that these changes appeared 
to be larger in healthy subjects.
 In the study of Furushima et al. [10], only the thickness of the lens was measured, 
and there is no information about the change in the shape and the refractive index 
of the lens due to acute hyperglycemia. Therefore, the aim of the present study 
was to induce hyperglycemia in healthy subjects under controlled circumstances, 
and accurately measure ocular geometry and refraction by means of corrected 
Scheimpﬂug imaging and Hartmann-Shack aberrometry, in order to investigate 
the mechanism underlying refractive changes during hyperglycemia. From the 
ocular geometry and refraction, in combination with the measurement of the axial 
length of the eye, it is also possible to calculate the equivalent refractive index of 
the lens [4, 5].
MATERIALS AND METHODS
Five healthy Caucasian subjects (2 males and 3 females) were recruited for this 
study. Mean age was 24.8 years (SD 4.6 and range 21.2 - 32.6) and mean body 
mass index (BMI) was 24.2 kg/m2 (SD 3.2 and range 21.4 - 29.7). The Medical 
Ethics Committee of the VU University Medical Center in Amsterdam approved 
the study protocol, and written informed consent was obtained from all subjects 
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after the nature of the study had been explained. Subjects with a history of diabetes 
mellitus (or a fasting plasma glucose > 5.5 mmol/l), a BMI of > 30 kg/m2, visual 
acuity of < 0.5 (Snellen), or a history of ocular pathology were excluded from 
the study. 
Procedure to induce hyperglycemia
After a 10-hour overnight fast, the subjects received a subcutaneous injection of 
100 µg synthetic somatostatin (Sandostatin, Novartis, Basel, Switzerland) in order 
to suppress the endogenous insulin secretion during glucose loading. Each subject 
had an oral glucose tolerance test (OGTT) (glucose 75 g) 30 minutes after the 
somatostatin injection. Blood glucose levels were measured with a blood glucose 
analyzer (HemoCue Diagnostics BV, Oisterwijk, the Netherlands). Endogenous 
insulin levels were determined with immunometric assays (Luminescence, Bayer 
Diagnostics, Mijdrecht, the Netherlands) in the Laboratory of Endocrinology of 
the Department of Clinical Chemistry in the VU University Medical Center. The 
subjects remained in a fasting state during the entire procedure.
 
Measurement of ocular parameters
Before and 120 minutes after the OGTT 1.0% cyclopentolate and 5.0% 
phenylephrine eye-drops were administered to the right eye of the subjects. 
Hartmann-Shack aberrometry was performed with an IRX3 aberrometer (Imagine 
Eye Optics, Paris, France) and Scheimpﬂug imaging was performed with a Topcon 
SL-45 Scheimpﬂug camera, in which the ﬁlm was replaced by a charge-coupled 
device (CCD) camera (St-9XE, SBIG astronomical instruments) with a range of 
16 bits of grey values (512 x 512 pixels, pixel size 20 x 20 μm, magniﬁcation: 
1x). Before and every 30 minutes after the OGTT, three measurements were made 
with each apparatus. To obtain accurate measurements of the shape of the lens, 
ray-tracing was performed to correct the Scheimpﬂug images for the distortion 
that is inherent to this technique [4, 5]. By combining the measurements of the 
corneal thickness (d1), the depth of the anterior chamber (ACD), the anterior 
(R1) and posterior (R2) radius of the cornea, the lens thickness (d3) and the 
anterior (R3) and posterior (R4) radius of the lens, the axial length of the eye, 
and ocular refraction, it was possible to calculate the equivalent refractive index 
of the lens (n lens) by means of an iterative process [5]. The axial length of the 
eye was measured with an IOL-master (Carl Zeiss Inc., North America). The 
equivalent refractive error (ERE) was calculated as: ERE = sphere + (cylinder / 
2). Furthermore, the higher order aberrations (HOA) of each eye were analyzed 
at a pupilsize of 5.7 mm and they were summarized in root mean square errors, 
including the third up to the eighth Zernike orders [31].
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Measurements at baseline and during hyperglycemia were compared in the whole 
group by means of Wilcoxon signed rank sum tests. A refractive change of more 
than 0.2 D and a change in HOA of more than 0.025 µm were considered to be 
meaningful, according to the precision (deﬁned as 95% conﬁdence interval) for 
measuring the ERE and HOA of the aberrometer [3, 27]. Error analysis indicated 
that a change in R1, R2, d1, ACD, d3, R3, R4, and n lens of more than 0.05 
mm, 0.05 mm, 0.02 mm, 0.14 mm, 0.15 mm, 0.30 mm and 0.40 mm, and 0.007 
respectively, could be considered as signiﬁcant, according to the precision of 
corrected Scheimpﬂug imaging [4]. In each subject individually, the signiﬁcance 
of a change was determined from the precision of the measurements and the 
difference in the ocular parameters at baseline and during hyperglycemia. P-
values ≤ 0.05 were considered statistically signiﬁcant. 
RESULTS
Figure 1 shows the changes in blood glucose after the OGTT. In all subjects the 
mean blood glucose levels rose from 4.0 mmol/l (range 3.4 to 4.5 mmol/l) to 18.4 
mmol/l (range 16.1 to 22.0 mmol/l) in 126 minutes (range 90 to 210 minutes) 
after the OGTT. Subject 01 had a delayed elevation of blood glucose level and 
therefore this subject received a second 75 g oral glucose load at time = 30 minutes. 
Figure 1 Changes in blood glucose (BG) levels in the ﬁve subjects after the administration 
of somatostatin and glucose; the oral glucose load (75 g) was administered at time = 0 
minutes.
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Furthermore, venous blood samples of subject 01 were taken from the antecubital 
vein, which was kept open with 0.9 % saline (100 cl). Endogenous insulin was 
suppressed by the subcutaneous injection of somatostatin during the glucose load 
to a mean value of 2.1 pmol/l (range 0.4 to 4.5 pmol/l), and remained below basal 
secretion level (< 110.0 pmol/l) for 147 minutes (range 75 to 270 minutes). 
 No signiﬁ cant change in ERE was found in the whole group or in four of 
the subjects individually. In subject 01 a hyperopic shift in ERE of 0.4 D was 
measured during hyperglycemia (p < 0.001). There was no signiﬁ cant change 
in the HOA in the group or in any of the subjects individually. No changes in 
Figure 2 Graphs of the normalized equivalent refractive error (ERE), lens thickness (d3), 
anterior chamber depth (ACD), anterior (R3) and posterior (R4) radius of the lens, and 
the refractive index of the lens (n lens) of the ﬁ ve subjects. Data are normalized by sub-
tracting the value at baseline from the measured value in each subject. In subject 01 a 
hyperopic shift of 0.4 D, an increase in R3 and decrease in n lens were found during 
hyperglycemia at T = 240 minutes (p < 0.01). The oral glucose load was administered 
at T = 0.
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Figure 3 Corrected Scheimpﬂug images of the right eye of subject 01: (a) at baseline time 
= 0 minutes, the shape of the cornea and lens are indicated with a solid line; (b) during 
hyperglycemia at time = 240 minutes after the ﬁrst oral glucose load, the shape of the 
cornea and lens are indicated with a line of dashes; (c) a drawing of the changes in the 
shape of the lens in hyperglycemic condition (line of dashes) compared to the normal 
condition (solid line).
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corneal thickness (d1), corneal shape (R1 and R2), anterior chamber depth 
(ACD), lens thickness (d3), or posterior lens shape (R4) were found in the group 
or in any of the subjects individually. In the whole group and in four subjects, 
no changes were found in the anterior radius of the lens (R3) or refractive index 
(n lens). However, in subject 01, the R3 and n lens changed signiﬁcantly during 
hyperglycemia, compared to normal conditions; R3 decreased from 11.65 to 9.69 
mm (mean decrease R3 = 1.96 mm; p < 0.001) and n lens decreased from 1.436 
to 1.422 (mean decrease n lens = 0.014; p = 0.003). Figure 2 presents graphs of 
the normalized ERE, ACD, d3, R3, R4 and n lens of the ﬁve subjects. Figure 3 
shows two corrected Scheimpﬂug images and a schematic drawing of the lens 
of subject 01, in order to illustrate the small differences in lens geometry during 
hyperglycemia compared to baseline. In all subjects, both hematological and 
ocular parameters normalized within 6 hours after the OGTT.  
DISCUSSION
Refractive changes occur frequently in patients with DM. The underlying 
mechanism is still unclear and therefore the aim of the present study was to measure 
ocular refraction and geometry during hyperglycemia, in an attempt to identify 
a possible explanation for these refractive changes. The effect of reproducible 
hyperglycemia was studied in healthy subjects without the systemic effects of 
DM. An OGTT in combination with a somatostatin injection was used to induce 
hyperglycemia. In an earlier study, this was shown to induce large changes in the 
refractive error and lens thickness [10]. Somatostatin inhibits insulin secretion [7] 
and to our knowledge, there are no reports of refractive errors or changes in the 
lens due to this agent. 
 In general and in four of the ﬁve subjects individually, no changes in ocular 
refraction or geometry were found during hyperglycemia. It could be that a more 
prolonged and severe hyperglycemia is needed to induce changes in refractive 
error or geometry of the eye. Glucose within the lens is metabolized via the 
sorbitol pathway, which consists of two enzymes that catalyze the conversion of 
glucose into its sugar alcohol sorbitol and the further conversion of sorbitol to 
fructose. These sugar alcohols tend to accumulate within the lens, because they 
penetrate cell membranes poorly. This accumulation of sugar alcohols causes the 
lens to swell. This process might have taken longer than the observation period of 
the present study. Furthermore, the subjects measured in the present study were 
young and it could be that their lenses, which still have a fast metabolic reaction 
capacity, tolerate short hyperglycemic stress without swelling.
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 These results are not in accordance with the ﬁndings of Furushima et al. [10], 
who observed a large myopic shift (-2 D) and a large increase in the thickness of 
the lens (1 mm) during hyperglycemia in healthy subjects. One main difference 
between the present study and the Furushima et al. study are the methods that 
were used to measure ocular refraction (aberrometry versus autorefractometry) 
and ocular geometry (corrected Scheimpﬂug imaging versus ultrasound 
biometry). However, the precision of aberrometry and autorefractometry are 
comparable for the measurement of defocus, astigmatism and, consequently, the 
equivalent refractive error [3, 27, 32]. Furthermore, the precision of corrected 
Scheimpﬂug imaging and ultrasound biometry are comparable as well. It could 
be that the difference in ethnicity (Caucasian subjects in the present study versus 
Asian subjects in the Furushima study) caused the inconsistency between the two 
studies, since Asian people generally have a more myopic ocular refraction than 
Caucasian subjects [12, 36].
 In the present study, small but signiﬁcant changes in ocular refraction and lens 
geometry were found in one subject. A hyperopic shift of 0.4 D was found, in 
combination with an increase in anterior convexity of the lens. A combination 
of hyperopia and an increase in lens thickness during hyperglycemia has been 
described by Kluxen et al. [18], who found a 6 D hyperopic shift and a 0.4 mm 
increase in lens thickness in a diabetic patient with hyperglycemia. Saito et al. 
[26] reported hyperopic shifts (1.1 to 4.9 D) and an increase of approximately 0.2 
mm in the thickness of the lens in ﬁve diabetic subjects during hyperglycemia. 
Therefore, it has been suggested that hyperglycemia causes a change in the 
refractive index of the lens [18, 21, 24, 26, 30]. The results of the present study 
support this hypothesis; in subject 01 a decrease in the equivalent refractive index 
of the lens was calculated during hyperglycemia. It could be suggested that if 
the change in the shape of the lens is small, hyperopia will predominate during 
hyperglycemia due to a decrease in the refractive index of the lens. Alternatively, 
if the change in the shape of the lens is large in comparison to the decrease in 
the refractive index of the lens, the overall refractive error will result in myopia. 
The controversy in the literature with regard to refractive changes during 
hyperglycemia could be explained by this underlying mechanism of a balance 
between changes in the shape or the refractive index of the lens, which eventually 
determine the overall refractive outcome [17, 20, 25, 34].
 It is surprising that in only one subject, a change in refraction and ocular 
parameters could be determined. It must be noted that the procedures for inducing 
hyperglycemia and monitoring blood glucose were, to some extent, different for 
subject 01, compared to the other subjects. Because of a delayed elevation in 
blood glucose level, a second oral glucose load (150 g instead of 75 g glucose) 
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was administered. Nevertheless, the maximum blood glucose value of subject 
01 did not exceed that of the other subjects and the endogenous insulin level 
was adequately suppressed during the glucose loading. Furthermore, in order to 
obtain sufﬁcient blood samples 0.9 % saline had to be administered to keep the 
antecubital vein open. Therefore, it could not be excluded that the administration 
of saline contributed to the refractive change and alterations in the lens of subject 
01. However, no studies have yet reported any refractive change due to saline 
administration. 
 The change in refractive error in patients with hyperglycemia could also be 
caused by a change in the shape of the cornea. However, previous research 
has shown that hyperglycemia has no inﬂuence on the shape of the anterior 
corneal surface [9, 21, 26, 29]. The results of the present study also agree with 
these ﬁndings. No change in the anterior or posterior corneal radius was found 
during hyperglycemia. Therefore, the cornea does not seem to play a role in the 
explanation of refractive changes during hyperglycemia. This also applies for 
the higher order aberrations. Applegate et al. [1] reported that an increase in the 
higher order aberrations could cause a decrease in visual acuity. However, no 
changes in the higher order aberrations were found in any of the subjects in the 
present study. Therefore, it can be assumed that blurred vision in hyperglycemia 
cannot be explained by changes in the higher order aberrations of the eye. 
 In sum, under the conditions of the present experiment induced hyperglycemia 
generally did  not cause changes in the refractive properties of the healthy 
human eye. However, there were interindividual variations, as illustrated by 
subject 01, who had a hyperopic shift of refraction and a change in shape and 
equivalent refractive index of the lens during hyperglycemia. This could provide 
an explanation for the mechanism underlying the refractive changes often 
experienced by patients with DM and hyperglycemia.
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ABSTRACT
Purpose To quantify the retinal thickness and the refractive error of the healthy 
human eye during hyperglycemia by means of optical coherence tomography 
(OCT) and Hartmann-Shack aberrometry.
Methods Hyperglycemia was induced in ﬁve healthy subjects who were given 
a standard oral glucose tolerance test (OGTT) after a subcutaneous injection 
of somatostatin. Main outcome parameters were the central, pericentral and 
peripheral thickness of the fovea, measured by means of optical coherence 
tomography (OCT3). Ocular refractive error was determined with Hartmann-
Shack aberrometry. Measurements at baseline and during maximal hyperglycemia 
were analyzed, and a change was considered clinically signiﬁcant if the difference 
between the measurements exceeded the threshold of 50 µm for retinal thickness 
and 0.2 D for refractive error.
Results During hyperglycemia (mean blood glucose level at baseline: 4.0 mmol/l; 
mean maximal blood glucose level: 18.4 mmol/l) no signiﬁcant changes could be 
found in the central, pericentral, or peripheral foveal thickness in any of the ﬁve 
subjects. One of the subjects had a hyperopic shift of 0.4 D, but no signiﬁcant 
change in refractive error was found in any of the other subjects.
Conclusions The present study shows that in healthy subjects induced 
hyperglycemia does not affect retinal thickness, but it can cause a small hyperopic 
shift of refraction.    
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INTRODUCTION
Patients with diabetes mellitus (DM) often experience subjective symptoms 
of blurred vision associated to hyperglycemia. The nature and origin of this 
phenomenon are still unclear. Blurred vision during hyperglycemia could be a 
result of transient refractive alterations due to changes in the lens [5, 12, 15, 25, 
27, 36, 37], but it could also be caused by changes in the retina. Macular edema, 
or retinal thickening due to abnormal ﬂuid accumulation within the macula, is 
a common cause of visual loss [1, 14, 22]. The degree of retinal thickening has 
been found to be signiﬁcantly correlated with visual acuity [24]. Furthermore, a 
change in retinal thickness, resulting in a change in axial eye length, could also 
induce a change in ocular refractive error. For instance, it can be calculated that 
with a 50 µm increase in retinal thickness, the ocular refractive error becomes 
0.15 D more hyperopic [30]. 
 Several studies have demonstrated that retinal thickness is affected by DM [2, 
7, 8, 18, 21, 23, 26, 32, 33, 35, 38]. In general, an increase in retinal thickness has 
been reported in patients with long-term DM and advanced stages of retinopathy 
[7, 8, 18, 32, 33, 35]. However, in diabetic patients with and without minimal 
diabetic retinopathy a decrease in retinal thickness has been observed [2, 23]. 
In healthy subjects, it has been shown that the average retinal thickness did not 
change during normo-insulinaemic hyperglycemia [13].   
 It is unclear whether the thickness of the different retinal areas, such as the foveal 
area, the pericentral foveal area, and the peripheral foveal area, changes during 
acute hyperglycemia and suppression of insulin. A change in retinal thickness and/
or ocular refractive error could explain the subjective symptoms of blurred vision 
in patients with DM and hyperglycemia. Therefore, in the present study the effect 
of hyperglycemia on retinal thickness and ocular refractive error was investigated 
in healthy subjects during suppression of endogenous insulin. Retinal thickness 
was measured by means of optical coherence tomography (OCT), which is a non-
invasive technique that provides cross-sectional retinal images, and produces an 
objective measurement of the retinal thickness, independent of the refractive 
status of the eye [10, 11, 29]. Furthermore, aberrometry was used to measure the 
ocular refractive error. This technique makes it possible to detect small changes 
in ocular refraction [19]. 
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MATERIALS AND METHODS
Five healthy subjects (2 males and 3 females) participated in the study. The 
mean age of the subjects was 24.8 years (range 21.2 - 32.6), and their mean 
Body Mass Index (BMI) was 24.2 kg/m2 (range 21.4 - 29.7). The subjects were 
screened during a ﬁrst visit, which included medical history-taking, a physical 
examination (measurement of visual acuity, weight, height and blood pressure) 
and collecting a fasting blood sample. Exclusion criteria were a history of DM 
(or a fasting plasma glucose > 5.5 mmol/l), a BMI of > 30 kg/m2, elevated blood 
pressure (> 140 / 85 mmHg), a visual acuity of < 0.5 (Snellen) or a history of 
ocular pathology. The investigators of the ocular parameters (NW and MD) were 
not informed about the blood glucose levels. Furthermore, the investigators who 
induced hyperglycemia (EE and SS) were not informed about the results of the 
ocular measurements. The study protocol was approved by the Medical Ethics 
Committee of the VU University Medical Center in Amsterdam, and written 
informed consent was obtained from all subjects after the purpose and nature of 
the study had been explained to them.  
Procedure to induce hyperglycemia
After a 10-hour overnight fast, the subjects were given a subcutaneous injection 
of a low dose (100 µg) of synthetic somatostatin (Sandostatin, Novartis, Basel, 
Switzerland) in order to suppress endogenous insulin secretion. Each subject 
underwent an oral glucose tolerance test (OGTT) (75 g glucose) 30 minutes 
after the somatostatin injection, and blood glucose levels were measured with a 
blood glucose analyzer (HemoCue Diagnostics BV, Oisterwijk, the Netherlands). 
Endogenous insulin levels were measured by means of immunometric 
assays (Luminescence, Bayer Diagnostics, Mijdrecht, the Netherlands) in the 
Endocrinology Laboratory at the Department of Clinical Chemistry of the VU 
University Medical Center. The subjects remained in fasting state during the 
entire procedure.
Ocular measurements
Retinal thickness was measured with the Stratus OCT (Model 3000, Carl 
Zeiss Meditec, Dublin, CA, USA), which combines a low coherence scanning 
interferometer (wavelength 820 nm) with a video camera to visualize the 
fundus of the eye. The fast macular thickness OCT scan protocol was used to 
obtain 6 cross-sectional macular scans, 6 mm in length, which are positioned 
at equally spaced angular orientations (300) centred on the fovea. The cross-
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sectional images were analyzed with OCT3 mapping software that uses an edge-
detection technique to locate the vitreoretinal interface and the anterior surface 
of the retinal pigment epithelium. Retinal thickness was deﬁned as the distance 
between these two surfaces. Two OCT scans were made of each subject before, 
and every 30 minutes during the period of hyperglycemia. In order to quantify 
the retinal thickness, the foveal map constructed by the software was divided into 
nine Early Treatment Diabetic Retinopathy Study (ETDRS) areas [6]: the central 
fovea (central circle with a diameter of 1 mm), and the pericentral area (donut-
shaped ring with an inner diameter of 1 mm and an outer diameter of 3 mm) 
and peripheral area (donut-shaped ring with an inner diameter of 3 mm and an 
outer diameter of 6 mm), both of which were divided into four quadrants. Retinal 
thickness was calculated for all separate areas, and for the average pericentral and 
peripheral regions. 
 Ocular refractive error was determined with an IRX3 aberrometer (Imagine Eye 
Optics, Paris, France), which performs wavefront analysis of the eye according 
to the Hartmann-Shack principle [19] After pupil dilation and paralysis of 
accommodation with 1.0% cyclopentolate and 5.0% phenylephrine eye-drops, a 
series of three aberrometry measurements was made before, and every 30 minutes 
during the hyperglycemic condition. From these measurements, the equivalent 
refractive error was calculated as: equivalent refractive error (ERE) = sphere + 
(cylinder / 2). 
 The measurements at baseline and during maximal hyperglycemia were 
analyzed, and any change was considered to be meaningful if the difference 
between the measurements was greater than the threshold of 50 µm for retinal 
thickness and 0.2 diopters (D) for ERE. The threshold of 50 µm exceeded the 
95% conﬁdence interval for the detection of a change in retinal thickness, which 
has been reported to be approximately 40 µm [4, 20, 28]. A refractive change of 
more than 0.2 D also surpasses the precision (deﬁned as 95% conﬁdence interval) 
of the aberrometer for measuring sphere, cylinder, and consequently ERE [3, 31]. 
In each subject, the signiﬁcance of a change was obtained from the precision 
of the measurement instruments and the difference in the ocular parameters at 
baseline and during hyperglycemia. In the whole group, the signiﬁcance of a 
change could be determined by means of Wilcoxon matched pairs signed rank 
sum tests. P-values ≤ 0.05 were considered to be statistically signiﬁcant.
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RESULTS
The changes in blood glucose after the administration of somatostatin and glucose 
are shown in Figure 1. Mean blood glucose levels rose from 4.0 mmol/l (range 
3.4 to 4.5 mmol/l) to 18.4 mmol/l (range 16.1 to 22.0 mmol/l) after the OGTT. 
Endogenous insulin was suppressed by the subcutaneous injection of somatostatin 
during the glucose load to a mean value of 2.1 pmol/l (range 0.4 to 4.5 pmol/l), 
and remained below basal secretion level (< 110.0 pmol/l) for 147 minutes (range 
75 to 270 minutes). Subject 01 had a delayed elevation of blood glucose level, 
compared to the other subjects. This person received a second 75 g oral glucose 
load after 30 minutes in order to induce a rise in the blood glucose level. In all 
subjects, the blood glucose and endogenous insulin levels normalized within 6 
hours after the OGTT.
Figure 1 Graph of normalized blood glucose levels in the ﬁve subjects after the 
administration of somatostatin and glucose. Data are normalized by subtracting the 
value at baseline from the measured value in each subject. The oral glucose load (75 g) 
was administered at T 0. Subject 01 received an extra 75 g oral glucose load at T 30.
 Figure 2 shows the normalized ERE of the ﬁve subjects during hyperglycemia. 
Mean ERE at baseline was 0.6 D (SD 0.6) and 0.7 D (SD 0.6) during maximal 
hyperglycemia, no signiﬁcant change was found in the group as a whole. A small, 
but signiﬁcant hyperopic shift of 0.4 D (SD 0.2) in ERE was measured in subject 
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Figure 2 Graph of the normalized equivalent refractive error (ERE) in diopters (D) of 
the ﬁve subjects. Data are presented as mean ± standard deviation; three measurements 
were made of each subject every 30 minutes during the procedure. Data are normalized 
by subtracting the value at baseline from the measured value in each subject. The oral 
glucose load was administered at T 0. * Signiﬁcant difference between ERE at T 0 and T 
210 (maximal hyperglycemia), p < 0.001.
01 during maximal hyperglycemia, compared to the start of the procedure (p < 
0.001). No signiﬁcant change in ERE was found in any of the other subjects. 
 Normalized retinal thickness parameters are shown in Figure 3a (central foveal 
area), 3b (average pericentral foveal area) and 3c (average peripheral foveal 
area). Average central foveal thickness, average pericentral foveal thickness, and 
average peripheral foveal thickness at baseline were 202 μm (SD 8), 277 μm (SD 
5), and 243 μm (SD 8). During maximal hyperglycemia average central foveal 
thickness, average pericentral foveal thickness, and average peripheral foveal 
thickness were 203 μm (SD 7), 275 μm (SD 3), and 242 μm (SD 9). No signiﬁcant 
differences were found in the group as a whole. Furthermore, none of the subjects 
had any signiﬁcant changes in the thickness of the central fovea, the pericentral 
fovea, or the peripheral fovea during maximal hyperglycemia, compared to 
baseline. The nine separate ETDRS areas were not affected by hyperglycemia. At 
baseline and during hyperglycemia any change in retinal thickness that occurred 
in the various areas was less than 15 µm, which was within the previously deﬁned 
threshold of 50 µm.
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Figure 3 Graphs and maps of normalized retinal thickness parameters in the ﬁve subjects 
during hyperglycemia: (a) central fovea, (b) pericentral fovea, (c) peripheral fovea. Data 
are normalized by subtracting the value at baseline from the measured value in each 
subject. Each measured area has been indicated by a dark grey area on the retinal maps. 
No signiﬁcant changes in retinal parameters were found in any of the subjects. The oral 
glucose load was administered at T 0.
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DISCUSSION
Blurred vision is a symptom that occurs frequently in patients with DM and 
hyperglycemia. The underlying mechanism is still unclear and therefore the 
present study was carried out in an attempt to identify a possible cause of this 
symptom. The effect of reproducible hyperglycemia on retinal thickness and 
refractive error was studied in healthy young subjects who did not suffer from the 
systemic effects of DM.  
 No changes in the thickness of the central, pericentral or peripheral foveal 
areas were found in any of the subjects during hyperglycemia. In addition, no 
signiﬁcant change was measured in any of the nine different ETDRS areas of the 
macula. In their study, Jeppesen et al. [13] also found no signiﬁcant difference in 
retinal thickness in healthy subjects during normo-insulinaemic hyperglycemia. 
Before and 180 minutes after the start of a hyperglycemic clamp they measured 
the average thickness of the retina, and found that retinal thickness was not 
affected by hyperglycemia. Although in the present study retinal thickness was 
measured under different circumstances than in the study of Jeppesen et al. (hypo-
insulinaemic hyperglycemia instead of normo-insulinaemic hyperglycemia), the 
results conﬁrm those of Jeppesen et al.. 
 Retinal thickness has been reported to change in patients with long-term DM 
and retinopathy. A morphological change in the retina may even occur in the 
early stages of diabetic retinopathy [2, 7, 8, 18, 21, 23, 26, 32, 33, 35, 38]. These 
changes in retinal thickness are usually due to abnormal ﬂuid accumulation 
resulting from a breakdown of the blood-retinal barrier [34]. Goebel et al. [8] 
measured retinal thickness by means of OCT in 136 patients with different stages 
of diabetic retinopathy and with a mean DM duration of 16 years. Mean foveal 
thickness was 307 ± 136 µm in the diabetic subjects, compared to 153 ± 15 µm 
in healthy subjects. It seems that only long-term hyperglycemia and/or long-
term ﬂuctuations in blood glucose levels have any signiﬁcant inﬂuence on the 
blood-retina barrier and retinal thickness. From the ﬁndings of the present study 
it appears that the blood-retina barrier does not seem to be affected by a single 
episode of acute hyperglycemia. Nevertheless, the fact that no change in retinal 
thickness could be determined, does not exclude the possibility that there could 
be early dysfunction of the blood retina barrier. Other means of examination 
could evidence such a dysfunction of the blood retina barrier following acute 
hyperglycemia.
 A factor that could have biased the results of this study is the administration of a 
synthetic somatostatin analogue to the subjects. Somatostatin is a peptide hormone 
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that inhibits several hormones, including IGF-1 and insulin. IGF-1 is a growth 
factor that is produced by the hypoxic retina to mediate angiogenesis, resulting 
in neovascularisation. Somatostatin analogues not only inhibit neovascularisation 
in patients with advanced diabetic retinopathy, but also stabilize the blood-
retinal barrier in patients with diabetic macular edema [16, 17]. It could have 
been possible that in the present study an increase in retinal thickness during 
hyperglycemia was prevented by somatostatin. Nevertheless, the efﬁcacy of 
synthetic somatostatin in the treatment of advanced diabetic retinopathy was 
investigated by Grant et al. [9]. With maximally tolerated doses of somatostatin 
(ranging from 200 to 5000 µg/day) after a period of 15 months 1 out of 22 eyes 
required panretinal photocoagulation, compared to 9 of 24 eyes that were not 
treated with somatostatin. From the results of the Grant et al. study it seems that 
only frequent, large doses of somatostatin over a long period of time have any 
signiﬁcant effect on the progression of diabetic retinopathy. Although the effect 
of somatostatin on the healthy retina has not been investigated yet, it seems to be 
unlikely that the results of the present study were biased by the administration of 
one single, low dose (100 µg) of somatostatin.
 In conclusion, the results of this study indicate that in healthy subjects, 
hyperglycemia does not cause any change in retinal thickness. Furthermore, ocular 
refraction in general was not affected by hyperglycemia. However, there were 
interindividual variations, as illustrated by subject 01, who had a hyperopic shift 
of refraction during hyperglycemia. Therefore, it seems that a refractive change 
during hyperglycemia can not be explained by a change in retinal thickness. It 
could well be that other refractive components, such as the lens, are involved in 
causing blurred vision and refractive alterations during hyperglycemia.  
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ABSTRACT
In the coming years there will be a considerable increase in the number of patients 
with diabetes mellitus, and this implies that there will also be an increase in the 
prevalence of diabetic macular edema.  Diabetic macular edema and diabetic 
retinopathy are the main causes of legal blindness in adults.  Macular edema, or 
retinal thickening due to abnormal ﬂuid accumulation within the macula, has been 
reported as a common cause of visual loss and the degree of retinal thickening has 
been found to be signiﬁcantly associated with visual acuity. The current therapy 
for diabetic macular edema consists of the prevention, detection and treatment 
of risk factors (such as hypertension, hyperglycemia, dyslipidemia, proteinuria 
and obesity) with additional laser treatment (photocoagulation), if necessary.  In 
many patients, photocoagulation may prevent or reduce vision loss, but it does 
not usually improve visual acuity.  New treatment strategies include intravitreal 
corticosteroids or vascular-endothelial growth factor (VEGF) inhibitors and oral 
protein kinase C-inhibitors, angiotensine-converting enzyme (ACE) inhibitors, 
acetylsalicylic acid or statins.  Long-term improvement is not always achieved, 
and the side-effects can be serious.
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INTRODUCTION
Diabetic retinopathy and diabetic macular edema are the main causes of legal 
blindness (i.e. maximum vision of 0.1) in adults under 65 years of age.  At present, 
the number of patients with diabetes mellitus worldwide is approximately 246 
million, and this is expected to increase to 380 million in 2025, mainly due to an 
increase in the number of patients with diabetes mellitus type 2.1
 Clinically relevant macular edema (Figure 1), deﬁned as retinal thickening, 
with or without exsudates within one papil diameter of the centre of the macula, 
has a prevalence of 10 % in the diabetes population as a whole.2 Among patients 
with diabetes mellitus type 1, diabetic macular edema seldom develops during 
the ﬁrst 5 years after the diagnosis. On the other hand, patients with diabetes 
mellitus type 2 have a 3-8 % risk of developing diabetic macular edema within 3 
years after the diagnosis.2
 Diabetic macular edema is a multifactorial disorder, resulting from 
microvascular changes in the retina, which cause abnormal permeability of the 
vascular walls.3 In general, two sub-types can be distinguished: focal and diffuse 
macular edema. In the focal type, thickening of the retina is caused by leakage 
from microaneurysmata and dilated capillaries, which is sometimes accompanied 
by hard exsudates (deposits of protein and fatty substances from the blood). The 
diffuse type, which can occur with or without cystoid edema, is characterized 
by generalized leakage from dilated capillaries in the macula region. Subjective 
symptoms of diabetic macular edema can include: blurred or unclear vision 
and metamorphopsia (distorted vision). However, it can also occur without 
complaints.
DIAGNOSIS
Diabetic macular edema can be assessed with fundus photography, slit-lamp 
examination (biomicroscopy), fundoscopy, measurement of vision acuity, and 
examination of the central visual ﬁeld. Gold standards for the detection of 
diabetic retinopathy and diabetic macular edema are 7-ﬁeld stereo-photography, 
biomicroscopy or ﬂuorescence angiography. Fluorescence angiography is 
necessary in order to identify diffuse and ischemic edema, especially if no 
abnormalities are found with fundus-photography (Figure 2) or fundoscopy, 
and if treatment is indicated. Moreover, increasing use is being made of optical 
coherence tomography, an objective, non-invasive method in which infra-red 
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light produces optical cross-sections of the retina. This makes early detection 
and follow-up of diabetic macular edema possible, because the thickness and the 
volume of the retina in the macular region can be determined.4
RISK FACTORS
Successful treatment of diabetic macular edema should focus on prevention of 
the development and exacerbation of various known risk factors.5 Risk factors for 
the development of the macular edema are longer duration of diabetes mellitus, 
hyperglycemia, hypertension, dyslipidemia, proteinuria, gravidity, ethnicity, 
and ophthalmological interventions, such as panretinal laser therapy or cataract 
extraction.2 Other risk factors include a rapid decline in elevated blood glucose 
levels, and an elevated body mass index (BMI) and hip-waist measurements 
(obesity).6 
 The Diabetes Control and Complications Trial and the United Kingdom 
microaneurysm bleeding
hard exsudates cotton wool exsudate
macula
a b
Figure 1 Digital fundus photos of the left eye of a patient with clinically relevant diabetic 
macular edema: (a) color photograph – remarkable are the many hard exsudates, 
bleedings and micro-aneurysms within one papil diameter of the centre of the macula; 
soft (“cotton wool”) exsudates can also be seen; (b) black and white photos of the same 
fundus – more details can be seen, due to the greater contrast.
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Figure 2 Photos of the left eye of a patient with cystoid diabetic macular edema: (a) 
fundus photo – very few abnormalities can be seen in the macular region; hard and 
soft (“cotton wool”) exsudates can be seen along the vascular curves; (b) ﬂuorescent 
angiogram: diffuse leakage in the vascular walls with cystoid macular edema; (c) picture 
obtained with optical coherence tomography: diffusely thickened macula with cystoid 
structures.
a
b
c
macula
cystoid macular edema
cystoid macular edema
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Prospective Diabetes Study have demonstrated that strict regulation of blood 
glucose levels in patients with diabetes mellitus type 1 and 2 can offer protection 
against both the development and progression of diabetic macular edema. In this 
respect, the aim should be to achieve an average blood glucose level (glycated 
hemoglobin; HbA1c) of less than 7 %.7, 8 Careful monitoring of blood pressure 
also appears to be effective: systolic blood pressure levels of less than 135 
mmHg and diastolic levels of less than 85 mmHg are recommended.9 From the 
Early Treatment of Diabetic Retinopathy Study it appears that hard exsudates 
in the retina are associated with increased levels of serum cholesterol.10 Serious 
proteinuria is associated with a 95 % higher risk of developing diabetic macular 
edema in patients with diabetes mellitus type 1.11 Gravidity can cause serious 
diabetic macular edema, especially in combination with hypertension and 
proteinuria. Diabetic macular edema usually disappears spontaneously in the 
third term of a pregnancy or after the partus, but the edema can also cause a 
serious, long-term deterioration in vision.12 In approximately 43 % of patients with 
proliferative diabetic retinopathy who receive panretinal laser treatment, diabetic 
macular edema can develop or exacerbate.13 Among diabetes patients who have 
undergone cataract extraction, 32-40 % develop macular edema, but in two thirds 
of these patients the edema disappears spontaneously within 6 months. After lens 
extraction, diabetic macular edema that was present before the operation can 
exacerbate, and therefore pre-operative laser coagulation is recommended.14
TREATMENT
Current treatment
Laser treatment should be considered for clinically relevant macular edema, 
especially if vision is threatened or has deteriorated.5 In patients with focal 
diabetic macular edema, laser coagulates are placed at the site of the leakage. For 
diffuse macular edema, with or without cystoid leakage, grid laser is applied, i.e. 
with laser coagulation in a lattice pattern. Laser treatment can prevent or slow 
down deterioration of the visual acuity of many patients, but it does not usually 
improve. Side-effects of laser therapy include: troublesome paracentral scotomes, 
spreading of the laser scars and an increase in scotomes, epiretinal ﬁbrosis, and, 
in exceptional cases, a sudden deterioration in vision due to a central increase in 
the edema.15
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New treatment strategies
For many patients the visual prognosis after laser treatment is only moderate, so 
that additional treatment strategies are needed. In patients with diabetic macular 
edema that is caused by traction of the posterior vitreous membrane on the macula, 
the posterior vitreous membrane and, if necessary, also the epiretinal ﬁbrosis can 
be removed in an operation (vitrectomy).16
 Various different pharmacological interventions are currently being 
investigated, and sometimes applied with success. An intravitreal injection with 
the corticosteroid triamcinolonacetonide initially appeared to have a beneﬁcial 
effect: there was a reduction in retinal thickening and an improvement in visual 
acuity. However, the effects of this treatment only last for an average of 3 to 
6 months, after which the visual acuity reduces again and the retina thickens. 
The side-effects can be serious: the intravitreal injection can cause bacterial 
endophthalmitis, and the corticosteroid can cause cataract, an increase in 
intraocular pressure and glaucoma.17, 18
 One way in which to prolong the effects of intravitreal corticosteroids is the 
placement of an intraocular implant, containing ﬂucinolon-acetonide, in the 
vitreous, which induces a gradual ﬂow of the corticosteroid. Frequent side-
effects of this intervention are an increase in intraocular pressure and cataract.19 
Corticosteroids can possibly reduce microvascular leakage by inhibiting the 
vascular-endothelial growth factor (VEGF), which regulates the proliferation of 
endothelial cells and plays a role in vascular wall leakage and neovascularisation 
as a reaction to ischemia of the retina.  In a short-term study, treatment with 
pegaptanib, a VEGF inhibitor, every 6 weeks has been investigated. There was 
improved visual acuity, the thickness of the macula decreased, and additional 
laser therapy was needed less rapidly.20 As yet, no further results of other studies 
on the effect of pegaptanib have been published.
 Another type of pharmacological treatment is selective inhibition of protein-
kinase C (PKC), an enzyme that can possibly increase the expression of VEGF in 
hyperglycemia. Oral PKC inhibitors are well accepted, and they improve the retinal 
circulation time in patients with diabetes mellitus.21 The effect of ruboxistaurin, 
a PKC inhibitor, has been investigated in two double-blind studies. In one of 
these studies the primary aims, i.e. a decline in diabetic macular edema and an 
improvement in visual acuity, were not achieved, but it did result in slowing 
down a reduction in visual acuity in certain patient groups.22 The results of the 
other study are similar. However, before any deﬁnite conclusions can be drawn 
about the beneﬁts of treatment with a PKC inhibitor, we must await the results 
of clinical trials that are currently being carried out (http://eyephoto.ophth.wisc.
edu/PresentationsPublications/PKCInhibitorTrials.pdf). Angiotensine-converting 
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enzyme (ACE) inhibitors and acetylsalicylic acid have no direct beneﬁcial 
effect, and research results must demonstrate whether statins can slow down the 
development or progression of diabetic macular edema.9, 10, 23
CONCLUSION
At the present, the most important aspect in the treatment of diabetic macular 
edema is an adequate and targeted identiﬁcation and treatment of risk factors. 
Further research in the coming years will have to indicate which additional 
therapy is the most beneﬁcial.
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Diabetes mellitus affects hundreds of millions of people worldwide, resulting 
in considerable morbidity and mortality. Well-known ocular complications of 
diabetes are diabetic retinopathy and cataract (Ch 1.3). Diabetes mellitus also has 
a signiﬁcant effect on the refractive properties of the human eye. In patients with 
diabetes the lens becomes thicker and the shape of its anterior and posterior surface 
becomes more convex (Ch 1.3.4). Furthermore, subjective symptoms of blurred 
vision and refractive changes are frequently reported features of dysregulated 
blood glucose levels (Ch 1.4.1).
 The exact inﬂuence of chronic and acute diabetes mellitus on the refractive 
properties of the eye is still a matter of discussion, mainly because appropriate 
tools to accurately measure the refractive components of the eye have only 
recently become available. Ocular refraction depends on the shape of the cornea 
and lens, the refractive indices of these ocular media, and the axial length of the 
eye. Therefore, accurate measurements of the refractive elements of the diabetic 
eye are a prerequisite for ﬁnding anomalies of the refractive system of diabetic 
patients and for investigating the underlying mechanism of blurred vision and 
refractive changes during sustained and acute hyperglycemia. The studies 
described in this thesis focused on the mechanisms underlying blurred vision and 
refractive changes in patients with diabetes mellitus by investigating sustained 
and transient changes in the refractive elements of the diabetic eye. Accurate 
measurements of the geometry of the anterior eye segment and the refractive error 
of the diabetic and healthy eye were obtained by means of corrected Scheimpﬂug 
imaging (Ch 1.5.1) and Hartmann-Shack aberrometry (Ch 1.5.2). The aims of the 
present study were:
- To accurately measure the thickness and the shape of the cornea, and the thickness, 
shape and internal structure of the lens in patients with diabetes mellitus type 1 
and type 2 (Chapters 2, 3, and 4).
- To investigate the mechanisms underlying blurred vision and refractive changes 
by measuring the geometry of the cornea and the lens, the ocular refractive error, 
and the retinal thickness of the eye during an episode of acute hyperglycemia 
Chapters 5, 6, 7 and 8).  
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Sustained inﬂuence of diabetes mellitus on the geometry of the cornea and the 
lens of the human eye
The main refractive components of the eye are the cornea and the lens. The 
anterior surface of the cornea contributes to approximately two-third of the total 
refractive power of the eye, and the remaining power is provided by the posterior 
corneal surface and the anterior and posterior surfaces of the lens. Changes in 
the radius of curvature of either the anterior or the posterior surface, or changes 
in the thickness of the cornea or the lens can alter the refractive power of the 
eye. In the present study diabetes mellitus type 1 and type 2 both appeared to 
have a small  but signiﬁcant effect on the posterior radius of curvature of the 
cornea; people with diabetes appeared to have a slight decrease in the radius 
of the posterior corneal surface, resulting in a small change in the refractive 
power of the posterior corneal surface. However, because of the small change 
in posterior corneal radius, and because the radius (and thus the power) of the 
anterior corneal surface was not affected by diabetes mellitus type 1 or type 2, it 
can be concluded that the cornea does not play a major role in sustained diabetic 
refractive alterations (Chapter 2).
 The normal healthy lens constantly grows during life and is characterized by 
an increase in thickness and a decrease in the anterior and posterior radius of 
curvature (i.e. an increase in convexity). From the observations in Chapter 3 it 
can be concluded that in patients with diabetes mellitus type 1 the most prominent 
changes in the anterior eye segment occur within the lens. The lenses of patients 
with diabetes type 1 were signiﬁcantly thicker and more convex than those of 
healthy subjects. The duration of the disease was an important determinant of 
changes in lens biometry; the increase in lens thickness with each year of diabetes 
was approximately twice the annual age-related increase. The decrease in the 
anterior and posterior radius of curvature of the lens with each year of diabetes was 
approximately two and three times the annual age-related decrease, respectively. 
This effect of diabetes type 1 on lens biometry was even more pronounced than 
has been reported in earlier Scheimpﬂug studies (for references see Ch 1.3.4), in 
which no correction had been made for the distortion inherent to Scheimpﬂug 
imaging (Ch 1.5.1). The increase in convexity of the lens with diabetes type 
1 is expected to result in an increase in the refractive power of the lens, and 
consequently in a myopic shift of ocular refraction. Surprisingly, however, the 
refractive power of the lens remained unaffected by diabetes mellitus. This can 
be explained by the fact that the equivalent refractive index of the lens decreases 
with diabetes, and that this decrease compensates for the more convex shape of 
the diabetic lens. As a result, the diabetic eye does not become more myopic with 
increasing duration of the disease. Finally, an essential difference was found in the 
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effect of diabetes type 1 and type 2 on lens biometry; the geometry of the lenses 
of patients with diabetes mellitus type 2 did not differ from that of healthy lenses. 
This may indicate a fundamental difference in pathogenesis between diabetes 
mellitus type 1 and type 2 (Chapter 3).
 In Chapter 4 the origin of the increased dimensions of the lens in patients with 
diabetes mellitus was further investigated. It was hypothesized that the increased 
size of the diabetic lens could be due to a more rapid growth of the lens, or to an 
overall swelling of the lens. A more rapid growth of the diabetic lens would lead 
to an increase in the thickness of one speciﬁc layer of the cortex of the lens, since 
the growth of the healthy lens has been reported to be entirely due to an increase in 
that particular cortical layer. However, when an overall swelling of the lens ﬁbers 
would occur, one would expect an increase in the thickness of all the different 
zones of the lens. In the study summarized in Chapter 4 it appeared that all layers 
in the lens were enlarged in patients with diabetes mellitus type 1. Therefore, it 
was concluded that the profound increase in the size of the lens of patients with 
diabetes mellitus type 1 is most likely the result of an overall swelling, affecting 
all parts of the lens due to an inﬂux of water (Chapter 4). Evidence in favor of an 
inﬂux of water in the lens is the observation that the equivalent refractive index 
of the lens decreases with diabetes (Chapter 3). Finally, consistent with the results 
described in Chapter 3, diabetes mellitus type 2 appeared to have no or very little 
effect on the thickness of the various layers of the lens (Chapter 4).
Transient inﬂuence of diabetes mellitus on the refractive properties and retinal 
thickness of the human eye
Blurred vision is a common ocular symptom of diabetes mellitus. Normal visual 
acuity requires a sharp image projected by the refractive system of the eye onto 
the retina, accurate translation of the image to action potentials by the retina, and 
processing of that information by the visual cortex of the brain. Errors in any 
part of the system could result in blurred vision. Therefore, the causes of blurred 
vision can be numerous, but are best considered by two determinants: the image 
formation system of the eye (i.e. the refractive system and the retina), and the 
image-processing system (e.g. the visual cortex and related areas in the brain). 
Changes in the image formation system include refractive errors and/or optical 
aberrations due to changes in the geometry of the cornea and the lens, and retinal 
disease such as for instance diabetic macular edema. The present study focused 
on changes in the image formation system as a possible cause of blurred vision in 
patients with diabetes mellitus. 
 First, the ocular refractive properties (geometry of the cornea and lens, 
refractive power and optical aberrations) of patients with diabetes mellitus type 
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1 and type 2 were measured during the presence and absence of symptoms of 
blurred vision and hyperglycemia. The optical properties of the cornea and lens 
were measured as described above by means of corrected Scheimpﬂug imaging, 
Hartmann-Shack aberrometry, and optical coherence tomography. From a group 
of 229 patients with diabetes mellitus, we studied those subjects (n = 25) who had 
subjective symptoms of blurred vision and hyperglycemia at the ﬁrst visit. After 
the ﬁrst visit they were asked to return for a second visit when the symptoms  of 
hyperglycemia and blurred vision had disappeared. A comparison of the results at 
the two visits revealed that no signiﬁcant changes had occurred in the thickness 
or shape of the cornea, nor in the thickness, shape and equivalent refractive index 
of the lens. Furthermore, only very small changes were observed in the refractive 
error and optical aberrations during hyperglycemia, which could not explain the 
symptoms of blurred vision. This indicated that the symptoms of blurred vision 
in patients with diabetes and moderate hyperglycemia do not seem to be caused 
by a change in the refractive components of the eye, and that a more severe and 
prolonged elevation of the blood glucose levels is needed to induce signiﬁcant 
changes in the refractive system of the eye (Chapter 5). This is demonstrated in 
Chapter 6, which provides a description of a case-report, from which it can be seen 
that severe prolonged hyperglycemia can cause changes in the refractive properties 
of the eye. In both eyes of a 27-year old man with newly diagnosed diabetes 
mellitus, severe hyperglycemia and symptoms of blurred vision, hyperopic shifts 
in refraction due to changes in the geometry of the lens were found. The thickness 
of the lens had increased, its anterior surface had become more convex, and the 
equivalent refractive index had decreased. After three weeks the blood glucose 
was at normal levels and the symptoms of blurred vision and ocular changes had 
disappeared.
 In order to further investigate the mechanisms underlying blurred vision and 
refractive changes, two experimental studies were performed. These studies 
were also meant to verify the controversial results of an earlier study, in which 
dramatic changes in lens thickness (1 mm) and ocular refractive error (-2 D) were 
reported in healthy subjects during induced acute hyperglycemia. In contrast 
to this earlier study, in which autorefractometry and ultrasound biometry was 
used, we used corrected Scheimpﬂug imaging, Hartmann-Shack aberrometry, 
and optical coherence tomography to measure the image formation system 
(i.e. refractive system and the retina) of healthy subjects during induced acute 
hyperglycemia. Surprisingly, in 4 out of 5 subjects no changes were found in 
the cornea and the lens, nor in the refractive error and ocular aberrations of the 
eye (Chapter 7). However, one subject had a hyperopic shift (+0.4 D) of ocular 
refraction, accompanied by a change in shape and refractive index of the lens 
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during hyperglycemia. 
 The results of Chapters 6 and 7 may provide an explanation for the controversy 
in the literature with regard to refractive changes during acute hyperglycemia. 
It could be that if the change in the shape of the lens is small, hyperopia will 
predominate during hyperglycemia, due to a decrease in the refractive index of 
the lens. Alternatively, if the change in the shape of the lens is large in comparison 
to the decrease in the refractive index of the lens, the overall refractive error 
will result in myopia. In summary, there seems to be a delicate balance between 
changes in the shape and the refractive index of the lens, which eventually 
determine the overall refractive outcome. 
 Finally, retinal thickness was measured during acute induced hyperglycemia 
(Chapter 8). Macular edema, or retinal thickening due to abnormal ﬂuid 
accumulation within the macula, has been reported as a common cause of visual 
loss and the degree of retinal thickening has been found to be signiﬁcantly 
associated with visual acuity (Chapter 9). However, in the present study, retinal 
thickness did not change during acute induced hyperglycemia, and so does not 
seem to be an explanation for blurred vision (Chapter 8). 
Conclusions
In this thesis we have shown that long-term diabetes mellitus type 1 has a major 
inﬂuence on the geometry of the lens. With increasing duration of the disease the 
diabetic lens becomes thicker and more convex as compared to a non-diabetic 
lens, as a result of overall swelling affecting all parts of the lens. These changes 
do not affect the refractive power of the lens due to a decrease in the equivalent 
refractive index of the lens. Furthermore, diabetes mellitus type 2 had very little 
effect on the refractive properties of the eye, which suggests a difference in the 
pathophysiological mechanisms underlying diabetes mellitus type 1 and type 2. 
 Severe acute hyperglycemia can cause changes in the refractive properties 
of the eye: a hyperopic shift in refraction is the result of a change in both the 
shape and the equivalent refractive index of the lens. Myopic and hyperopic shifts 
reported in the literature may be explained by the fact that both the shape and the 
equivalent refractive index of the lens change during hyperglycemia. Therefore, 
we hypothesize that a subtle balance exists between changes in the shape and the 
refractive index of the lens, which will eventually determine the overall refractive 
outcome. Subjective symptoms of blurred vision are not necessarily caused by 
a change in the image formation system of the eye, but they could also be the 
result of alterations in the image-processing system in the brain. Further research 
could possibly provide more insight into the role of image-processing in the brain 
during acute metabolic dysregulation. 
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Wereldwijd zijn er miljoenen mensen met diabetes mellitus, hetgeen resulteert 
in aanzienlijke morbiditeit en mortaliteit. Bekende oogheelkundige complicaties 
van diabetes mellitus zijn diabetische retinopathie en cataract (Hoofdstuk 1.3). 
Diabetes mellitus heeft ook een signiﬁcant effect op de refractieve eigenschappen 
van het menselijk oog. Bij patiënten met diabetes mellitus wordt de lens dikker 
en de vorm van het voorste en achterste lens oppervlak wordt boller (Hoofdstuk 
1.3.4). Daarnaast komen subjectieve symptomen van wazig zien en veranderingen 
van de refractie regelmatig voor bij acute ontregelde bloedglucosewaarden 
(Hoofdstuk 1.4.1). 
 Zowel de exacte invloed van het langdurig hebben van diabetes mellitus, 
alsmede het effect van acute ontregelde diabetes mellitus op de refractieve 
eigenschappen van het oog is nog een punt van discussie, voornamelijk vanwege 
het feit dat er pas recentelijk een methode beschikbaar is gekomen om alle 
optische elementen van het oog nauwkeurig te meten. De refractie van het oog 
is afhankelijk van de vorm van het hoornvlies en de lens, de brekingsindices van 
de oculaire media en de oogaslengte. Daarom zijn nauwkeurige metingen van de 
refractieve elementen van het diabetische oog belangrijk om afwijkingen te vinden 
in het refractieve systeem van patiënten met diabetes mellitus en daarnaast om 
het onderliggende mechanisme van wazig zien en refractieveranderingen tijdens 
acute ontregelde diabetes te onderzoeken. Het onderzoek dat beschreven is in 
dit proefschrift richtte zich op het onderliggende mechanisme van wazig zien 
en refractieveranderingen bij patiënten met diabetes mellitus door middel van 
het onderzoeken van langdurige en voorbijgaande (reversibele) veranderingen 
in de refractieve componenten van het diabetische oog. Nauwkeurige metingen 
van de geometrie van het voorste oogsegment en de refractie van het diabetische 
en gezonde oog werden verkregen met behulp van gecorrigeerde Scheimpﬂug 
fotograﬁe (Hoofdstuk 1.5.1) en Hartmann-Shack aberrometrie (Hoofdstuk 1.5.2). 
De doelstellingen van deze studie waren: 
 
- Het nauwkeurig meten van de dikte en de vorm van het hoornvlies, en de dikte, 
de vorm en de inwendige structuur van de lens bij patiënten met diabetes mellitus 
type 1 en type 2 (Hoofdstukken 2, 3, en 4).
- Het onderzoeken van het onderliggende mechanisme van wazig zien en refractie 
veranderingen tijdens acute hyperglykemie (hoge bloedglucose waarden) door 
middel van metingen van de geometrie van het hoornvlies en de lens, de refractie 
afwijking en de dikte van het netvlies van het oog (Hoofdstukken 5, 6, 7 en 8).  
Nederlandse samenvatting
164
Langdurige invloed van diabetes mellitus op de geometrie van het hoornvlies en 
de lens van het menselijk oog
De belangrijkste refractieve componenten van het oog zijn het hoornvlies en de 
lens. De voorzijde van het hoornvlies draagt ongeveer twee-derde bij aan het 
totale refractieve vermogen van het oog, de achterzijde van het hoornvlies en 
de voor- en achterzijde van de lens zorgen voor het overige deel. Het refractieve 
vermogen van het oog kan veranderen door veranderingen in de dikte of de 
kromming van het oppervlak van de voor- of achterzijde van het hoornvlies en 
de lens. In de huidige studie bleken zowel diabetes mellitus type 1 als ook type 
2 een klein maar signiﬁcant effect te hebben op de kromming van het oppervlak 
van de achterzijde van het hoornvlies; mensen met diabetes blijken een enigszins 
boller oppervlak van de achterzijde van het hoornvlies te hebben dan gezonde 
mensen, hetgeen resulteert in een kleine verandering in het refractieve vermogen 
van de achterzijde van het hoornvlies. Echter, omdat deze verandering zeer 
klein was en diabetes mellitus verder geen invloed had op de vorm (en tevens 
het refractieve vermogen) van de voorzijde van het hoornvlies, concluderen wij 
dat het hoornvlies geen grote rol speelt bij langdurige refractieveranderingen ten 
gevolge van diabetes mellitus (Hoofdstuk 2).  
 De gezonde lens blijft groeien gedurende het leven, hetgeen betekent dat de 
dikte toeneemt en de voor- en achterzijde van de lens boller worden. Uit de 
observaties beschreven in Hoofdstuk 3 wordt duidelijk dat de meest prominente 
veranderingen in de geometrie van het voorste oogsegment ten gevolge van 
diabetes mellitus plaatsvinden in de lens. De lenzen van patiënten met diabetes 
type 1 waren signiﬁcant dikker en boller dan de lenzen van gezonde mensen. De 
duur van de ziekte was een belangrijke determinant van de veranderingen in de 
biometrie van de lens; de toename van de lensdikte met elk jaar van het hebben 
van diabetes was ongeveer twee keer het normale effect van veroudering op de 
lens. Het boller worden van de voor- en achterzijde van de lens met elk jaar 
diabetes was respectievelijk twee en drie keer het normale verouderingseffect 
op de lens. Dit effect van diabetes mellitus type 1 op de biometrie van de lens 
was zelfs nog groter dan eerdere Scheimpﬂug studies hebben gerapporteerd 
(Hoofdstuk 1.3.4). In deze eerdere studies werd echter geen rekening gehouden 
met een zekere mate van beeldvervorming die inherent is aan Scheimpﬂug 
fotograﬁe (Hoofdstuk 1.5.1). Logischerwijs zou het boller worden van de lens 
ten gevolge van diabetes een toename in het refractieve vermogen van de lens 
bewerkstelligen, met een daarbij gepaard gaande myopisering van de refractie van 
het oog. Echter, verbazingwekkend genoeg veranderde het refractieve vermogen 
van de lens niet door diabetes mellitus. Dit kan verklaard worden door het feit 
dat de equivalente brekingsindex van de lens afneemt door diabetes en dat deze 
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afname in brekingsindex compenseert voor het boller worden van de diabetische 
lens. Dit mechanisme heeft tot gevolg dat het diabetische oog niet meer myoop 
wordt met toenemende duur van de ziekte. Tot slot werd er een essentieel verschil 
in het effect van diabetes mellitus type 1 en type 2 op de biometrie van de lens 
gevonden; de geometrie van de lens van patiënten met diabetes mellitus type 2 
verschilde niet van die van gezonde mensen. Dit duidt aan dat er mogelijk een 
fundamenteel verschil in pathogenese bestaat tussen diabetes mellitus type 1 en 
type 2 (Hoofdstuk 3).
 In hoofdstuk 4 werd de oorsprong van de toegenomen lensomvang bij patiënten 
met diabetes mellitus onderzocht. De hypothese was dat de toegenomen omvang 
van de diabetische lens veroorzaakt wordt door ofwel een versnelde groei van 
de lens, ofwel door een gegeneraliseerde zwelling van de lens. Een versnelde 
groei van de lens zou gekarakteriseerd worden door een toename van de dikte 
van één speciﬁeke laag in de cortex van de lens, omdat het aangetoond is dat 
de groei van de gezonde lens het gevolg is van een toename van die speciﬁeke 
corticale lenslaag. Echter, indien er sprake zou zijn van een zwelling van de lens 
of van de individuele lensvezels, dan zou men een een toename van de dikte van 
alle verschillende lenslagen kunnen verwachten. Uit het onderzoek beschreven 
in Hoofdstuk 4 bleek dat alle verschillende lagen van de lens van patiënten met 
diabetes mellitus type 1 in dikte toenamen. Daarom werd geconcludeerd dat de 
toegenomen omvang van de lens door diabetes mellitus type 1 hoogstwaarschijnlijk 
veroorzaakt werd door een gegeneraliseerde zwelling van alle delen van de lens 
door een inﬂux van water (Hoofdstuk 4). Bewijs voor een inﬂux van water in de 
lens is de observatie dat de equivalente brekingsindex van de lens afneemt door 
diabetes mellitus (Hoofdstuk 3). Tot slot, overeenkomstig met de resultaten die 
beschreven zijn in Hoofstuk 3, blijkt diabetes mellitus type 2 slechts een minimaal 
effect te hebben op de verschillende lagen van de lens (Hoofdstuk 4).   
Kortdurende invloed van diabetes mellitus op de refractieve eigenschappen en de 
dikte van het netvlies van het menselijk oog
Wazig zien is een veelvoorkomend oogheelkundig symptoom van diabetes 
mellitus. Voor een normale gezichtsscherpte zijn de volgende factoren 
noodzakelijk: een beeld dat scherp op de retina geprojecteerd wordt door het 
refractieve systeem van het oog, een nauwkeurige vertaling van lichtstralen naar 
actiepotentialen door de retina en het verwerken van die informatie door de visuele 
cortex van de hersenen. Het falen van een of meerdere onderdelen binnen dit 
systeem kan resulteren in wazig zien. Dit betekent dat de oorzaken van wazig zien 
veelvuldig kunnen zijn en dat zij het beste onderverdeeld kunnen worden in twee 
determinanten: het beeldvormende systeem van het oog (het refractieve systeem 
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en het netvlies) en het beeldverwerkende systeem (de hersenen). Veranderingen 
in het beeldvormende systeem houden in: refractie afwijkingen en/of optische 
aberraties door veranderingen in de geometrie van het hoornvlies en de lens, en 
netvlies afwijkingen zoals diabetisch macula oedeem. Deze studie richtte zich op 
veranderingen in het beeldvormende systeem als mogelijke oorzaak van wazig 
zien bij patiënten met diabetes mellitus.
 In eerste instantie werd het oculaire refractieve systeem (geometrie van het 
hoornvlies en de lens, refractie en optische aberraties) gemeten bij patiënten 
met diabetes mellitus type 1 of type 2 tijdens het aan- of afwezig zijn van de 
symptomen van wazig zien en hyperglykemie. De optische eigenschappen van 
het hoornvlies en de lens werden gemeten zoals boven beschreven door middel 
van gecorrigeerde Scheimpﬂug fotograﬁe, Hartmann-Shack aberrometrie en 
optische coherentie tomograﬁe. Uit een groep van 229 patiënten met diabetes 
mellitus includeerden wij diegenen (n = 25) die subjectieve klachten van wazig 
zien en hyperglykemie hadden. Na een eerste serie metingen werden zij gevraagd 
om terug te komen voor een tweede serie metingen, wanneer de symptomen 
van wazig zien en hyperglykemie verdwenen waren. Een vergelijking tussen 
de resultaten van beide metingen maakte duidelijk dat er geen signiﬁcante 
veranderingen konden worden aangetoond in de dikte of de vorm van het 
hoornvlies, of in de dikte, vorm en equivalente brekingsindex van de lens. 
Verder waren er slechts minimale veranderingen in de refractie en de optische 
aberraties van het oog tijdens hyperglykemie, die niet de symptomen van 
wazig zien konden verklaren. Dit betekende dat de symptomen van wazig zien 
bij patiënten met diabetes en matige hyperglykemie niet veroorzaakt lijken te 
worden door een verandering in de refractieve componenten van het oog en dat 
een ernstigere en langere verhoging van de bloedglucose spiegels waarschijnlijk 
nodig is om signiﬁcante veranderingen in het refractieve systeem van het oog te 
bewerkstelligen (Hoofdstuk 5). Dit wordt als zodanig aangetoond in Hoofdstuk 
6, waarin een case-report beschreven wordt, waaruit blijkt dat langdurige ernstige 
hyperglykemie veranderingen in de refractieve eigenschappen van het oog kan 
veroorzaken. In beide ogen van een 27-jarige man met recent gediagnostiseerde 
diabetes mellitus, ernstige hyperglykemie en symptomen van wazig zien, werden 
hypermetrope veranderingen ten gevolge van veranderingen in de geometrie 
van de lens gevonden. De dikte van de lens was toegenomen, het oppervlak van 
de voorzijde van de lens was boller geworden en de equivalente brekingsindex 
was afgenomen door de hoge bloedglucose waarden. Na drie weken was de 
bloedglucose genormaliseerd en waren de symptomen van wazig zien en de 
veranderingen in de lens verdwenen.   
 Met het doel om het onderliggende mechanisme van wazig zien en refractie 
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veranderingen te onderzoeken werden nog twee experimentele studies uitgevoerd. 
Deze studies werden ook verricht om de opvallende resultaten te veriﬁëren van 
een eerdere studie, waarin grote veranderingen in lensdikte (1 mm) en refractie 
van het oog (-2.0 D) gemeten werden in gezonde proefpersonen gedurende 
acuut geïnduceerde hyperglykemie. In tegenstelling tot deze eerdere studie, 
waarin de metingen verricht werden met autorefractometrie en echograﬁe, 
gebruikten wij gecorrigeerde Scheimpﬂug fotograﬁe, Hartmann-Shack 
aberrometrie en optische coherentie tomograﬁe om het beeldvormende systeem 
(het refractieve systeem en het netvlies) van gezonde proefpersonen gedurende 
acute geïnduceerde hyperglykemie te meten. Tot onze verbazing vonden wij bij 
4 van de 5 proefpersonen geen veranderingen in het hoornvlies of de lens en ook 
niet in de refractie of de aberraties van het oog (Hoofdstuk 7). Echter, één van 
de proefpersonen had een hypermetrope verandering (+0.4 D) van de refractie, 
gepaard gaande met een verandering in de vorm en de equivalente brekingsindex 
van de lens tijdens hyperglykemie.  
 De resultaten van Hoofdstukken 6 en 7 zouden een verklaring kunnen vormen 
voor de controverse in de literatuur met betrekking tot refractie veranderingen 
gedurende hyperglykemie. Het zou zo kunnen zijn dat indien de verandering van 
de vorm van de lens klein is, hypermetropie zal predomineren door een afname in 
de brekingsindex van de lens. Andersom, indien de verandering van de vorm van 
de lens relatief groot is in vergelijking met de afname in de brekingsindex van de 
lens, zal de totale refractie resulteren in myopie. Samengevat lijkt er een delicaat 
evenwicht te bestaan tussen veranderingen in de vorm en de brekingsindex van 
de lens, welke uiteindelijk de uitkomst van de refractie bepaalt.   
 Tot slot werd de dikte van het netvlies tijdens acute geïnduceerde hyperglykemie 
ook onderzocht (Hoofdstuk 8). Het is beschreven dat macula oedeem, ofwel een 
verdikking van het netvlies door abnormale vloeistof accumulatie in de gele 
vlek, een veelvoorkomende oorzaak is van het verlies van de gezichtsscherpte. 
Daarnaast is de mate van de verdikking van het netvlies signiﬁcant geassocieerd 
met de gezichtsscherpte (Hoofdstuk 9). Echter, in deze studie veranderde de dikte 
van het netvlies niet tijdens acute geïnduceerde hyperglykemie en leek het de 
symptomen van wazig zien niet te kunnen verklaren (Hoofdstuk 8). 
Conclusie
In dit proefschrift hebben wij aangetoond dat diabetes mellitus type 1 op de lange 
termijn een grote invloed heeft op de geometrie van de lens. Met een toename van 
de duur van de diabetes wordt de lens dikker en boller dan de gezonde lens, door 
een gegeneraliseerde zwelling van alle verschillende lagen van de lens. Deze 
veranderingen hebben geen invloed op het refractieve vermogen van de lens door 
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een daling van de equivalente brekingsindex van de lens. Verder had diabetes 
mellitus type 2 slechts een minimaal effect op de refractieve eigenschappen van het 
oog, hetgeen een verschil in de onderliggende pathofysiologische mechanismen 
van diabetes mellitus type 1 en type 2 suggereert.
 Ernstige acute hyperglykemie kan veranderingen in de refractieve 
eigenschappen van het oog bewerkstelligen: een hypermetrope verschuiving van 
de refractie is het resultaat van een verandering in de vorm en de equivalente 
brekingsindex van de lens. Myope en hypermetrope veranderingen in de refractie, 
zoals gerapporteerd in de literatuur, zouden verklaard kunnen worden door een 
verandering in zowel de vorm alsook de equivalente brekingsindex van de lens 
tijdens hyperglykemie. Derhalve veronderstellen wij dat er een subtiele balans 
bestaat tussen veranderingen in de vorm en de brekingsindex van de lens, die 
uiteindelijk de uitkomst van de refractie zal bepalen. Subjectieve symptomen 
van wazig zien worden niet noodzakelijk veroorzaakt door een verandering 
in het beeldvormende systeem van het oog, maar deze zouden ook het gevolg 
kunnen zijn van veranderingen in het beeldverwerkende systeem in de hersenen. 
Verder onderzoek zou eventueel meer inzicht kunnen verlenen in de rol van het 
beeldverwerkende systeem gedurende acute metabole ontregeling.
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